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Abstract 
DNA damage induces MDC1 recruitment and establishes a signalling platform 
that mediates the DNA damage response (DDR). I show that Bod1L plays a 
central role in DDR by controlling MDC1 and PP2A-B56 localisation to damaged 
DNA. Bod1L depletion leads to micronuclei formation in undamaged cells and 
hypersensitivity to genotoxic stress. Bod1L binds to chromatin and is 
phosphorylated by ATM at sites of DNA damage. In Bod1L-depleted cells, ATM 
activity is normal, but there is over-accumulation of MDC1 at damaged sites 
caused by hyper-phosphorylation of MDC1-T4. I show that PP2A-B56 
phosphatase can dephosphorylate MDC1-T4 following DNA damage and that 
MDC1 accumulation is limited by PP2A-B56. PP2A-B56 binds Bod1L 
exclusively in damaged cells and requires Bod1L for localisation to damaged 
DNA.  
 
In addition to mediating repair, DNA damage triggers cell-cycle arrest, allowing 
adequate time for DNA repair to occur and to prevent transmission of any DNA 
lesion to daughter cells. The data presented in this thesis provides evidence 
that Bod1L acts as a regulator of Chk2 activation, acting to release Chk2 from 
the well-characterised inhibitory Chk2/PP2A-B56 phosphatase complex upon 
DNA damage, thus allowing the kinase to phosphorylate downstream 
substrates. 
 
Overall, Bod1L makes three critical contributions to the DNA damage response: 
it promotes the initial targeting of MDC1, limits MDC1 accumulation by targeting 
PP2A-B56 to dephosphorylate MDC1-T4 and regulates the phosphorylation and 
activation of the transducer kinase Chk2. 
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Chapter 1 – Introduction 
1.1 DNA and DNA replication 
Deoxyribonucleic acid (DNA) is a molecule responsible for carrying the genetic 
code necessary for the development, function and survival of the cell. In order 
to pass on this genetic information from one generation to the next, cells must 
precisely replicate their genomes before each cell division, ensuring that the 
genetic code passed on to each daughter cell is an exact copy of the maternal 
DNA. To ensure that DNA is replicated only once during the cell cycle, a 
complex mechanism exists, which couples the synthesis of new DNA to the 
progression of the cell cycle (Walter and Newport, 2000). Due to their size, 
eukaryotic genomes are replicated from many replication origins distributed 
along multiple chromosomes during S-phase of the cell cycle, allowing for the 
replication of large amounts on DNA in a relatively short period of time (Diffley, 
2011). 
 
To regulate the replication origins that are used during S-phase, thus ensuring 
that origins are not fired inappropriately, a pre-replicative (pre-RC) complex is 
formed during G1 phase of the cell cycle. This process involves the hierarchical 
assembly of a number of replication proteins, including the origin recognition 
complex (ORC), Cdt1 protein, Cdc6 protein, and mini-chromosome 
maintenance proteins (Mcm2-7) (Bell and Dutta, 2002). As this complex can 
only be assembled on chromatin during G1 phase of the cell cycle, it prevents 
the re-replication of DNA from occurring during S-phase, thus maintaining the 
high fidelity duplication of the genomic code (Blow and Dutta, 2005). During 
transition of the cell cycle from G1 to S-phase, the cyclin-dependent protein 
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kinase 1 (CDK1), together with the Cdc7/Dbf4 kinase (DDK) transition the pre-
RC complex into an active replication fork (Diffley, 2011). During this process, 
Cdc6 is lost from the complex and Cdc45 and GINS are loaded onto the MCM2-
7 proteins. This Cdc45-MCM-GINS (CMG) helicase complex, in association with 
additional accessory proteins, is required for DNA unwinding, allowing for 
replication of the leading and lagging DNA strands (Costa et al., 2011). 
 
Once the cell passes into S-phase, the initiation complex becomes the 
replisome, which is responsible for coordination of DNA replication. The CMG 
helicase complex unwinds DNA and 5’-3’ replication of the DNA is performed by 
DNA polymerase α/ε (leading strand) and DNA polymerase δ (lagging strand) in 
a complex consisting of a number of accessory factors. As these DNA 
polymerases require a primer on which to commence DNA synthesis, DNA 
polymerase α acts to synthesise such a primer in association with an RNA 
primase, on both leading and lagging strands prior to DNA synthesis by either 
Pol ε or Pol δ (McCulloch and Kunkel, 2008). As DNA replication of the lagging 
strand by Pol δ is discontinuous due to the continual unwinding of the maternal 
DNA, multiple DNA fragments are generated by the DNA-synthesis action of Pol 
δ. These 100-400 nucleotide fragments are termed Okazaki fragments. The 
short flaps created between each of the discontinuous fragments following 
ligation, are cleaved by structure-specific endonucleases and the remaining 
nicks ligated by DNA ligase 1 (Burgers, 2009). Following replication of the entire 
genome during S-phase, any damaged DNA or replication errors are corrected 
during the following G2-phase, following which a single copy of the genome is 
segregated into each daughter cell during mitosis. 
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1.2 Causes and types of DNA damage 
As alluded to in the previous section, the DNA is under constant threat of 
damage from both endogenous sources such as replication errors, as well as 
exogenous sources such as radiation or genotoxic chemicals. These threats 
have the potential to result in the formation of a number of different DNA 
lesions. These can range from very common but minor lesions such as single-
strand breaks (SSBs) and oxidative damage, to severe and highly toxic DNA 
double-strand breaks (DSBs), which pose a serious threat to the genomic 
stability of the cell (Hoeijmakers, 2009)(Figure 1.1). Left unrepaired, or repaired 
improperly, this genomic instability can combine with other genetic and 
epigenetic events to influence the oncogenic potential of the cell, possibly 
leading to tumorgenesis and the formation of cancerous lesions (Hanahan and 
Weinberg, 2000). So important is maintaining genomic stability, that it 
underlines the six biological capabilities acquired during the development of 
human tumours (Hanahan and Weinberg, 2011), with elevated levels of DNA 
damage commonly detected in early tumours (Bartkova et al., 2005). To 
overcome the vast array of DNA lesions that occur often simultaneously within 
the cell, a number of different pathways have evolved to counteract potential 
genomic instability. These complex mechanisms act in synchrony to detect and 
signal the presence of a DNA lesion; working in harmony to prevent cell-cycle 
progression and allow adequate time for DNA repair. Collectively these 
mechanisms have been termed the DNA damage response (DDR). Failing 
proper repair, the mechanism triggers cellular apoptosis or senescence to 
prevent the transmission of the DNA lesion to daughter cells (Ciccia and 
Elledge, 2010; Jackson and Bartek, 2009).  
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Figure 1.1: Types of DNA damage and repair mechanisms
Common forms of genotoxic stresses and poisons, along with examples of lesions induced by 
these agents. The DNA repair mechanism aligned with each type of damage is highlighted 
below. Adapted from (Hoeijmakers, 2001) 
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The importance of the DDR in the prevention of tumorgenesis is highlighted by 
the number of mutations in critical DDR components, such as p53 and ATM, 
present in early stage tumours (Negrini et al., 2010). Thus it is likely that tumour 
progression overcomes the barrier of DDR activation through mutations in 
critical DDR components, allowing rapid proliferation despite the presence of 
genomic instability (Bartek et al., 2007). Whilst mutations in these key 
components can drive tumorgenesis and proliferation, it renders cells 
harbouring such mutations hyper-sensitive to DNA damaging agents due to a 
lack of robust repair pathways (Helleday et al., 2008). Targeting cells with 
compromised DNA repair, for example the use of Poly(ADP-ribose) polymerase 
(PARP) inhibitors in cells with BRCA1/2 mutation, results in profound 
chromosomal instability, cell cycle arrest and subsequent apoptosis (Farmer et 
al., 2005). The use of such compounds, in combination with traditional 
chemotherapies has been successful in the treatment of previously resistant or 
difficult to treat cancers (Cheung-Ong et al., 2013; Lord and Ashworth, 2012).
1.3 ATM mediated DNA damage response 
1.3.1 DNA double-strand break and the Phosphoinositide 3-kinase family 
As mentioned previously, of the various different forms of DNA lesion bought 
about from endogenous and exogenous sources, the DNA double strand break 
is the most toxic to the cell, with a single DSB enough to induce apoptosis and 
cell death (Jackson, 2002). These breaks are generated when the two 
complementary strands on DNA are broken in close enough proximity that the 
chromatin structure and base-pairing are insufficient to keep the two DNA 
strands together (Jackson, 2002). This physical dissociation, coupled with base-
pair damage mean that simple DNA ligation is insufficient for repair, with 
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Figure 1.2: The cellular response to DNA damage
Schematic representation of the cellular response to DNA damage, divided into sensor, 
transducer and effector proteins. ATM is activated in response to damaged DNA, whose 
downstream phosphorylation activates a range of transducer proteins. Transducer prote
activation leads to downstream interaction or modulation of effector proteins leading to a range 
of cellular effects to the initial damage event. Adapted from (Chen and Stubbe, 2005)
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complex processing needed before repair can be carried out. Whilst DSBs can 
be caused by a variety of exogenous sources, such as ionising radiation (IR) 
and chemicals used for chemotherapy (Hoeijmakers, 2001), such breaks are 
often generated deliberately or accidently during a defined biological process 
(Jackson, 2002) (Figure 1.1). These processes include the deliberate 
generation of DSBs for V(D)J recombination, a process which occurs in 
developing B-/T-lymphocytes to generate antigen binding diversity (Fugmann et 
al., 2000). As well as deliberate DSB formation, these toxic breaks can also be 
generated naturally when replication forks encounter blocking lesions (such as 
reactive oxygen species (ROS)) leading to fork collapse (Shrivastav et al., 
2008). 
 
The repair of DSBs is mediated by the activity of the phosphatidylinositol 3-
kinase-related kinase (PI3K) family, primarily by DNA-dependent protein kinase 
(DNA-PK) and Ataxia-telangiectasia mutated (ATM), which act to sense and 
transduce the DDR signalling to the effector proteins (Figure 1.2). ATM is 
responsible for the phosphorylation of over 700 downstream proteins in 
response to DNA damage, giving scope to the scale and involvement of the 
DDR in almost all cellular processes (Matsuoka et al., 2007). An additional PI3K 
family member, Ataxia-telangiectasia mutated and rad3-related kinase (ATR) is 
principally involved in the repair of single-stranded DNA breaks occurring as a 
result of replication stress (Brown and Baltimore, 2003). ATM and DNA-PK are 
both involved in the repair of DSBs, with the later functioning within the non-
homologous end-joining pathway discussed in section 1.4.2. 
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1.3.2 The ATM mediated signalling response to DSBs 
Upon the formation of a DSB, the MRN complex consisting of MRE11, RAD50 
and NBS1 is rapidly recruited to the broken DNA ends, which acts to both tether 
the free DNA ends and recruit ATM (Lamarche et al., 2010). Through a C-
terminal binding motif on NBS1, inactive ATM is recruited to the newly formed 
DSB, where it is subsequently activated by ATP-driven conformational changes 
in the MRN complex (Falck et al., 2005; Lee et al., 2013; Uziel et al., 2003). In 
the absence of DNA damage, the ATM kinase exists as an inactive dimer 
(Shiloh and Ziv, 2013). Recruitment of ATM to DSBs by MRN facilitates the 
autophosphorylation of ATM at S367, S1893, S1981 and S2996, in addition to 
the histone acetyltransferase Tip60 dependent acetylation on K3016, which 
result in the activation of the kinase (Bakkenist and Kastan, 2003; Kozlov et al., 
2011; 2006; Sun et al., 2005). The MRN complex is also required for targeting 
Tip60 to H3K9me3, which is required to activate the acetyltransferase activity of 
Tip60 (Sun et al., 2009). These multiple post-translational modifications (PTMs) 
cause the inactive ATM dimer to dissociate, leading to the formation of active 
monomers (Shiloh and Ziv, 2013)(Figure 1.3). 
 
Once activated, one of the first targets of ATM is histone H2AX, a histone 
variant of H2A that includes a longer C-terminal tail containing a conserved 
SQEY-COOH motif (Rogakou et al., 1998). Phosphorylation of the conserved 
S139 by ATM, in addition to the dephosphorylation of Y142 by the EYA 
phosphatase, initiates the recruitment of a number of downstream factors to the 
DSB, which can be visualised as a microscopic focus (Cook et al., 2009; Lukas 
et al., 2003; Rogakou et al., 1999). Phosphorylated γH2AX provides a binding 
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Figure 1.3: Multi-step signalling pathway of DNA double strand break 
recognition 
Double strand break formation leads to the activation and of ATM via MRN complex and TIP60. 
Phosphorylation of Chk2 and p53 leads to cell cycle arrest. Phosphorylation of the histone 
variant H2AX initiates the H2AX signalling cascade resulting in the direct and indirect 
recruitment of MDC1, RNF8/RNF168, BRCA1-A complex and 53BP1. The formation of these 
protein complexes at sites of DNA damage lead to the cellular processes outlined at the bottom 
of the figure Adapted from (Bohgaki et al., 2010; Ciccia and Elledge, 2010) 
29 
platform for a major phospho-scaffold protein Mediator of damage checkpoint 1 
(MDC1), which interacts with γH2AX via its tandem BRCA1 carboxy-terminal 
(tBRCT) domain (Stucki et al., 2005). The principle purpose for the recruitment 
of MDC1 to DNA lesions is to act as a phosphoscaffold for the recruitment of a 
number of downstream proteins. MDC1 binds to NBS1 via the SDT-repeat 
domain of MDC1 and the FHA domain of NBS1, which serves to re-recruit the 
MRN complex to sites of damage (Chapman and Jackson, 2008; Melander et 
al., 2008; Spycher et al., 2008; Wu et al., 2008). MDC1 binding to the MRN 
complex at DSBs allows for the recruitment of additional ATM to DSBs via a 
positive feedback loop. The increased ATM recruitment serves to amplify the 
γH2AX phosphorylation and signalling in the region surrounding the DSB (Lou 
et al., 2006). This local increase in activated ATM also enables the 
phosphorylation of a number of key transducer kinases, such as Chk2 and p53, 
which act to control the cell cycle during the DDR (Ahn et al., 2000; 2002; Lukas 
et al., 2004b)(Figure 1.2). The control of cell-cycle during the DDR is discussed 
in depth in section 1.6. 
 
In addition to the ATM-dependent recruitment of MRN to DSBs, MDC1 also 
functions to recruit a number of additional components to sites of damage. 
MDC1 is phosphorylated directly by ATM at the TQXF cluster, which promotes 
binding to the FHA domain of the E3 ubiquitin ligase RNF8 (Huen et al., 2007; 
Kolas et al., 2007; Mailand et al., 2007). RNF8, along with HERC2 and UBC13, 
are responsible for the ubiquitination (Lys-63) of H2A and H2AX in the 
chromatin region flanking the break (Bekker-Jensen et al., 2009; Mailand et al., 
2007). This facilitates the recruitment of RNF168 to these ubiquitylated 
histones. RNF168, together with UBC13, catalyses the monoubiquitination of 
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the histones specifically on K13-15, which results in the conjugation of K63 
ubiquitin chains at these sites (Mattiroli et al., 2012). As well as acting as a 
binding platform, ubiquitination of H2A and H2AX surrounding the DSB is 
believed to relax the chromatin structure, facilitating the recruitment of 
additional repair factors such as p53-binding protein 1 (53BP1) and Breast 
cancer susceptibility gene 1 (BRCA1) (Doil et al., 2009; Kolas et al., 2007; 
Stewart et al., 2009). In addition, the SUMO E3-ligases PIAS1 and PIAS4 are 
recruited to DSBs via their SAP domains and have been shown to be important 
in the robust recruitment of 53BP1, BRCA1 and RNF168 to damage sites 
(Galanty et al., 2010). 
 
Recruitment of 53BP1 to DSBs is unusual in that initial recruitment of the 
protein is dependent on histone H4 di-methylated lysine 20 (H4K20me2) and 
histone H3 di-methylated lysine 79 (H3K79me2), rather than direct protein-
protein interaction. These histone marks are revealed following the chromatin 
relaxation mediated by RNF8 and RNF168 (Botuyan et al., 2006; Huyen et al., 
2004; Sanders et al., 2004)(Figure 1.3). It has also been shown that the direct 
ubiquitination of 53BP1 by RNF168 is important for proper 53BP1 recruitment to 
DSBs (Bohgaki et al., 2013). These methylated histones are recognised by the 
Tudor domain of 53BP1 (Zgheib et al., 2009). In addition, acetylation by Tip60 
limits 53BP1 association with damaged chromatin, a mechanism believed to 
control the relative DSB chromatin occupancy and repair activities of BRCA1 
and 53BP1 (Tang et al., 2013). Recently an additional regulatory mechanism 
has been identified, which acts to prevent 53BP1 recruitment to DSBs during 
mitosis. Phosphorylation of 53BP1 at T1609 and S1618 in the well-conserved 
ubiquitination-dependent recruitment (UDR) motif prevents 53BP1 recruitment 
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to H2A (Lee et al., 2014; Orthwein et al., 2014). This mechanism exists to 
prevent Aurora B kinase–dependent sister telomere fusions that produce di-
centric chromosomes and aneuploidy when the DSB machinery is active during 
mitosis (Orthwein et al., 2014). Once recruited at DSBs, 53BP1 has a 
multifaceted role. 53BP1 is a key regulator of DSB repair pathway choice. 
During G1, it promotes non-homologous end-joining (NHEJ)-mediated DSB 
repair by supressing DNA end resection (Bunting et al., 2010). This pathway 
choice is mediated by mutual antagonism with breast cancer 1 (BRCA1). During 
S-G2 phase of the cell cycle, BRCA1 and CtIP promote DNA end-resection and 
thus homologous recombination-mediated DSB repair (Escribano-Diaz et al., 
2013). Whilst the function of 53BP1 at DSB is understood, the mechanism into 
how 53BP1 blocks resection in G1 and how this is counteracted by BRCA1-CtIP 
to promote HR repair in S/G2 phase remains unknown (Panier and Boulton, 
2013). 
 
The K63-ubiquitin chains generated by the activity of RNF8 and RNF168 are 
also recognised by the ubiquitin-interacting motif (UIM) of RAP80, which recruits 
the BRCA1-A complex, through an interaction with the scaffold protein ABRA1 
(Ciccia and Elledge, 2010; Huen et al., 2007; Kolas et al., 2007; Wang and 
Elledge, 2007). The recruitment of BRCA1-A to DSBs is also dependent on 
sumoylation. The SUMO E3-ligases PIAS1 and PIAS4 are recruited to DSBs via 
their SAP domains. PIAS4 is believed to stimulate the ubiquitin ligase activity of 
RNF8/UBC13, thus promoting recruitment of RNF168 and therefore BRCA1-A 
to sites of damage. PIAS1 is believed to directly sumoylate BRCA1 to stimulate 
its ubiquitin ligase activity (Galanty et al., 2010; Morris et al., 2010). RAP80 also 
contains a SUMO-interacting motif (SIM) which has been shown to be 
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necessary for DSB recruitment (Guzzo et al., 2012). Furthermore, RNF4, a 
SUMO-targeted ubiquitin E3-ligase that synthesises hybrid SUMO-ubiquitin 
chains, localises to DSBs and is critical for the recruitment of RAP80 and 
BRCA1 to sites of DNA damage (Guzzo et al., 2012). Loss of RNF4 results in 
defective loading of replication protein A (RPA) and Rad51 onto ssDNA, 
suggesting the importance of this protein in DSB repair (Yin et al., 2012). Once 
recruited to DSB, the BRCA1-A complex is involved in the DNA damage repair 
and the activation of cell-cycle checkpoints (Huen et al., 2009). 
1.4 DNA double strand break (DSB) repair 
Eukaryotic cells typically repair DSBs by one of two primary mechanisms: non-
homologous end-joining (NHEJ) or homologous recombination (HR). Typical 
DSBs caused by doses of ionising radiation or structure-specific nucleases can 
be repaired using either pathway due to the availability of both DNA ends. 
DSBs caused by replication fork collapse are primarily repaired by HR, as these 
fork collapses produce a one-sided DSB, known as a double-strand end (DSE) 
(Rothstein et al., 2000; Shrivastav et al., 2008). The DSE has no second end to 
re-join and as such this break is incompatible with repair by NHEJ. 
Inappropriate activation of the NHEJ repair pathway following replication fork 
collapse is associated with detrimental genome rearrangements and cell death 
(Saberi et al., 2007). 
 
NHEJ does not require sequence homology and as such is active throughout 
the cell cycle, therefore this repair pathway constitutes the major DSB repair 
mechanism in eukaryotic cells (Lieber, 2010). Whilst somewhat of a 
generalisation, this method of repair is termed “error-prone”, as the lack of 
homologous sequence surrounding the break risks potential nucleotide loss 
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during the repair process. In contrast to this, repair of DSBs by HR is 
considered “error-free”, as the mechanism utilises homologous sequences to 
align the DSB ends prior to ligation and thus limit any risk of nucleotide loss 
(Aparicio et al., 2014). Whilst repair by HR is possible during both the S and G2 
phase of the cell cycle, recent evidence suggests that HR is only favoured 
during S-phase, with NHEJ the preferred mechanism to repair DSBs during the 
remaining cell cycle (Aparicio et al., 2014; Shahar et al., 2011; Shibata et al., 
2011). Indeed the findings suggest that the principle role for HR repair is mainly 
in the repair of challenging DSBs, in contrast to uncomplicated lesions that are 
frequently repaired by NHEJ (Shahar et al., 2011; Shibata et al., 2011). 
Interestingly, lower organisms with mutations in key HR components show a 
much higher degree of radiosensitivity compared with mammalian cells with 
similar mutations. This suggests that a certain degree of redundancy is 
incorporated into the mammalian DNA repair system, unsurprising given the 
importance of maintaining genomic stability (Kakarougkas and Jeggo, 2014). 
 
Several factors can determine the repair pathway chosen to repair a detected 
DSB. As discussed above, HR repair is only possible during S and G2 phase of 
the cell cycle and as such DSBs occurring during G1 are primarily repaired 
using NHEJ. DSBs detected during mitosis display diminished DNA repair, with 
the DSBs marked for repair after mitotic exit (Giunta and Jackson, 2011). 
Recent evidence suggests that this process protects the uncapped telomeric 
ends from the DSB repair machinery (Orthwein et al., 2014). Another critical 
mediator of repair pathway choice is the stability of DNA ends following a DSB. 
The initiation of 5’-3’ resection of DNA ends commits cells to HR repair, 
preventing repair by NHEJ (Chapman et al., 2012; Symington and Gautier, 
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2011). In addition to cell-cycle stage and stability of DNA ends, the interplay 
between 53BP1 and BRCA1 is crucial as a determinant of pathway choice. 
RIF1 and PTIP are recruited to DSBs via an interaction with ATM-
phosphorylated 53BP1 (Callen et al., 2013; Escribano-Diaz et al., 2013; Munoz 
et al., 2007). RIF1/PTIP/53BP1 can then act to restrict BRCA1 accumulation at 
damage sites outside the S/G2 phases of the cell cycle, thus promoting repair 
by NHEJ. During S/G2 phases, BRCA1/CtIP can accumulate at the site 
surrounding the DSB and can render this region permissive to end resection, 
thus promoting repair by HR. Exactly how RIF1/PTIP/53BP1 can exclude 
BRCA1/CtIP from breaks during G1 remains unclear (Panier and Boulton, 
2013). 
1.4.1 Homologous Recombination 
As mentioned above, BRCA1 has been shown to be critical for the initiation of 
DNA repair by HR. The protein acts to recruit and activate a number of proteins 
which facilitates repair (Chapman et al., 2012). The presence of single-strand 
DNA at the DSB end is necessary to initiate the search for sequence homology, 
which is generated by the nucleolytic degradation of the 5’ strand of a DSB end, 
exposing a single-stranded 3’ DNA terminus, in a process termed end resection 
(Aparicio et al., 2014). Resection is initiated by the MRN complex, which binds 
the DNA ends through RAD50 and resects the DNA via the action of MRE11. 
MRE11 cooperates with CtIP, a protein which is proteolytically degraded during 
G1 phase, to generate 3’ ssDNA overhangs through a combination of 
endonucleolytic cleavage, followed by 3’-5’ exonucleolytic processing (Shibata 
et al., 2014). Proteolytic degradation of CtIP during G1 phase acts as a further 
safeguard to ensure that HR can only occur during S/G2 phases (Germani et 
al., 2003). The initial processing of DNA ends by MRE11/CtIP provides a 
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substrate for the exonucleases EXO1 and DNA2 together with the helicase 
BLM, which act synergistically to unwind DNA and continue the DNA resection 
(Nimonkar et al., 2011). 
 
The exposed ssDNA is coated with RPA, forming an RPA-ssDNA nucleoprotein 
filament. The binding of RPA serves to prevent the degradation or annealing of 
the ssDNA strand and also act to promote downstream DNA-processing protein 
recruitment, assembly and interaction (Chen et al., 2013; Fan and Pavletich, 
2012; Zou et al., 2006). Rad51 is then recruited by BRCA2/PALB2 to the 
nucleoprotein filament, which displaces RPA from the ssDNA, resulting in 
Rad51-ssDNA nucleoprotein filament formation (Xia et al., 2006). These 
filaments, along with the ATPase Rad54, undergo homology searching and 
invade the homologous sister chromatid, forming a displacement-loop (D-loop) 
structure which contains the novel heteroduplex DNA and the displaced strand 
of donor DNA (Alexeev et al., 2003; Renkawitz et al., 2014).  
 
Once formed, the D-loop is extended by DNA polymerases using the 
homologous strand as template. This DNA synthesis leads to the dissociation of 
Rad51 from heteroduplex DNA (Solinger et al., 2002). During the post-synapsis 
phase, the D-loop can be removed and the break resolved in a number of 
different ways. In the presence of a second DNA end, the predominant pathway 
for DSB repair is synthesis-dependent strand annealing (SDSA). Newly 
synthesised DNA is displaced from the D-loop and annealed to the resected 
DNA of the second end (Pâques and Haber, 1999). The process, thought to be 
promoted by the RTEL helicase following Rad51 displacement (Barber et al., 
2008), removes the need for cross-overs and as such removes any potential 
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risk of genomic rearrangements (Heyer et al., 2010). If the original break 
occurred as a result of fork-collapse then the DSE created cannot undergo 
repair by SDSA as there is no resected second end to anneal to. Such breaks 
undergo a process termed break-induced replication (BIR), whereby the 
reassembly of a new replication fork at RAD51-generated D loop intermediates 
occurs (Llorente et al., 2008). Whilst this process repairs such breaks 
effectively, restoring the integrity of the chromosome, it can lead to loss of 
heterozygosity of all genetic information distal to the DSB (Heyer et al., 2010). A 
third alternative pathway for repair, involves the formation of double-Holliday 
junctions (dHJs), which form following ligation of the invading strand with the 
second end captured by D-loop branch migration (Nimonkar and 
Kowalczykowski, 2009). The dHJ formed can then be dissolved by the 
BLM/TOPOIIIα complex, or cleaved by the structure-specific endonucleases 
GEN1, MUS81/EME1, or SLX1/SLX4, producing either a crossover or non-
crossover product (Ciccia and Elledge, 2010; Fekairi et al., 2009; Ip et al., 2008; 
Munoz et al., 2009; Svendsen et al., 2009). Aside from resolution of the dHJs 
by BLM/TOPOIIIα, resolution by GEN1, MUS81/EME1 or SLX1/SLX4 can lead 
to a loss of heterozygosity and can cause genomic rearrangements. As such 
resolution of dHJs by these structure-specific nucleases is highly regulated 
(Ciccia and Elledge, 2010). 
1.4.2 Non-homologous end joining (NHEJ) 
NHEJ, the major repair pathway for DSBs, is active throughout the cell cycle as 
the repair process is not reliant on a homologous DNA strand to act as 
template. DSB DNA ends are rapidly bound (within seconds) by the Ku70/Ku80 
heterodimer, which may assist in tethering the broken DNA ends (Kim et al., 
2005). Once bound, the Ku heterodimer translocates inwards, facilitating the 
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loading and activation of the catalytic subunit of the PIKK kinase, DNA-PK 
(DNA-PKcs) (Mahaney et al., 2009; Yoo and Dynan, 1999). The translocation of 
Ku allows the DNA-PK to interact across the DSB in a “synaptic complex”, 
which stimulates the kinase activity of DNA-PK and tethers the DNA ends 
together (DeFazio et al., 2002). The presence of DNA is also necessary for the 
full activation of the DNA-PK kinase activity (Gottlieb and Jackson, 1993). 
Active DNA-PK then phosphorylates a number of targets on SQ/TQ sites, 
including the Ku70/80 heterodimer, XRCC4 and Artemis, as well as 
autophosphorylation which is believed to be required for its release from DSBs 
in vivo (Douglas et al., 2002; Lee et al., 2004; Ma et al., 2005a; Mahaney et al., 
2009). DNA breaks that contain non-ligatable ends are first processed by the 
Artemis/APLF nucleases which possesses DNA-PK-dependent endonuclease 
and DNA-PK-independent 5’-3’ exonucleases activity (Iles et al., 2007; Ma et 
al., 2005b). In addition, polynucleotide kinase (PNK) is also involved in DNA 
end-processing, possessing both 3’-DNA phosphatase and 5’-DNA kinase 
activities, allowing removal of non-compatible/non-ligatable end groups from 
DNA ends (Mahaney et al., 2009).  
 
Once processed, DNA ends are ligated by DNA ligase IV in complex with 
XRCC4, with the help of the stimulatory factor XLF (Ahnesorg et al., 2006). 
XRCC4 possesses no enzymatic activity, instead acting as a scaffold to recruit 
ligation factors such as DNA ligase IV to the break and stimulate their activity to 
seal the break (Grawunder et al., 1997; Nick McElhinny et al., 2000). 
1.4.3 Annealing-dependent repair pathways 
Whilst the majority of DSBs are repaired by one of the two repair pathways 
detailed above, other modes of repair are observed in normal and pathological 
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settings. These alternative end-joining (Alt-EJ) pathways are often activated if 
one of the two major pathways becomes compromised. In a situation where HR 
repair is compromised, for example in BRCA1/2 deficient cells, microhomology-
mediated end-joining (MMEJ) and single-strand annealing (SSA) can repair a 
DSB whose resection has rendered the break incompatible with NHEJ repair 
(Aparicio et al., 2014). These pathways undergo base pairing between strands 
of exposed homologous sequences on separate ssDNA overhangs, followed by 
further processing to fill in any gaps and ligate the nicks. Short homologous 
tracks are generally repaired by MMEJ, with longer tracks relying on SSA 
(Deriano and Roth, 2013). Both MMEJ and SSA pathway operate in the 
absence of classical NHEJ factors such as Ku70/80, XRCC4 and DNA ligase IV 
(Hartlerode and Scully, 2009), yet are reliant on the resection activity of the 
MRN-CtIP complex to expose regions of microhomology (Bennardo et al., 
2008). DNA ligation is believed to be carried out using DNA ligase III/XRCC1, 
with some additional contribution from DNA ligase I (Dueva and Iliakis, 2013). 
Whilst these alterative repair pathways are capable of repairing DNA breaks in 
the absence of HR or NHEJ components, it is believed that the use of these 
pathways is associated with the formation of pathological chromosomal 
deletions and translocations in cancer cells (Della-Maria et al., 2011; Greenman 
et al., 2007).  
1.4.4 Pathologies associated with defective DSB repair 
A robust and functional response to DNA damage is critical to maintain cell 
viability and help prevent genomic instability and the downstream 
consequences of this. The importance of the DNA repair pathways is 
highlighted by the clinical severity of mutations in any of the key components of 
the DDR. Several mutations in the number of key DDR proteins have been 
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identified, with many clinical features of these mutations overlapping (Figure 
1.4).  
 
One of the best characterised of the conditions associated with defective DSB 
repair is Ataxia-Telangiectasia (AT), a neurodegenerative disease that presents 
during early childhood (Gatti et al., 2001). The prominent neurological sign of 
AT is a significant loss of cerebellar function, which results in increasing 
uncoordinated or ataxic movements and ocular telangiectasia (dilated eye blood 
vessels) (McKinnon, 2004). In addition to the well-characterised 
neurodegeneration and neurological clinical features, patients with AT also 
display a number of cellular features, including radiosensitivity and heightened 
susceptibility to lymphoreticular cancer such as leukaemia and lymphoma 
(Frappart and McKinnon, 2006; Gumy-Pause et al., 2003). AT arises as a result 
of mutations in the ATM gene. Whilst over 400 unique mutations have been 
reported for ATM in AT patients, extending the full length of the gene, almost all 
of these mutations are truncating or slice-site mutations that give rise to short, 
unstable ATM proteins (Lavin, 2008). Given a lack of functional ATM and the 
important role that this kinase plays in maintaining genomic stability, it is 
unsurprising that patients diagnosed with AT are prone to chromosomal 
instability and cancer predisposition. It still remains unclear as to whether the 
other pathophysiologies associated with AT arise as a direct result of 
unrepaired DNA damage, and the subsequent cell death, or indirectly due to the 
build-up of oxidative stress as a consequence of the persistence of breaks in 
DNA (Lavin, 2008). 
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Figure 1.4: Pathologies resulting as a consequence of improper DNA 
damage repair 
Representation of the consequences of mutated ATM, Mre11 or NBS1 on robust DNA repair. 
Mutation in ATM and Mre11 lead to Ataxia-Telangiectasia or Ataxia-Telangiectasia-Like-
Disorder (ATLD) respectively. Mutations in NBS lead to Nijmegen Breakage Syndrome. 
Adapted from (McKinnon, 2009). 
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A syndrome similar in clinical presentation to AT is Ataxia-Telangiectasia-Like 
Disorder (ATLD), characterised by a hypomorphic mutation in the MRE11 gene 
(Stewart et al., 1999). The cellular features of ATLD are extremely similar to AT 
and include radiosensitivity, radioresistant DNA synthesis (RDS; suggestive of 
defective cell-cycle arrest) and an abrogation of the ATM signalling pathway 
(Stewart et al., 1999). Whilst ATLD patients suffer from the progressive 
cerebellar ataxia seen with AT patients, they show no telangiectasia and the 
onset of neurological effects is much later in presentation, suggestive that the 
condition is less severe than AT (Taylor et al., 2004). Whilst the ATLD is 
extremely rare in comparison to AT, with only 6 cases currently identified (Pitts 
et al., 2001), the similarity in clinical presentation and cellular pathophysiology 
of the two conditions suggest that disruption of any part of the early repair 
machinery can have severe consequences on human health (Taylor et al., 
2004). 
 
Whereas mutation in ATM and MRE11 produce very similar clinical and cellular 
traits, mutation in another component of the MRN complex, NBS1, termed 
Nijmegen breakage syndrome (NBS), leads to a subtly different clinical 
presentation (Shiloh, 1997; Varon et al., 1998). In addition to similar cellular 
pathophysiology to AT/ATLD such as radiosensitivity, immunodeficiency and 
increased cancer risk, NBS patients also display characteristic facial 
appearance, microcephaly and growth retardation (Digweed and Sperling, 
2004). Over 90% of patients are homozygous for the same mutation which 
causes a deletion of five base pairs, leading to a frame shift and truncated form 
of NBS1 (Digweed and Sperling, 2004). One question that remains unanswered 
is why do NBS patients not get cerebellar degeneration that is commonly 
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associated with AT and ATLD patients, despite these proteins functioning in 
overlapping pathways. It has been hypothesised that the hypomorphic mutant 
NBS1 protein expressed in all NBS patients retains sufficient function to prevent 
progressive Purkinje and granule loss associated with the development of 
progressive cerebellar ataxia, yet the function of this protein is not sufficient to 
maintain robust DDR (Reynolds and Stewart, 2013). In addition, it has been 
proposed that the lack of functional ATM in AT patients prevents ATM/p53 
dependent apoptosis from occurring, allowing relatively normal brain 
development even in the presence of unrepaired DSBs. In NBS patients, 
functional ATM can activate the apoptotic pathway in response to the genomic 
instability arising from truncated NBS1 due to the intact NBS1 C-terminal ATM 
interacting domain, leading to neuronal cell death during development and the 
downstream development of microcephaly (Reynolds and Stewart, 2013; Shull 
et al., 2009). 
1.5 Key initial components of the DNA damage repair machinery 
In response to DNA-damage, a large macromolecular assembly of proteins 
forms at the chromatin flanking the break. The formation of this protein cluster is 
highly ordered and occurs in a strictly hierarchical fashion, with regulation of 
protein interactions controlled by a variety of PTMs including phosphorylation, 
ubiquitination and sumoylation (Bekker-Jensen and Mailand, 2010). A number 
of key proteins that are recruited to the break during the early phases of the 
DDR mediate these PTMs and are critical in maintain a robust response to DNA 
damage (Jungmichel and Stucki, 2010). 
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1.5.1 MDC1 
MDC1 (previously referred to as Nuclear Factor with BRCT Domains (NFBD1)) 
is a large phospho-scaffold binding protein involved in mammalian cell DNA 
damage repair. MDC1 was functionally characterised in a number of 
independent studies that highlighted a key role for the protein in the recruitment 
of DNA repair factors to DNA lesions, in addition to regulating downstream 
signalling associated with DNA damage response and checkpoint signalling 
(Goldberg et al., 2003; Lou et al., 2003; Peng, 2003; Shang et al., 2003; 
Stewart et al., 2003; Xu, 2003). 
1.5.1.1 MDC1 structure and functional domains 
1.5.1.1.1 Fork-head associated (FHA) domain 
MDC1 is a large, 2,089 amino acid nuclear protein with distinct functional 
domains, which are critical for protein-protein interactions with DNA damage 
repair and signalling components (Figure 1.5A). At the extreme N-terminus of 
MDC1 is a conserved fork-head associated (FHA) domain, whose precise 
function remains largely inconclusive. Loss of this phospho-specific interaction 
module from MDC1 leads to a multitude of DNA damage repair defects 
including compromised repair and checkpoint signalling defects, suggesting the 
importance of this FHA domain (Lou et al., 2003; 2006; Zhang et al., 2005). 
One of the first proteins identified as interacting with the MDC1-FHA was the 
phosphorylated phospho-T68 Chk2 (Lou et al., 2003). The study demonstrated 
that phospho-T68 could immunoprecipitate with MDC1 from cell extracts, with 
the FHA domain of MDC1 critical in this interaction. Suppression of MDC1 
expression resulted in defective S-phase checkpoint activation and reduced 
apoptosis, consistent with the role of Chk2 in the damage response (Zannini et 
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al., 2014). This phenotype could only be rescued with exogenously expressed 
MDC1 containing the FHA domain (Lou et al., 2003). Whilst this study 
demonstrated an interaction between MDC1 and Chk2 in response to DNA 
damage, subsequent studies have been unable to detect Chk2 accumulation at 
DNA damage foci, despite strong MDC1 localisation (Lukas et al., 2003). In 
addition, the process of auto- and trans-phosphorylation that activates Chk2, 
results in the loss of the ‘priming’ phospho-T68 phosphorylation (Ahn and 
Prives, 2002), which was shown as critical for the MDC1-Chk2 interaction (Lou 
et al., 2003). This suggests that the interaction between the two proteins may 
be very transient, or temporally restricted, with more work needed to understand 
the functional consequences of such an interaction (Jungmichel and Stucki, 
2010). MDC1 has also been shown to be loosely associated with ATM, an 
interaction which is reduced upon exposure to IR (Stewart et al., 2003). This 
interaction was later shown to be mediated through the FHA domain of MDC1 
(Lou et al., 2006). The study demonstrated that MDC1 bound to both γH2AX 
and ATM to form a positive feedback loop, promoting the further 
phosphorylation of γH2AX, thus amplifying the DNA damage response. Loss of 
MDC1, prevented active ATM from accumulating at DNA lesions as determined 
using immunofluorescence, which led to defective ATM signalling and IR 
sensitivity (Lou et al., 2006). Several independent studies have demonstrated 
that the FHA domain of MDC1 is required for robust HR repair, with this domain 
required for interaction with Rad51 (Xie et al., 2007; Zhang et al., 2005). Whilst 
MDC1 and Rad51 do not co-localise at DNA lesions (Goldberg et al., 2003), 
suppression of MDC1 expression resulted in impaired Rad51 foci formation and 
hypersensitivity to MMC (Zhang et al., 2005). 
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Figure 1.5: Schematic illustration of MDC1 domains and modifications 
(A) Schematic representation of the identified domains and interaction partners of MDC1. MDC1 
contains an N-terminal FHA interaction domain responsible for oligomerisation and signalling. 
Clusters of SDT and TQXF repeats are responsible for facilitating key interactions responsible 
for DNA repair and checkpoint arrest. A large proline-serine-threonine rich region plays an 
unknown role in regulating DNA repair. Two C-terminal BRCT domains are crucial for H2AX 
signalling and mitotic regulation. Adapted from (Jungmichel and Stucki, 2010). 
(B) Schematic representation of selected phosphorylation modifications identified for MDC1. 
ATM phosphorylations are coloured in red, CKII phosphorylations are coloured in blue. 
Phosphorylation data compiled from (Matsuoka et al., 2007; Spycher et al., 2008). 
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A recently identified phosphorylation site at the extreme N-terminus of the 
MDC1 FHA domain has been shown by multiple independent studies to be 
required for MDC1 dimerisation at DNA lesions, with the function of MDC1 as a 
scaffold at sites of damage dependent on this dimerisation/oligomerisation. 
Phosphorylation of the MDC1 FHA domain at T4, primarily by ATM, stimulates 
the dimerisation of MDC1 and accumulation of downstream DDR factors at sites 
of DNA damage (Jungmichel et al., 2012; Liu et al., 2012; Luo et al., 2011). The 
subsequent increase in local density of MDC1 at DNA lesions promotes 
accumulation of activated ATM at sites flanking DNA damage, further facilitating 
ATM-dependent phosphorylation of H2AX and the amplification of DNA damage 
signals (Lou et al., 2006). Despite these observations, it remains largely unclear 
what impact the attenuation of MDC1 dimerisation has on the cells ability to 
promote DNA repair and checkpoint activation. 
1.5.1.1.2 SDT-repeat domain 
Distal to the FHA domain of MDC1 lies the SDT-repeat region, consisting of 
conserved repeats of 8-10 amino acids comprising serine and threonine 
residues embedded in an acidic sequence environment (Jungmichel and Stucki, 
2010). The acidophilic casein kinase 2 (CK2) phosphorylates multiple sites 
within this region, promoting the damage-independent interaction between the 
SDT-repeat of MDC1 and the FHA and BRCT domains of NBS1 (Chapman and 
Jackson, 2008; Melander et al., 2008; Spycher et al., 2008; Wu et al., 2008). 
Expression of MDC1 lacking the SDT-repeat region leads to reduced MRN 
staining at IRIF, suggesting that whilst the interaction between MDC1 and NBS1 
is not essential for the initial recruitment of the MRN complex to sites of DNA 
damage, sustained interaction at the DNA lesions is dependent on MDC1 
binding (Chapman and Jackson, 2008; Jungmichel and Stucki, 2010). Figure 
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1.5B demonstrates the number of CK2 phosphorylation sites present in the 
SDT-repeat region of MDC1 as identified by mass-spectrometry; a number of 
which have been shown as important for maintenance of the MDC1-NBS1 
interaction (Spycher et al., 2008). Progressive attenuation of the SDT-repeat 
region of MDC1 prevents binding to NBS1, with a reduction in associated NBS1 
dependent on the number of S/T to A mutations present (Melander et al., 2008; 
Spycher et al., 2008). Consistent with this, mutations in either the FHA or BRCT 
domain of NBS1 abolish the interaction and impair the localisation of the MRN 
to IRIF (Lloyd et al., 2009; Wu et al., 2008). Although the interaction between 
MDC1 and NBS1 has been well studied, the functional consequence of the 
interaction remain elusive. One school of thought is that MDC1-MRN interaction 
may act to enhance the DSB-induced signalling via a positive feedback loop, 
promoting phosphorylation of distal chromatin regions and thus increasing the 
protein density at DNA lesions (Spycher et al., 2008). Other groups are more 
specific in suggesting that the interaction is required for intra S-phase 
checkpoint activation in response to damage (Wu et al., 2008); a role with which 
MDC1 has previously been linked (Goldberg et al., 2003; Stewart et al., 2003). 
1.5.1.1.3 TQXF-Cluster 
C-terminal to the SDT-repeats, is a cluster of four TQ motifs which are followed 
by a phenylalanine at the +3 position, referred to as the TQXF cluster (Coster 
and Goldberg, 2010). This region has been shown to bind the E3 ubiquitin 
ligase RNF8, with the FHA domain of RNF8 binding to the phosphorylated 
threonine residues (Huen et al., 2007; Kolas et al., 2007; Mailand et al., 2007). 
In addition to an FHA domain, RNF8 also contains a RING domain, the function 
of which is critical for BRCA1 and 53BP1 recruitment to DNA lesions. Mutation 
or deletion of this domain prevented the poly-ubiquitination of histones H2A and 
48 
H2AX at DNA lesions and prevented BRCA1 and 53BP1 recruitment (Huen et 
al., 2007; Kolas et al., 2007; Mailand et al., 2007). Phosphorylation of MDC1 at 
the TQXF cluster is ATM mediated and damage dependent, thus recruitment of 
RNF8 to sites of DNA damage occurs in a damage-dependent manner. Like the 
SDT-repeat domain on MDC1, a redundancy of phosphorylation sites exists, 
with binding of RNF8 to MDC1 at the TQXF-cluster requiring only a single 
phosphorylated threonine residue (Coster and Goldberg, 2010; Kolas et al., 
2007). A recent study found that an additional level of control exists to regulate 
the MDC1 and RNF8 interaction during mitosis. Previous observation had 
shown that RNF8 was not recruited to sites of DNA damage during early 
mitosis, with full DDR only occurring in the following G1 phase (Giunta et al., 
2010; Giunta and Jackson, 2011). This idea was further explored to show that 
the during mitosis, the mitotic kinase CDK1 phosphorylates RNF8 outside of the 
FHA domain, preventing RNF8 binding to phosphorylated MDC1 in response to 
DNA damage during mitosis (Orthwein et al., 2014). Blocking CDK1 
phosphorylation of RNF8 restored the interaction with MDC1, subsequently 
activating DNA repair during mitosis, which paradoxically is deleterious due to 
DNA repair occurring at telomeres, resulting in telomeric fusion (Orthwein et al., 
2014) 
1.5.1.1.4 Proline-Serine-Threonine (PST)-rich domain 
The precise role of the poorly conserved Proline-Serine-Threonine (PST)-rich 
region of MDC1 remains elusive, with a number of independent studies 
demonstrating differing roles for this domain of MDC1 (Jungmichel and Stucki, 
2010).  MDC1 has previously been reported to play a role in mitosis, with the 
protein heavily phosphorylated during the mitotic cell cycle phase (Figure 1.5B) 
(Dephoure et al., 2008). MDC1 has been shown to bind with a subunit of the 
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anaphase-promoting complex/cyclosome (APC/C), an interaction dependent 
upon the C-terminal BRCT and PST-rich domain. This interaction regulates 
normal metaphase-to-anaphase transition via modulation of APC/C E3 ubiquitin 
ligase activity (Coster et al., 2007; Townsend et al., 2009). Mutated MDC1 
lacking the PST-rich region was unable to bind APC/C in vitro and was unable 
to rescue the metaphase mitotic block caused by siRNA depletion of 
endogenous MDC1 (Townsend et al., 2009). In addition to a probable role in 
controlling MDC1 function during mitosis, the PST-rich region has also been 
implicated in the regulation of DNA repair by both NHEJ (Lou et al., 2004) and 
HR repair (Xie et al., 2007). In regulating NHEJ, it was proposed that MDC1 
binds the DNA-PK complex, with down regulation of MDC1 by siRNA resulting 
in defective phospho-DNA-PKcs foci formation and defective NHEJ repair (Lou 
et al., 2004). In addition, more recent work has demonstrated a function of the 
MDC1 PST-rich domain in maintaining robust HR repair. Whilst deletion of the 
PST-rich domain did not affect MDC1 recruitment to γH2AX, DNA repair by HR 
was compromised (Xie et al., 2007). More work is needed to elucidate the 
precise mechanism by which deletion of the PST-rich region leads to 
compromised HR repair. 
1.5.1.1.5 Tandem BRCA1 carboxy-terminal (tBRCT) domains 
The most C-terminal functional regions of MDC1 are the tandem BRCA1 
carboxy-terminal (tBRCT) domains, deletion of which abrogates MDC1 foci 
formation in response to DNA damage (Shang et al., 2003). Several 
independent studies showed that the tBRCT domain of MDC1 displayed high 
specificity for the ATM-phosphorylated C-terminus of histone H2AX, allowing 
the downstream protein recruitment associated with MDC1 at DNA lesions (Lee 
et al., 2005; Lou et al., 2006; Stucki et al., 2005). Although the binding of γH2AX 
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is likely the principle function of the tBRCT domains, other binding partners 
have been associated with this domain. As mentioned previously, MDC1 
interacts with a phosphorylated subunit of the APC/C complex, phospho-
CDC27, which occurs through both the PST-rich domain and the tBRCT domain 
(Coster et al., 2007). As the C-terminal phosphorylation motif of CDC27 is 
similar to γH2AX, it is likely that both proteins bind MDC1 via the same 
mechanism (Coster and Goldberg, 2010). In addition to the evidence that the 
tBRCT domain binds to γH2AX and components of the APC/C, some tentative 
evidence exists that MDC1 binds 53BP1 through the same region. One 
exploratory study established that 53BP1 and MDC1 interact directly through 
the tBRCT domain of MDC1 and residues 1288 –1409 of 53BP1, in the 
presence of DNA damage. They went on to demonstrate that the interaction is 
required for 53BP1 focus formation (Eliezer et al., 2008). Subsequent studies 
have gone on to show that RNF168 also interacts with 53BP1 in damaged cells, 
with the loss of RNF168 attenuating the 53BP1–MDC1 interaction (Bohgaki et 
al., 2013).  Consistent with this, the interaction of exogenous 53BP1 and MDC1 
was enhanced in the presence of exogenous RNF168 protein, suggesting that 
RNF168 interacts with 53BP1 and MDC1, which facilitates the formation of a 
protein complex that includes these three proteins (Bohgaki et al., 2013). 
1.5.1.2 MDC1 and DNA repair 
The process of DNA repair begins with the rapid assembly of a number of DDR 
proteins at the chromatin regions flanking the break. The initial recruitment of 
proteins to the DNA lesion leads to substantial downstream amplification, which 
promotes the recruitment, retention and activation of downstream DDR 
components, leading to DNA repair (Coster and Goldberg, 2010). The process 
of converting initially small protein recruitment to a signal large enough to 
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trigger full activation of the DDR is critical and largely dependent on the activity 
of the phospho-scaffold protein MDC1 (Lou et al., 2006). 
 
As discussed previously, ATM-dependent phosphorylation of the C-terminal tail 
of histone variant H2AX at chromatin regions flanking the double-strand break 
initiates the signalling cascade associated with DNA repair, providing a binding 
platform for MDC1 through the tBRCT domain (Lee et al., 2005; Stucki et al., 
2005). In addition to the well-characterised S139 phosphorylation of γH2AX, an 
additional modification has been shown to promote DNA repair in damaged 
cells. WSTF (Williams–Beuren syndrome transcription factor) phosphorylates 
Y142 of H2AX in undamaged cells, preventing interaction of γH2AX with 
downstream DDR components. Upon damage, the novel phosphatase EYA 
dephosphorylates this residue, which promotes the interaction between 
phosphorylated S139 γH2AX and MDC1 (Cook et al., 2009; Xiao et al., 2008) It 
has been shown that the γH2AX-MDC1 interaction serves a dual purpose. 
Firstly, MDC1 acts to facilitate the recruitment of down-stream repair proteins to 
sites of DNA damage (Stucki and Jackson, 2006). Loss of MDC1 prevents the 
retention of NBS1 and 53BP1 at damage sites (Bekker-Jensen, 2005; Lukas et 
al., 2004a), and also ATM via the interaction with the MRN complex (Falck et 
al., 2005). Secondly, the interaction between γH2AX and MDC1 is vital for 
signal amplification at IRIF. Through an interaction with γH2AX at the tBRCT 
domains and ATM at the FHA domains, MDC1 accumulates activated ATM 
flanking the sites of DNA damage, facilitating further ATM-dependent 
phosphorylation of H2AX and the amplification of DNA damage signals (Lou et 
al., 2006). Indeed, loss of MDC1 prevents this localised amplification, resulting 
in reduced γH2AX S139 phosphorylation and compromised protein recruitment 
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to IRIF (Lou et al., 2006; Stucki et al., 2005). Once recruited to DNA lesions, 
MDC1 is phosphorylated directly by ATM at the TQXF cluster, which promotes 
binding to the FHA domain of the E3 ubiquitin ligase RNF8 (Huen et al., 2007; 
Kolas et al., 2007; Mailand et al., 2007). The recruitment of RNF8 to DNA 
lesions is important to generate the ubiquitin-conjugates required for 53BP1 and 
BRCA1 recruitment to the IRIF, with disruption of the MDC1-RNF8 interaction 
leading to loss of 53BP1 and BRCA1 recruitment (Huen et al., 2007; Mailand et 
al., 2007). 
 
Whilst the role of MDC1 in recruitment and amplification at DNA lesions is well 
explored, the function of MDC1 in DNA repair is less well understood. In DNA 
repair by NHEJ, it was shown that MDC1 binds the DNA-PK complex, with 
down regulation of MDC1 resulting in defective phospho-DNK-PKcs foci 
formation and defective NHEJ repair (Lou et al., 2004). In addition, MDC1 has 
been shown to be necessary robust HR repair, via a direct interaction with 
Rad51 (Xie et al., 2007; Zhang et al., 2005). Whilst MDC1 and Rad51 do not 
co-localise at DNA lesions (Goldberg et al., 2003), suppression of MDC1 
expression resulted in increased Rad51 degradation, coupled with impaired 
Rad51 foci formation and hypersensitivity to MMC (Zhang et al., 2005). 
 
Unlike γH2AX, which is extensively targeted by Ser/Thr protein phosphatases 
following resolution of damage (discussed in depth later) (Freeman and 
Monteiro, 2010), very little is known about dephosphorylation of MDC1. MDC1 
has been shown to be removed from DNA foci via ubiquitin mediated 
degradation (Shi et al., 2008). Sumoylation of MDC1 by PIAS4 at lysine 1840 
targets the protein for ubiquitination and degradation by the E3 ligase RNF4 
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(Galanty et al., 2012; Yin et al., 2012). Consistent with mis-localisation and 
persistence of DNA foci, mutation of the MDC1 K1840 resulted in impaired RPA 
and Rad51 accumulation at IRIF and defective homologous recombination (Luo 
et al., 2012).   
 
1.5.1.3 MDC1 involvement in cell cycle control, apoptosis and mitosis  
In addition to the key function of MDC1 in recruitment of DDR proteins to sites 
of damage and amplification of ATM signalling, MDC1 has also been implicated 
in the function of the intra-S-phase checkpoint. Loss of MDC1 resulted in a 
defective intra-S-phase checkpoint (Stewart et al., 2003), with cells displaying 
radio resistant DNA synthesis (RDS) (Goldberg et al., 2003; Lou et al., 2003), 
consistent with DNA synthesis occurring despite the presence of damaged DNA 
(Falck et al., 2001). Two parallel pathways regulate the intra-S-phase 
checkpoint, both regulated by ATM. ATM phosphorylation of Chk2 at T68 
induces the destruction of CDC25A, which locks the CDK2/CycE S-phase 
promoting complex in an inactive form (Falck et al., 2002). Several independent 
studies have demonstrated that MDC1 binds phosphorylated Chk2, implicating 
MDC1 in the pathway (Lou et al., 2003; Wu et al., 2012). In addition ATM 
phosphorylation of NBS1, resulting in activation of the MRN complex, can also 
lead to activation of the intra-S-phase checkpoint, however the precise 
molecular mechanism remains unclear (Falck et al., 2002). It has been shown 
that disruption of NBS1-MDC1 binding results in a failure of NBS1 accumulation 
at DNA lesions and impairment of intra-S-phase checkpoint activation (Wu et 
al., 2008). In summary, whilst it is clear that MDC1 plays a key a critical role in 
the regulation or activation of the intra-S-phase checkpoint, the precise 
molecular mechanism for this remains unclear. 
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A growing body of evidence exists which supports the idea that MDC1 is able to 
supress apoptosis during the DNA damage response, allowing time for DNA 
repair. MDC1 was demonstrated to bind p53 through the tBRCT domain, with 
over-expression of MDC1 resulting in the inhibition of ATM-dependent 
phosphorylation of p53 at S15, leading to destabilisation of the protein and a 
reduction in the transcription of pro-apoptotic genes (Nakanishi et al., 2007). A 
subsequent study also revealed that MDC1 binds to and stabilises MDM2 
through the tBRCT domain, with stabilised MDM2 then able to target p53 for 
ubiquitination and proteosomal degradation (Inoue et al., 2008). 
 
As mentioned previously, MDC1 has been reported to play a role in mitosis, 
with strong evidence that the protein is heavily phosphorylated during the 
mitotic cell cycle phase (Figure 1.5B) (Dephoure et al., 2008). The anaphase-
promoting complex/cyclosome (APC/C) is responsible for the proteasome-
mediated degradation of cell cycle regulators during mitosis and is required for 
sister separation during anaphase and mitotic exit (McLean et al., 2011; 
Vodermaier, 2004). MDC1 has been shown to bind with a subunit of APC/C, an 
interaction dependent upon the C-terminal BRCT and PST-rich domain (Coster 
et al., 2007; Townsend et al., 2009). Mutated MDC1 lacking the PST-rich region 
was unable to bind APC/C in vitro and was unable to rescue the metaphase 
mitotic block caused by siRNA depletion of endogenous MDC1 (Townsend et 
al., 2009). In addition to promoting mitotic progression, MDC1 has also been 
implicated in the regulation of the spindle assembly checkpoint (SAC). The 
Goldberg group demonstrated that following SAC activation, ATM 
phosphorylates histone H2AX at mitotic kinetochores, which promotes MDC1 
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localisation to mitotic kinetochores (Eliezer et al., 2014). The study went on to 
show that kinetochore localised MDC1 was needed for kinetochore localisation 
of the inhibitory mitotic checkpoint complex components, Mad2 and Cdc20, and 
for the maintenance of the mitotic checkpoint complex integrity (Eliezer et al., 
2014). Whilst the precise function of MDC1 at kinetochores remains unclear; the 
involvement of MDC1 in the SAC does propose a possible link between the 
DDR and cell cycle regulation. 
1.5.2 The MRN Complex 
The MRN complex, consisting of the core components MRE11, RAD50 and 
NBS1, plays a critical role in sensing damaged DNA, propagating resultant 
signalling and repairing the damaged DNA (Czornak et al., 2008). The different 
activities of the MRN complex are functionally distinct and are dependent on 
key regions and domains of the various components (Buis et al., 2008). The 
importance of the complex in robust DNA repair is highlighted by the number of 
conditions arising as a result of genetic mutations in any of the components as 
discussed previously. Indeed, null mutations in any of the three genes leads to 
embryonic lethality in mice (Luo et al., 1999; Xiao and Weaver, 1997; Zhu et al., 
2001). 
1.5.2.1 MRN complex components 
1.5.2.1.1 MRE11 
MRE11 is an 80 kDa protein which acts as the core of the MRN complex, 
interacting independently with both NBS1 and RAD50, whilst also forming 
homodimers and multimers with itself (D'Amours and Jackson, 2002; Desai-
Mehta et al., 2001). The MRE11 dimer acts as the core MRN complex, binding 
two molecules of RAD50, with the MRE11-RAD50 complex finally binding a 
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single molecule of NBS1 (van der Linden et al., 2009). The N-terminal region of 
MRE11 contains four phosphoesterase motifs which are necessary for the 3’-5’ 
double-strand DNA exonuclease activity and single-stranded/double-stranded 
endonuclease activity (Paull and Gellert, 1998; Trujillo et al., 1998). This activity 
has been demonstrated as being structure specific, with MRE11 nuclease 
activity most active at blunt ended or 3’-recessed DNA (Trujillo and Sung, 
2001). Both the exo- and endonuclease activity of MRE11 can be regulated via 
the binding of the other MRN components RAD50 and NBS1. Rad50 binding to 
MRE11 stimulates both exo- and endonuclease activity, whilst NBS1 binding 
only stimulates the endonuclease activity of MRE11 (Paull and Gellert, 1999; 
Trujillo and Sung, 2001). 
1.5.2.1.2 RAD50 
RAD50 is a large, 150 kDa protein which contains walker A and B nucleotide-
binding motifs at both the N- and C-terminal ends, which have been shown to 
be crucial for MRN function (D'Amours and Jackson, 2002). RAD50 shares 
structural similarity with the ‘structural maintenance of chromosome’ (SMC) 
proteins, which act to regulate chromatid cohesion. The principle function of 
RAD50 is to bind DNA ends and hold them in close proximity (de Jager et al., 
2001). In the presence of ATP, the two walker A and B motifs facilitate RAD50 
binding and unwinding of DNA (Chen et al., 2005a; de Jager et al., 2002). Once 
bound, a central hinge region between the two walker A and B motifs allows the 
protein to fold onto itself forming a functional ATP-binding domain (Hopfner et 
al., 2000). The presence of ATP forces the RAD50-MRE11 complex into a state 
that promotes the intercomplex interaction required for DNA tethering (Moreno-
Herrero et al., 2005). The importance of such DNA tethering is clear and there 
have been several suggestions as to how this tethering activity can promote 
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survival in response to DSB. It has been suggested that the tethering of DNA 
ends could facilitate the search for homology regions, crucial for HR repair. In 
addition it has also been suggested that the DNA tethering may prevent 
physical separation of chromatid fragments and promote the local activity of 
DNA ligases during NHEJ repair (Chen et al., 2001; D'Amours and Jackson, 
2002). 
1.5.2.1.3 NBS1 
The NBS1 protein lacks any enzymatic activity but is essential for the 
recruitment of the MRN complex to the nucleus and sites of DNA damage via 
the NLS present in NBS1 (Desai-Mehta et al., 2001). The presence of the N-
terminal FHA and tBRCT domains of NBS1 allows interaction and recruitment of 
key DDR factors to DSBs, which includes CtIP and MDC1 (Lloyd et al., 2009; 
Williams et al., 2009). The interaction between MDC1 and NBS1 has been 
shown to be necessary for chromatin retention of the MRN complex at DNA 
lesions (Chapman and Jackson, 2008; Spycher et al., 2008). In addition, the C-
terminal end of NBS1 contains an ATM interacting motif which facilitates the 
recruitment and activation of ATM at sites of DNA damage (Falck et al., 2005; 
Lee and Paull, 2005; You et al., 2005).  
1.5.2.2 MRN complex and ATM activation 
The ATM kinase plays a central role in the signalling associated with the 
response to DNA damage. The MRN complex plays a crucial role both in the 
recruitment of ATM to sites of DNA damage and the subsequent activation of 
the kinase locally at DSB (Uziel et al., 2003). ATM binding to such sites is 
dependent on functional MRE11, with initial MRN recruitment to DSB possibly 
dependent on Rad17 activity (Uziel et al., 2003; Wang et al., 2014). 
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The ability of the MRN complex to activate ATM has been demonstrated in vitro, 
with inactive ATM dimers activated in the presence of DNA and MRN (Lee and 
Paull, 2005). The unwinding of DNA ends by MRN was essential for this ATM 
activation, consistent with observations that ssDNA acts as a conserved signal 
for DNA damage (D'Amours and Jackson, 2002; Lee and Paull, 2005). More 
recent work has demonstrated that the ATP-bound form of MRN is the critical 
conformation for ATM activation (Lee et al., 2013). Whilst it is likely that the core 
MRE11-RAD50 complex is necessary for ATM activation, it has been reported 
that the C-terminal region of NBS1 is critical for ATM interaction and 
localisation, with wild type MRN not necessary for the MRN-ATM interaction 
(Falck et al., 2005). Interestingly, IR treatment does not enhance the ATM-MRN 
complex formation, instead the study found that DNA ends stabilises the 
interaction (Falck et al., 2005). 
1.5.2.3 MRN complex involvement in DNA damage repair 
In addition to a role in recruiting and activating ATM, the MRN complex also 
plays a role in DNA repair which is independent of ATM activation (Buis et al., 
2008). Whilst it has previously been reported that the MRN complex associates 
at DNA lesions via an interaction with γH2AX (Kobayashi et al., 2002), more 
recent studies have consistently reported that the MRN complex binds to MDC1 
at DSB, likely through FHA domain of NBS1 (Lukas et al., 2004a). Consistent 
with this, abrogation of MDC1 binding to γH2AX prevents MRN recruitment to 
sites of DNA damage, suggesting that MDC1-MRN are directly interacting (Lou 
et al., 2006; Lukas et al., 2004b). Several studies demonstrated that the SDT-
repeat region of MDC1 bound to the FHA domain of NBS1, facilitating this 
binding (Chapman and Jackson, 2008; Melander et al., 2008; Spycher et al., 
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2008). The MRN complex bound to DNA ends can then act to tether the break 
facilitating repair by NHEJ or alternatively initiate resection prior to repair by 
homologous recombination. MRE11 together with CtIP initiates 5’-3’ resection 
(which is continued by EXOI/DNA2 in conjunction with the BLM helicase), 
allowing for downstream RPA coating and subsequent processing (Gravel et 
al., 2008; Renkawitz et al., 2014). 
1.6 Transducer kinases and cell-cycle control during DSB repair 
1.6.1 Cell-cycle checkpoints in response to DNA damage 
The DNA damage checkpoint network is composed of a number of DNA 
damage sensor kinases (the PI3Ks such as ATM and DNA-PK), transducer 
kinases (such as Chk1/Chk2) and effector molecules (such as p53), whose 
substrates and activities mediate cell cycle arrest at various stages of the cell 
cycle, DNA repair, and cell death via apoptosis (Figure 1.2) (Bartek and Lukas, 
2007). It has long been understood that the DNA damage response temporarily 
halts cell growth and proliferation, allowing time for precise DNA repair, after 
which normal cell homeostasis is restored. However it is becoming more 
apparent that the activity is a much more two-way process; with cell cycle 
machinery acting to regulate the DDR via repair pathway choices, and vice 
versa, with the precise mechanism of DDR arrest of the cell cycle dependent on 
cell cycle stage (Shaltiel et al., 2015). 
 
The basic mammalian cell cycle consists of four distinct phases. The first of 
these phases is S-phase (synthesis) during which the genome of the cell is 
duplicated to provide an exact copy for subsequent daughter cells. This is 
followed by G2 (gap phase 2), during which protein synthesis is performed to 
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ensure a viable proteome for both daughter cells. The daughter cells are 
produced during the M-phase (mitotic), in which DNA is condensed into 
chromosomes, which separate forming two identical daughter cells. Finally, G1 
(gap phase 1) allows the newly formed daughter cells to synthesise proteins 
and grow in size in preparation for the new S-phase (Hartwell and Kastan, 
1994). A number of checkpoints exist between the various cell cycle stages, to 
ensure that progression is only permitted if relevant criteria are met. In addition 
to these homeostatic checkpoints, a number of DNA damage dependent 
checkpoints are present to ensure that the cell cycle is stalled to aid in DNA 
repair (Figure 1.6) (Houtgraaf et al., 2006). The figure highlights the three main 
checkpoints which can be activated in response to DNA damage: G1/S 
checkpoint, intra S-phase checkpoint and G2/M checkpoint. Whilst all three 
checkpoints temporarily stall the cell cycle during different phases, they operate 
via a common set of sensor kinases, transducer kinases and effector molecules 
(Tasat and Yakisich, 2010; Wang et al., 2009b). 
 
The precise function and activity of the sensor kinases ATM and DNA-PK have 
been covered in detail in previous sections of this chapter. This section will look 
to explore the complex signal transduction associated with the transducer 
kinases Chk1 and Chk2, incorporating the multifaceted role of the effector 
molecule p53 during the arrest of the cell cycle in response to DNA damage. 
1.6.2 Chk1 
Checkpoint kinase 1 (Chk1) is responsible for the phosphorylation of key 
regulators of the cyclin dependent kinases (CDK) in response to DNA damage, 
resulting in the inactivation of CDK and blockade of cell cycle progression (Patil 
et al., 2013). Chk1 protein is highly conserved between eukaryotic species and 
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contains an N-terminal kinase domain in addition to a SQ/TQ cluster domain 
(Sanchez et al., 1997). Damaged DNA leads to the activation of the PI3K 
kinase ATR, which phosphorylates Chk1 at S317 and S345, resulting in 
activation of the kinase and initiation of the downstream signal transduction (Liu 
et al., 2000; Zhao and Piwnica-Worms, 2001). It has been shown that the N-
terminal kinase domain of Chk1 is constitutively active, with ATR 
phosphorylation driving conformational change which allows the kinase domain 
to interact with Chk1 substrates (Patil et al., 2013). Phosphorylation by Chk1 
can promote to DNA repair pathway choices, activate any of the three cell-cycle 
checkpoints or inhibit p53-dependent apoptosis in damaged cells (Dai and 
Grant, 2010; Roos and Kaina, 2006). 
 
Arrest of the cell cycle by Chk1 is achieved via the phosphorylation of the 
CDC25 family of phosphatases. Chk1 is capable of phosphorylating two (A and 
C) mammalian isoforms, dependent on the checkpoint activated (Sanchez et 
al., 1997). Phosphorylation of CDC25A by Chk1 at S123 leads to ubiquitination 
of CDC25A followed by proteosomal degradation. Loss of CDC25A 
phosphatase activity results in sustained inhibitory phosphorylation of CDK1 
and CDK2 leading to activation of G1/S, intra S-phase and G2/M checkpoints 
(Donzelli and Draetta, 2003; Mailand et al., 2000). Activated Chk1 also 
phosphorylates CDC25C at S216, creating a binding site for 14-3-3 proteins 
that leads to CDC25C nuclear export (Peng et al., 1997; Pines, 1999). Lack of 
active CDC25C phosphatase in the nucleus prevents CDK1/Cyclin B 
dephosphorylation and thus activates the G2/M checkpoint (Sanchez et al., 
1997). In addition to arresting the cell cycle in response to DNA damage, Chk1 
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Figure 1.6: Activation of cell cycle checkpoints following DNA damage 
Schematic representation of cell cycle shows three major checkpoints in the cell cycle following 
DNA damage: G1/S checkpoint, Intra S-phase checkpoint and G2/M checkpoint. Compiled from 
(Tasat and Yakisich, 2010; Wang et al., 2009b). 
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is also able to slow DNA replication in a CDC25/CDK independent manner, by 
regulating the association between Cdc45 and Mcm7 at origins of replication 
(Liu et al., 2006). 
 
Chk1 participates not just in the arrest of cell cycle progression upon damage, 
but also in the repair process itself, phosphorylating key repair proteins upon 
activation by ATM or ATR. Phosphorylation of the Fanconi Anaemia complex 
protein FANCE at T346 and S374 facilitates the repair of DNA inter-strand cross 
link damage by promoting interaction with FANCD2 at DNA lesions (Wang et 
al., 2007). Chk1 is also a key regulator of genomic stability by HR repair, via an 
interaction with Rad51. Chk1 interacts with, and phosphorylates Rad51 at T309 
promoting recruitment of Rad51 to DNA lesions (Sørensen et al., 2005). In 
addition, Chk1 phosphorylates the BRCA2 C-terminal domain at T3387; a 
modification which is critical role in regulating the binding of Rad51 to BRCA2 
and subsequent recruitment of Rad51 to DNA lesions (Bahassi et al., 2008). 
Cells depleted of Chk1, or expressing a phosphorylation-deficient mutant, failed 
to form Rad51 foci and displayed persistent, unrepaired DNA double-strand 
breaks (Smith et al., 2010). 
 
Multiple studies have revealed that Chk1 inhibition or depletion led to a 
significant increase in cell death after treatment with genotoxic stress 
suggesting a possible role for Chk1 inhibition of apoptosis upon DNA damage 
via ATM and ATR dependent suppression of caspase 2 and caspase 3 
activation (Myers et al., 2009; Sidi et al., 2008). This presents Chk1 as a 
promising cancer therapy target, as inactivation or inhibition of Chk1 kinase 
activity could promote p53-independent activation of apoptosis in p53 deficient 
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cancerous cells (Zhou and Bartek, 2004). Combination therapy of Chk1 
inhibitors with either anti-mitotics (Xiao et al., 2005) or DNA-damaging 
irradiation treatment, enhanced therapeutic efficacy (Koniaras et al., 2001). 
Clinical data further validates evidence that targeting Chk1 may have positive 
clinical outcomes. A patient with an advanced, gemcitabine-resistant, 
pancreatic tumour was treated with MMC and responded positively for over 36 
months due to the tumour carrying mutations in PALB2 which disrupted key 
BRCA1 and BRCA2 interactions (Villarroel et al., 2011). 
1.6.3 Chk2 
Chk2 is the second transducer kinase to play an important role during the DNA 
damage response to mediate cell cycle arrest at various stages of the cell cycle, 
DNA repair, and cell death via apoptosis (Bartek and Lukas, 2007). Chk2 is 
principally involved in the response to DSBs, mediated by the activity of ATM 
(Zannini et al., 2014). Chk2 contains an N-terminal SQ/TQ cluster, the site of 
phosphorylation by PIKK-kinases, in addition to an FHA interaction domain and 
a C-terminal kinase domain (Ahn et al., 2004). ATM principally activates Chk2 in 
response to DNA damage. Active ATM phosphorylates inactive monomeric 
Chk2 at T68, which induces a conformational change inducing Chk2 
dimerisation through binding to the FHA domain of another Chk2 monomer 
(Ahn et al., 2000; 2002). The process of dimerisation triggers extensive Chk2 
autophosphorylation of the kinase domain (Guo et al., 2010), in addition to 
phosphorylation of the active loop at T383, T387 and S516 (Schwarz et al., 
2003). This process of auto- and trans-phosphorylation activates the kinase and 
the resultant active Chk2 splits to form active monomers, resulting in the loss of 
the ‘priming’ phospho-T68 phosphorylation (Ahn and Prives, 2002). 
Phosphorylation of Chk2 at this site is highly dynamic and regulated by the 
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action of Ser/Thr protein phosphatases, which will be discussed later in this 
chapter. Chk2 phosphorylates in excess of 24 proteins at a RxxS or RxxT motif 
in response to DNA damage (Seo et al., 2003), which can act to promote DNA 
repair, activate the G2/M or S-phase checkpoint or promote apoptosis should 
damage be deemed un-repairable (Zannini et al., 2014). 
 
Much like ATR-regulated Chk1, ATM-regulated Chk2 can phosphorylate both 
CDC25A and CDC25C, preventing the phosphatase activity and thus stalling 
cell cycle progression (Donzelli and Draetta, 2003). Indeed, following activation 
by ATM, Chk2 can also phosphorylate CDC25C on S216, creating a binding 
site for 14-3-3 scaffold proteins, resulting in CDC25C nuclear export (Peng et 
al., 1997; Pines, 1999). Lack of active CDC25C phosphatase in the nucleus 
prevents CDK1/Cyclin B dephosphorylation at T14 and thus activates the G2/M 
checkpoint (Sanchez et al., 1997). In the presence of DNA damage, activated 
Chk2 also phosphorylates CDC25A at S123, which targets the phosphatase for 
proteosomal degradation (Falck et al., 2001). This loss of functional CDC25A 
activity results in the sustained phosphorylation and inhibition of phospho-T14-
CDK2, activating the G1/S checkpoint. In addition, the lack of active 
CDK2/Cyclin E and Cdc45 loading inhibits both early and late origins resulting 
in an intra S-phase arrest (Donzelli and Draetta, 2003). Robust signalling of the 
ATM-Chk2-CDC25A-CDK2 pathway is critical to prevent radio-resistant DNA 
synthesis (Falck et al., 2001; 2002). As well as activating the G1 checkpoint 
through phosphorylation and degradation of CDC25A, Chk2 phosphorylates 
p53 at S20 in response to DNA damage, leading to stabilisation of p53 and 
transcription of p21, which inhibits CDK2 and sustains the G1/S checkpoint 
(Chehab et al., 2000; Hirao et al., 2000; Mirzayans et al., 2012). 
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In a manner similar to Chk1, Chk2 phosphorylates BRCA2 at T3387, which 
disrupts the BRCA2-Rad51 constitutive interaction, promoting Rad51 
recruitment to DNA lesions (Bahassi et al., 2008). In addition, Chk2 
phosphorylates BRCA1 at S988 which further facilitates the recruitment of 
Rad51 to sites of damage, in addition to supressing the NHEJ repair pathway 
(Lee et al., 2000). The promotion of HR repair over NHEJ repair is dependent 
mainly upon BRCA1 phosphorylation by Chk2 and is not dependent on ATM 
phosphorylation of BRCA1 (Zhang et al., 2004). As well as regulating the 
recruitment of Rad51 to DNA lesions, Chk2 phosphorylation has also recently 
been shown to control heterochromatin remodelling at sites of damage to allow 
for the recruitment of repair factors. Chk2 dependent phosphorylation of 
Krüppel-associated box (KRAB)-associated protein 1 (KAP1) at S473 
attenuated binding of KAP1 with the heterochromatin packaging factor 
heterochromatin protein 1-β (HP1-β). Release of HP1-β relaxes the chromatin 
structure, leading to chromatin restructuring at sites of DNA damage (Hu et al., 
2012). 
 
Unlike Chk1, DNA damage dependent phosphorylation by Chk2 promotes 
apoptosis in cells where the amount of DNA damage is irreparable (Ciccia and 
Elledge, 2010). Chk2 control apoptosis through phosphorylation of p53, which 
serves as a regulator of the apoptotic process that can modulate key control 
points in both the extrinsic and intrinsic pathways (Fridman and Lowe, 2003). 
Damage-dependent phosphorylation of p53 at multiple C-terminal 
phosphorylation sites stabilises the p53 protein and causes the dissociation and 
degradation of the p53 inhibitor MDMX (Chen, 2012; Ou et al., 2005). Indeed, 
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direct phosphorylation of MDMX by Chk2 promotes binding of MDMX with 14-3-
3 proteins, preventing normal localisation between the nucleus and cytoplasm, 
resulting in MDM2-dependent degradation of MDMX (Chen et al., 2005b; 
LeBron et al., 2006). Due to the pro-apoptotic role of Chk2 in response to 
genotoxic stress, the use of Chk2 inhibitors as single or combination therapy in 
cancer has yielded mixed results. On the one hand, inhibition of Chk2 prevents 
cell-cycle checkpoint activation and repair pathway choice, which would have a 
negative effect on cell survival; yet conversely, preventing apoptotic induction 
through p53 may be detrimental. Despite this, several recent studies have 
demonstrated that inhibition of Chk2 in combination with standard 
chemotherapies led to improved clinical outcome in multiple cancer types 
(Duong et al., 2013; Gutiérrez-González et al., 2012). Chk2 specificity is 
challenging to achieve, with many compounds also active on Chk1, as such 
most clinical success with such combination therapy has been achieved using 
dual-specificity transducer kinase inhibitors (Garrett and Collins, 2011). 
1.7 The role of Serine/Threonine protein phosphatases in response to 
DNA damage 
1.7.1 Overview of phosphatases in the DDR 
There are multiple phosphatases involved in the DNA damage response which 
act at all stages in the process. A mass-spectrometry based approach to assess 
the nuclear phospho-proteome during the DNA damage response identified 594 
unique phosphorylation events upon damage, but in addition observed a 
considerable number of sites that underwent DNA damage-induced 
dephosphorylation (Bennetzen et al., 2010). This evidence highlights the 
importance of the phosphatases in all stages of DDR; from initiating DNA-
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damage repair by dephosphorylation of protein targets, to reversal of the 
damage-induced phosphorylation events upon resolution of DNA damage 
repair. Figure 1.7 demonstrates the complexity and cross-talk that exists 
between the phosphatases and phosphorylation targets. The large number of 
phosphatases linked with specific process, such as the dephosphorylation of 
γH2AX is intriguing, with some groups suggesting that these phosphatases do 
not act redundantly, rather each might respond to different types of DNA 
damage (Nakada et al., 2008). 
 
Despite the extensive research that has gone into PI3K signalling in response 
to DNA damage (reviewed in (Jackson and Bartek, 2009)), understanding of 
phosphatase activity in this process is rudimentary (Freeman and Monteiro, 
2010). Whilst figure 1.7 demonstrates that many phosphatases involved in DDR 
have been described, it is as yet unknown which phosphatase or phosphatases 
are associated with a number of the critical DNA damage protein complexes 
such as MDC1 and MRN. This section will outline the unique and 
complementary roles played by the phosphatases involved with DNA damage 
repair. 
1.7.2 PP1 
The Serine/Threonine Protein Phosphatase 1 (PP1) is one of multiple protein 
phosphatases to play a key role during multiple phases of the DNA damage 
response. Mammalian cells possess three closely related PP1 catalytic 
subunits, PP1α, PP1γ and PP1δ that differ in sequence mainly in their C-
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Figure 1.7: The multiple targets of the Ser/Thr phosphatases in DNA 
damage repair 
Regulation of DNA damage repair signalling proteins by the Ser/Thr family of protein 
phosphatases. Phosphorylations in orange are ATM targets, phosphorylations in pink are Chk2 
targets. Adapted from (Freeman and Monteiro, 2010). 
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terminal and N-terminal sequence (Cohen, 2002). The different PP1 catalytic 
isoforms are expressed fairly ubiquitously across multiple tissue types, however 
these different isoforms of PP1 have been shown to display distinct subcellular 
localisation (Andreassen et al., 1998). There does appear to be some 
redundancy in PP1 function, with regard to the different PP1-complexes formed. 
Studies in mice have demonstrated that mice with PP1γ-/- deletion are viable but 
display male infertility. This suggests that although PP1α may compensate for 
the loss of PP1γ during early embryonic development, the PP1γ complex is 
critical for functional spermiogenesis in these animals (Varmuza, 1998). 
 
Like many of the Ser/Thr protein phosphatases, PP1 activity and specificity is 
controlled mainly through association with a large number of regulatory subunits 
that can modulate catalytic activity as well as drive specific sub-cellular 
localisation (Bollen et al., 2010). Unlike holocomplexes of PP2A, the regulatory 
subunits of PP1 do not appear to share recognisable sequence similarities; 
instead they contain a PP1C binding motif RVxF, allowing binding of the 
regulatory subunit to the hydrophobic groove of the catalytic subunit. 
Interestingly, several PP1 substrates also contain this consensus motif, allowing 
binding to the PP1 catalytic subunit (Wakula et al., 2003). 
 
PP1 phosphatase targets multiple proteins and pathways involved in the DNA 
damage response. The importance of the phosphatase at DNA lesions is 
demonstrated by a recent study which demonstrated that simultaneous 
inhibition of PP1 and PP2A activated DNA damage signalling in xenopus egg 
extracts, despite the absence of actual DNA damage (Peng et al., 2010). In 
addition, this study demonstrated that the PP1γ interacting protein Repoman 
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(Recruits PP1 onto mitotic chromatin at anaphase) extensively co-localised with 
ATM on chromatin, with inhibition of either PP1γ or Repoman enhancing ATM 
activation in response to DNA damage. This suggests that the levels of 
PP1γ/Repoman present on chromatin determines the threshold for the initiation 
of DNA damage signalling. It also appears that PP1, in combination with 
another regulatory subunit, ‘Inhibitor-2’, is phosphorylated by ATM upon DNA 
damage leading to dissociation of the PP1 catalytic subunit from inhibitor-2 
resulting in increased cellular PP1 activity (Guo et al., 2002a; Tang et al., 2008). 
Although the necessity for ‘primed’ and active PP1 early in the DDR is clear, the 
physiological effect of such activity remains ambiguous. Both studies did 
however conclude that the early DNA damage-induced PP1 activity may play a 
role in inhibiting Aurora A activity, thus preventing histone H3 phosphorylation 
and G2/M progression (Guo et al., 2002a; Tang et al., 2008).  
 
An example of a PP1 interaction that is critical for maintaining robust HR-
mediated DNA damage repair, is the interaction of PP1α with BRCA1, mediated 
through the RVxF motif (Yu et al., 2008). PP1 has been shown to 
dephosphorylate BRCA1 at the S988 Chk2 phosphorylation site, in addition to 
the S1524 ATM site, with over-expression of the PP1 phosphatase preventing 
the hyper-phosphorylation of BRCA1 in response to DNA damage (Liu et al., 
2002; Yu et al., 2008). Mutation of the PP1-BRCA1 binding site negatively 
affected HR-mediated DNA repair and reduced the localisation of Rad51 to 
DNA lesions (Hsu, 2007; Yu et al., 2008). PP1 Nuclear Targeting Subunit 
(PNUTS) is another abundant nuclear PP1 binding factor, which binds to the α 
and γ isoforms of PP1C via the RVxF motif, specifically at telomeric regions of 
chromatin (Allen et al., 1998; Landsverk et al., 2005; Trinkle-Mulcahy et al., 
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2006). Studies have shown that PNUTS is rapidly recruited to sites of DNA 
damage, with loss of the protein leading to activation of the G2 cell-cycle 
checkpoint (Landsverk et al., 2010). In addition, multiple DNA damage markers 
including γH2AX, 53BP1, RPA and Rad51 persist for prolonged periods of time 
in cells depleted of PNUTS, coupled with a loss of clonogenic survival. PNUTS 
has also been shown to interact with the telomeric protein TRF2 (Kim et al., 
2009), a member of the shelterin complex of proteins, necessary for the 
inactivation of the DDR at telomeric DNA ends (Sfeir and de Lange, 2012). 
Given that several TRF2-interacting components are implicated in the DDR, the 
association of PNUTS with TRF2 may suggest that PNUTS/PP1α/γ may be 
involved in inhibition of specific damage repair pathways at telomeres (Kim et 
al., 2009; Küntziger et al., 2014). 
 
Finally, PP1 also plays a crucial role in the control of key signalling pathways 
during the DNA damage response via interaction with regulatory interacting 
proteins. DNA damage induced p53 dephosphorylation at S15 and S37 is 
believed to be controlled by PP1, mediated through the interaction of PP1 with 
PNUTS and GADD34 (Growth arrest and DNA damage-induced gene 34) 
(Haneda et al., 2004; Lee et al., 2007; Li et al., 2006). Inhibition of PP1 
dramatically increased dephosphorylation at S15/S37 and PP1 was shown to 
dephosphorylate these residues both in vitro and in vivo, decreasing the 
transcriptional activity associated with p53 (Li et al., 2006).  
1.7.3 PP2A 
One of the most ubiquitous protein phosphatases involved in the DNA damage 
response is the Ser/Thr-specific phosphoprotein phosphatase PP2A. PP2A 
exists as a heterotrimeric complex consisting of a catalytic subunit (PPP2CA 
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and PPP2CB), a regulatory subunit and a structural subunit (PPP2R1A and 
PPP2R1B)(Figure 1.8A-D) (Janssens et al., 2008). The regulatory subunit is 
believed to confer the specificity to the PP2A holocomplex, directing 
interactions and localisation (Janssens et al., 2008; Westermarck and Hahn, 
2008). Structural assessment of the differing PP2A heterotrimers reveals clear 
structural diversity of the holocomplex dependent on regulatory subunit 
composition (Figure 1.8E-F). Unlike the catalytic and structural subunits, 
multiple classes of regulatory subunits can form holocomplexes. Four distinct 
families of regulatory subunit have been identified (B/B55, B’/B56, B’’/PR72, 
B’’’/striatin), with the B56 containing holoenzyme complexes the best studied 
with regard to DNA damage repair (Janssens et al., 2008; Lee and Chowdhury, 
2011; McCright et al., 1996). Each of the PP2A-B56 subunits are highly 
conserved throughout higher eukaryotic species, with some evidence of over-
lapping functions and compensation upon gene deletion (Sommer et al., 2015). 
The individual B-subunits are expressed at a much lower copy number than the 
core catalytic-structural dimer, with the regulatory subunits undergoing rapid 
degradation when not complexed with the structural subunit (Ruediger et al., 
1994; Strack et al., 2004). Despite the abundant expression of PP2A, protein 
levels are tightly controlled to prevent the potentially lethal uncontrolled activity 
of PP2A in cellular processes (Baharians and Schönthal, 1998; Sents et al., 
2012). 
 
In general, PP2A function is controlled by either post-translational modification 
of the various subunits that control holocomplex assembly, or via the activity of 
a number of cellular PP2A inhibitory proteins (Janssens et al., 2008). A diverse 
range of inhibitory proteins have been shown to modulate PP2A function in cell 
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Figure 1.8: Crystal structure of the PP2A-B56 Ser/Thr phosphatase holo-
complex 
(A) Crystal structure and cartoon representation of the PP2A-B56 holoenzyme. Structural (A) -
isoform subunit is coloured in green. Regulatory (B56) B56  subunit is shown in yellow. 
Catalytic (C) -isoform is coloured in blue. Stick model of the non-competitive inhibitor of PP2A, 
microcystein-LR, is shown bound to catalytic subunit. Manganese co-factors are shown in 
purple bound to catalytic subunit   (PDB: 2iae). 
(B) Structural -isoform highlighted in blue. 
(C) Regulatory B56  subunit highlighted in blue. 
(D) Catalytic -isoform highlighted in blue. 
(E, F) Comparison of the structural variance between the PP2A-B56  holo-enzyme complex (E) 
and the PP2A-B55 containing complex (F)(PDB: 3dw8). B56  and B55 regulatory subunits are 
coloured in yellow. Structural -isoform subunit is coloured in green. Catalytic -isoform is 
shown in blue. 
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signalling pathways (I2/SET, CIP2A) (Li et al., 1996) and during mitotic 
progression (Bod1, ENSA, ARPP19) (Gharbi-Ayachi et al., 2010; Mochida et al., 
2010; Porter et al., 2013), as well as playing an important role in DNA damage 
and repair signalling, opposing ATM/ATR-dependent phosphorylation events 
(TIPRL) (McConnell et al., 2007). The numerous roles of PP2A within the DNA 
damage response, in addition to other cellular processes, are a principle reason 
for its appeal as an anti-cancer target for novel pharmaceuticals. Multiple PP2A 
inhibitors in phase I clinical trials have recently been shown to hypersensitise 
tumour cells to DNA damaging agents, identifying this pathway as a promising 
combination therapy in cancer treatment (Chang et al., 2015; Lv et al., 2014; 
Wei et al., 2013). 
 
PP2A has been shown to play a key role in regulating ATM during the DNA 
damage response. Khanna and colleagues found that treatment of cells with 
Okadaic acid (OA) at doses that only inhibit PP2A, induces autophosphorylation 
of ATM on S1981 in the absence of DNA damage (Goodarzi et al., 2004). They 
went on to demonstrate that ATM interacts with the structural subunit of PP2A, 
with ATM immunoprecipating a functional PP2A complex, suggesting that the 
PP2A complex keeps ATM in a dephosphorylated state, a result confirmed by 
the Sablina group (Kalev et al., 2012). In line with these observations, inhibition 
of PP2A using OA, induced ATM autophosphorylation in undamaged cells (Yan 
et al., 2010). Ionising radiation induced a dissociation of ATM and PP2A, 
resulting in the inactivation of PP2A and the autophosphorylation of ATM at 
S1981. This is consistent with previous observations that activation of ATM in 
response to IR, caused dissociation of the B55 regulatory subunit from the core 
PP2A dimer (Guo et al., 2002b), thus suggesting a mechanism for ATM to 
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control PP2A activity. Following activation of the kinase, ATM is able to directly 
phosphorylate and specifically regulate the B56γ and B56δ PP2A heterotrimers, 
resulting in the PP2A-B56γ mediated inhibition of cell proliferation and 
dephosphorylation of p53 (Shouse et al., 2011). 
 
In addition to PP6, PP2A positively regulates the DNA-PK activity upon DNA 
damage, acting to dephosphorylate Ku70 and Ku80, which leads to increase 
DNA-PK activity and promotion of the NHEJ repair pathway (Douglas et al., 
2001; Wang et al., 2009a). DNA damage induced by camptothecin leads to the 
physical association of PP2A with Ku70/80, resulting in the dephosphorylation 
of both subunits as well as DNA-PKcs, removing the inhibitory 
autophosphorylations and promoting the formation of a functional kinase 
complex on DNA (Chan and Lees-Miller, 1996; Wang et al., 2009a). 
 
Potentially linked with the interaction between PP2A and ATM, PP2A, along 
with a number of additional Ser/Thr protein phosphatases, dephosphorylates 
γH2AX upon the resolution of DNA damage (Chowdhury et al., 2005). PP2AC 
co-localises with γH2AX at IRIF leading to prolonged γH2AX phosphorylation 
and defective DNA repair (Chowdhury et al., 2005). More recent work observed 
that the PP2A-B56ε was the heterotrimeric regulatory subunit responsible for 
γH2AX dephosphorylation, with the B56ε containing hetero-trimer translocating 
from the cytoplasm to the nucleus upon treatment with camptothecin. Specific 
depletion of the B56ε isoform led to defective cell-cycle checkpoint control in 
addition to compromised HR repair measured by comet assay. (Li et al., 2015). 
The large number of phosphatases linked with γH2AX dephosphorylation is 
intriguing, with some groups suggesting that these phosphatases do not act 
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redundantly, rather each might respond to different types of DNA damage 
(Nakada et al., 2008).   
 
As mentioned previously, under normal homeostatic conditions, the activity of 
p53 is supressed. DNA damage associated post-translational modification of 
p53 stabilises the protein, activating down stream signalling pathways (Levine, 
1997; Vousden and Lu, 2002). In response to DNA damage, the catalytic 
subunit of PP2A, in a complex with the regulatory subunit B56, physically binds 
p53, mediating the dephosphorylation of p53 at multiple phosphorylation, thus 
stabilising the protein and promoting downstream p53 signalling (Dohoney et 
al., 2004; Li et al., 2007; Mi et al., 2009a). Inhibition of PP2A using small-
molecule inhibitors (Gordon et al., 2015), or depletion of subunits of the 
holocomplex attenuated p53 dephosphorylation, reduced p53 stabilisation and 
reduced downstream signalling  (Li et al., 2007; Mi et al., 2009a). 14 tumour-
derived PP2A-B56γ mutations were recently identified in human cancer cells, 
although little frequency data for such mutations suggests that these occur 
rarely. The mutations prevented the PP2A holocomplex from binding to and 
dephosphorylating p53, thus losing the tumour suppressive function of the 
phosphatase (Nobumori et al., 2013). The process of PP2A-p53 binding is 
regulated by ATM, which phosphorylates both p53 at S15 and PP2A-B56γ3 at 
S510, promoting interaction. This process also serves to upregulate B56γ3 
expression upon DNA damage by blocking MDM2-mediated B56γ3 
ubiquitination (Shouse et al., 2011; 2008).  
 
Upon DNA damage, ATM phosphorylates Chk2 at phospho-T68, enabling FHA-
dependent dimerisation and subsequent activation (Ahn et al., 2004). Several 
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studies have demonstrated binding of Chk2 with both PP2A-B56γ and PP2A-
B56α in the absence of DNA damage, mediating dephosphorylation of 
phospho-T68 Chk2 by PP2AC (Dozier et al., 2004; Freeman et al., 2010; Liang 
et al., 2006). This interaction is hypothesised to keep Chk2 in an inactive state 
under basal ATM kinase activity (Carlessi et al., 2010). Activation of ATM in 
response to genotoxic stress led to damage-dependent deactivation of this 
interaction and negative feedback loop, allowing the phosphorylation of Chk2 by 
ATM and subsequent downstream signalling (Freeman et al., 2010). Indeed, 
inhibition of PP2A using LB100, led to phosphorylation and activation of 
CDC25C/CDK1, a known Chk2 target, suggesting that in the absence of active 
PP2A, Chk2 is erroneously activated (Wei et al., 2013). PP2A also antagonises 
the ATR-dependent phosphorylation of the transducer kinase Chk1 at S317 and 
S345, with PP2A simultaneously regulated by phosphorylated Chk1 (Leung-
Pineda et al., 2006). Existing in an ATR-Chk1-PP2A regulatory feedback loop, 
ATR phosphorylates Chk1 upon damage, which is then subject to regulation by 
Chk1-regulated PP2A via a decrease in the transcription of cancerous inhibitor 
of PP2A (CIP2A) (Khanna et al., 2013). This feedback loop functions to keep 
Chk1 largely inactive during homeostatic conditions, but primed to respond to 
DNA damage (Khanna et al., 2013; Leung-Pineda et al., 2006). 
1.7.4 PP4 
PP4 is a phosphatase which is structurally and functionally similar to PP2A, 
consisting of a catalytic subunit in complex with one of a number of regulatory 
subunits (PP4R1, PP4R2, PP4R3α, PP4R3β and PP4R4) (Chen et al., 2008). 
There is multiple instances of redundancy between PP2A and PP4, consistent 
with the similarity between the phosphatase sequences (Freeman and 
Monteiro, 2010). PP4C exhibits differing localisation that is dependent on 
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regulatory subunit, much the same as PP2A. PP4C/R3β is primarily localised to 
the nucleus and does not co-localise with γH2AX foci post-damage (Chowdhury 
et al., 2008). Despite this, the PP4 holocomplex has been shown to carry out a 
number of roles during the DNA damage response, both during early foci 
formation phases, to later resolution of DNA damage complexes. During 
complex assembly and homologous repair, a PP4 complex containing the 
PP4R2 regulatory subunit mediates an interaction between the PP4C subunit 
and RPA2, allowing efficient dephosphorylation of RPA2, thus promoting 
efficient Rad51 loading (Lee et al., 2010). Several recent studies have also 
highlighted the role for PP4 in regulating protein recruitment to DNA lesions 
dependant upon cell cycle stage. The PP4C/R3β complex dephosphorylates 
PLK1 phosphorylation sites on 53BP1, promoting recruitment of the protein to 
chromatin during G1 phase of the cell cycle (Lee et al., 2014). Failure to 
maintain this phosphorylation balance on 53BP1 led to mitotic defects 
associated with telomeric fusion events occurring as a result of DSB repair of 
telomeres (Lee et al., 2014; Orthwein et al., 2014). 
 
During the resolution of DNA damage complexes, PP4 has been shown as 
essential for the dephosphorylation of γH2AX at repaired sites of DNA damage 
in both yeast and mammalian cells (Nakada et al., 2008). In addition, a PP4C-
PP4R3β complex is also responsible for dephosphorylation of phospho-S824 
KAP-1, regulating the role of KAP-1 in chromatin compaction and gene 
expression, promoting the progression of cell cycle post-DNA damage (Lee et 
al., 2012; Liu et al., 2014). Depletion of PP4 leads to prolonged G2/M 
checkpoint after DNA damage repair along with prolonged chromatin relaxation. 
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1.7.5 PP5 
The precise and full function of PP5 in the DDR is currently unclear, most in part 
due the low basal activity and expression of the phosphatase (Chen and 
Cohen, 1997; Chinkers, 2001). The principle function of PP5 identified so far is 
the modulation of the PIKK kinase activity in response to DNA damage. Unlike 
PP2A and Wip1, PP5 functions to activate the response to DNA damage via 
ATM. PP5 was found to physically bind ATM in a damage inducible manner (Ali 
et al., 2004), with a depletion of PP5, or expression of catalytically-dead 
phosphatase, leading to attenuated ATM signalling, reduction in the 
phosphorylation of ATM targets and loss of the intra S-phase checkpoint arrest 
(Ali et al., 2004; Yong et al., 2007). The precise mechanism for this finding 
remains unclear, however one explanation is that PP5 may dephosphorylate a 
hitherto unknown inhibitory phosphorylation site on ATM, promoting the 
activation of the kinase (Peng and Maller, 2010). 
 
PP5 has also been shown to exhibit more specific effect on DDR, aside from 
changes to global ATM signalling upon DNA damage. A recent study using the 
yeast two-hybrid-system identified a damage-dependent interaction between 
53BP1 and PP5, which controlled the phosphorylation status of 53BP1 in 
response to DNA damage (Kang et al., 2009). Loss of this interaction prevented 
the dephosphorylation of phospho-S25/S1778 53BP1 resulting in persistent 
DNA damage foci and compromised NHEJ repair. 
1.7.6 PP6 
In comparison to the other protein phosphatases described within this chapter, 
little has been investigated into the role of PP6 in the DNA damage response. 
Like PP5, PP6 is classified as a PP2A-like phosphatase due to similarity with 
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the catalytic subunit of PP2A and sensitivity to catalytic site inhibitors such as 
Okadaic acid and microcystin (Honkanen and Golden, 2002). The phosphatase 
exists as a heterotrimer consisting of a catalytic subunit (PP6C), a regulatory 
subunit (PP6R1, PP6R2 and PP6R3) plus an ankyrin repeat subunit (ARS-A, 
ARS-B and ARS-C) (Stefansson and Brautigan, 2006; Stefansson et al., 2008). 
 
The DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a critical 
role in the repair of DSB by NHEJ and is autophosphorylated in response to 
ionising radiation (Hammel et al., 2010). Various independent studies have 
reported that activated DNA-PKcs interacts with the intact PP6 holocomplex, 
with depletion of PP6C or regulatory subunits leading to hypersensitivity to IR 
and delayed release from the G2/M checkpoint (Douglas et al., 2010; Mi et al., 
2009b). In addition, RNAi silencing of PP6C led to sustained phosphorylation of 
γH2AX at DNA lesions and compromised HR repair (Douglas et al., 2010; 
Zhong et al., 2011). Consistent with this, bacterially expressed PP6C-
complexes exhibit phosphatase activity against γH2AX in vitro (Zhong et al., 
2011). There does appear to be some discrepancy over whether the DNA-PKcs 
and PP6 interaction is damage-dependent and whether this interaction is 
necessary for DNA-PK activation following DNA damage. One study revealed 
that the binding between the two proteins increases following IR and promotes 
the activation of DNA-PK in response to DNA damage (Mi et al., 2009b). 
However a more recent study demonstrated that the PP6-DNA-PK interaction is 
constitutive and is not affected by the presence of DNA damage; with the 
interaction instead facilitating the recruitment PP6 to sites of damage, 
modulating the dephosphorylation of γH2AX (Douglas et al., 2010). Further 
investigation is needed to address the reason for these conflicting models. 
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In addition, mutations in the catalytic subunit of PP6, PPP6C, have been shown 
to act as drivers for the development of melanoma. PPP6C is mutated in 
between 9-12% of melanoma samples, with such mutations compromising 
assembly of the PP6 holoenzyme and subsequent phosphatase activity 
(Hammond et al., 2013). Cells with mutated PPP6C (H114Y), display elevated 
Aurora A activity, which results in chromosome instability and DNA damage 
generated by Aurora-A associated micronucleation (Hammond et al., 2013). 
1.7.7 Wip1 
Wip1 (wild-type p53-inducible phosphatase 1), also known as PPM1D, is a 
member of the PP2C family of protein phosphatases. Unlike the phosphoprotein 
phosphatase (PPP) family (PP1/PP2A etc.), the PP2C phosphatases lack 
regulatory subunits, with specificity instead determined by specific regulatory 
and targeting domains. In addition, the catalytic activity of these protein 
phosphatases in unaffected by PPP inhibitors such as Okadaic acid and 
microcystin (Fiscella et al., 1997). Wip1 targets multiple DNA damage repair 
proteins via the pSQ/pTQ motif which are phosphorylated in response to DNA 
damage by ATM or ATR (Yamaguchi et al., 2007). The importance of this 
phosphatase is demonstrated by the evidence that Wip1 is an oncogene that is 
amplified and overexpressed in multiple human cancer types, including breast 
and ovarian carcinomas (Lu et al., 2008). 
 
It appears that a major function of Wip1 is in the reversal of cell cycle 
checkpoints and signalling pathways, resuming normal homeostatic function 
following the completion of DNA damage (Shimada and Nakanishi, 2013).  
Wip1 constitutively interacts with ATM and dephosphorylates ATM at S1981 
upon resolution of DNA damage (Shreeram et al., 2006). In line with this 
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function, depletion of Wip1 led to constitutively active ATM in the absence of 
DNA damage, with overexpression of Wip1 suppressing ATM activation at DNA 
lesions. The evidence of Wip1 as a negative regulator of ATM is further 
strengthened with mice studies demonstrating that deletion of Wip1 in ATM-/- 
mice partially rescued many of the ATM deficiency phenotypes associated with 
these animals, such as radiosensitivity and fertility defects (Darlington et al., 
2011). 
 
Whilst the precise mechanistic events leading up to DNA repair remain well 
understood, the process of deactivating these mechanisms and returning cells 
to their homeostatic state is poorly understood. Multiple independent recent 
publications have highlighted the role of Wip1 in the direct dephosphorylation of 
γH2AX upon resolution of DNA damage, promoting the dissolution of DNA 
damage foci (Cha et al., 2010; Macurek et al., 2010; Moon et al., 2010). 
Fluorescently labelled Wip1 localised at IRIF, with overexpression of Wip1 
leading to a decrease in the number and intensity of γH2AX foci, resulting in the 
delayed recruitment of DNA repair factors (Macurek et al., 2010). In addition, 
overexpression of Wip1 delayed the repair of DSB as determined using comet 
assays (Cha et al., 2010). 
 
Wip1 has also been shown to play a critical role in the regulation of key 
signalling cascades in response to DNA damage. Wip1 expression upon DNA 
damage is driven in a p53 dependent manner (Bulavin et al., 2002; Song et al., 
2010). In a negative feedback mechanism, Wip1 then dephosphorylates p53 at 
S15 and the E3-ubiquitin ligase MDM2 at S395, both sites phosphorylated by 
ATM in response to DNA damage (Lu et al., 2005). These dephosphorylations 
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collectively enhance the MDM2 affinity for p53, destabilise the p53 protein and 
leading to its proteolysis by MDM2, thus relieving the cell-cycle arrest 
associated with the DNA damage response (Lu et al., 2007). Another key cell 
cycle related function of Wip1 is the dephosphorylation of Chk1 following the 
resolution of DNA damage. Wip1 dephosphorylates the ATR-mediated S345, 
resulting in decreased Chk1 activity which correlates with a reduction in intra S-
phase and G2/M checkpoint signalling (Lu et al., 2005). A physical interaction 
between Wip1 and Chk2, dependent on ATM phosphorylation of phospho-T68 
Chk2, has also shown to be critical in the reversal of cell cycle checkpoints 
following damage resolution (Yoda et al., 2006). Wip1 dephosphorylates 
phospho-T68 Chk2, promoting cell cycle progression. Knockdown of Wip1, or 
expression of a phosphatase-deficient mutant (D314A), resulted in sustained 
phosphorylation of Chk2 and subsequently prevented cell cycle progression 
post-damage (Fujimoto et al., 2005). Consistent with these observations, 
ectopic expression of Wip1 prevented Chk2 activation and the subsequent 
contribution of the kinase to the G2/M checkpoint (Oliva-Trastoy et al., 2006). 
1.8 Bod1L and the Bod1 family of proteins 
1.8.1 Identification and function of Bod1 
Bod1 and Bod1L are members of the Fam44 family of previously unknown 
function proteins (Figure 1.9A). An additional family member, Fam44C shares a 
strong degree of sequence homology with Fam44B (Bod1), however its function 
remains unknown (Figure1.10B) (Porter et al., 2007). Fam44A (Bod1L) also 
shares a region of N-terminal homology with Bod1, however it contains an 
additional large C-terminal extension of approximately 300 kDa. This large C-
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terminal extension does not appear to relate to any other known protein, or 
share sequence homology with known protein groups. 
 
Work from a previous independent study identified Bod1 from a Xenopus laevis 
proteomic screen looking to identify novel factors required for proper 
chromosome segregation (Porter et al., 2007). The screen utilised in vitro 
assembled chromosomes and observed by immunofluorescence that Bod1 
localises to kinetochores and mitotic spindle poles during mitosis. Using RNA 
interference (RNAi), the authors found that when Bod1 protein levels were 
depleted, elongated mitotic spindles with severe bi-orientation defects were 
detected. More detailed examination of the phenotype revealed that Bod1 
knockout did not affect the microtubule-kinetochore interaction nor the activity 
or localisation of the Aurora B kinase, but rather led to defects in the correct 
localisation and phosphorylation of the microtubule depolymerase mitotic 
centromere- associated kinesin (MCAK). 
 
A more recent study, following on from work describing Bod1 as critical for 
correct bi-orientation during mitosis, highlighted the sequence similarity 
between Bod1 and the PP2A-B55 inhibitors Ensa and Arpp-19 (Porter et al., 
2013). Ensa and Arpp-19 have been identified as inhibitors of PP2A-B55 and 
are critical in allowing activity of Cdk1/CyclinB and promoting entry into mitosis 
(Gharbi-Ayachi et al., 2010; Mochida et al., 2010). The reports identifying Ensa 
and Arpp-19 as PP2A-B55 inhibitors described a critical aspartate residue that 
is conserved in the Bod1 sequence (Gharbi-Ayachi et al., 2010). The Bod1 
study showed that in addition to this conserved aspartate residue, an upstream 
Cdk site that is not present in Ensa and Arpp-19 is critical for Bod1 activity as a  
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Figure 1.9: The Fam44 family of proteins  
(A) Schematic representation of the annotated domains of the Fam44 family of proteins. The 
T95 phosphorylation site identified on Bod1 has been highlighted. 
(B) Alignment of the three Fam44 family members. Black arrows indicate the residues shown to 
be important for PP2A-B56 inhibition by Fam44B (Bod1) (Porter et al., 2013). 
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specific inhibitor of kinetochore associated PP2A-B56 during mitosis. Loss of 
Bod1 from mammalian cells releases the inhibition of the PP2A-B56 
phosphatase, resulting in the loss of phospho-epitopes at the kinetochore 
during mitosis. The authors demonstrate that this hyperactivity of PP2A-B56 
results in the delocalisation of the critical kinetochore components Plk1 and 
Sgo1, resulting in the bi-orientation phenotype observed. During normal mitotic 
conditions, Bod1 acts as an additional level of regulatory control over the PP2A-
B56 phosphatase ensuring specificity of action. Intriguingly, although the critical 
aspartate (D98) and upstream CDK site (T95) are conserved between Fam44B 
(Bod1) and Fam44C, these two residues are not conserved in Bod1L in any 
species investigated (Figure 1.9B). This is despite the surrounding sequence of 
all three family members being highly conserved. 
1.8.2 Shg1/COMPASS domain 
Post-translational modifications described previously, such as phosphorylation 
by ATM and the down-stream ubiquitin modifications mediated by E3-ubiquitin 
ligases such as RNF8 and RNF168, all occur in response to damage, 
specifically at DNA lesions. Unlike these modifications, histone methylation 
involved in the DNA damage response appears to occur more constitutively 
throughout the cell-cycle. 
 
Contained within the Bod1-homology domain of Bod1L (and the family member 
Bod1) is a region of homology with the Complex proteins associated with SET1 
protein (COMPASS) component Shg1. The COMPASS complex, first identified 
in saccharomyces cerevisiae, is responsible for histone H3 lysine 4 (H3K4) 
methylation and is evolutionary highly conserved (Shilatifard, 2012). In yeast 
cells, the sole methyltransferase, Set1p, assembles with a number of accessory 
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proteins (Sdc1p, Swd1p, Swd2p, Spp1p, Swd3p, Shg1p and Bre2p) to generate 
the COMPASS complex (Miller et al., 2001). In higher eukaryotic cells, at least 
six H3K4 methyltransferases have been identified (Set1a, Set1b, MLL1-5) 
leading to the formation of six COMPASS-like complexes (Eissenberg and 
Shilatifard, 2010; Shilatifard, 2012). The individual methyltransferases share 
common accessory proteins, consisting of Wdr5, Rbbp5, Ash2l and Dpy30, with 
specificity likely determined by the methyltransferase present in the complex 
(Dehe et al., 2006; Dou et al., 2006). 
 
Both mono- (me) and tri-methylation (me3) of H3K4 have been shown to be 
involved in the DNA damage response in both yeast and mammalian cells. As 
mentioned previously, histone methylation appears to occur constitutively, with 
the active removal of H3K4me3 occurring at sites of damage identified by 
γH2AX staining. A recent study by the Friedl group demonstrated that the anti-
correlation of H3K4me3 and γH2AX staining increases with time post-
irradiation, suggesting that the histone methylation is actively removed over 
time (Seiler et al., 2011). Studies in yeast have revealed that in cells with a 
Δset1 mutation preventing H3K4 methylation, are defective in NHEJ repair and 
show compromised S-phase progression in the presence of replication stress 
(Faucher and Wellinger, 2010). Both these examples, in addition to other work, 
highlight the function of H3K4 modification in altering chromatin structure at 
sites of DNA damage to allow for robust repair (Nakamura et al., 2011). 
 
As alluded to previously, the six mammalian COMPASS complexes contain a 
multiple accessory subunits, a number of which are found unanimously across 
all of the COMPASS complexes (Dehe et al., 2006; Dou et al., 2006). The 
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precise function of each of these subunits remains unknown, however a 
complex of subunits lacking the methyltransferase Set1 homologue were 
demonstrated as displaying intrinsic methyltransferase activity toward H3K4, 
suggestive that a degree of redundancy may exist within each COMPASS 
complex (Patel et al., 2009). Recent data has shown that Bod1L interacts with 
one key accessory subunit, Ash2L, suggestive of Bod1L being part of the 
Ash2L containing H3K4 methyltransferase complex. In addition, the study also 
identified that H3K4 methyltransferase complexes bind to the Bod1L promoter, 
implying that regulation of chromatin structure at Bod1L locus might be 
important to regulating the H3K4 di- and tri-methylation (Ciotta, 2011). A more 
recent study identified both Bod1 and Bod1L as interacting partners of the 
Dpy30 (WRAD) complexes, with Bod1L and Bod1 exclusively present in 
Set1A/Set1B methyltransferase complexes (van Nuland et al., 2013). This study 
also identified a Set1B independent interaction between Bod1 and Bod1L, 
implying that these two proteins may form a heterodimer. Given the inclusion of 
Bod1L in methyltransferase complexes, coupled with the Shg1 homology, both 
of these studies proposed that Bod1L may function as the higher eukaryotic 
paralogue of yeast Shg1 (Ciotta, 2011; van Nuland et al., 2013). 
1.8.3 Bod1L is required to suppress deleterious resection of stressed replication 
forks 
A recently published paper from the Stewart group identified Bod1L as a 
component of pathway that safeguards genome stability following replication 
stress (Higgs et al., 2015). Loss of Bod1L resulted in sensitivity to replication 
stress, resulting in catastrophic genome instability. They showed that Bod1L 
functions downstream of BRCA2 to stabilise Rad51 nucleofilaments at 
damaged replication forks, protecting such damaged forks and preventing 
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resection by DNA2. As Rad51 localisation to forks is unaffected following Bod1L 
depletion, this strongly suggests that Bod1L acts to stabilise these filaments 
once formed. Whilst this study reveals an interesting functional consequence of 
Bod1L depletion, little mechanistic detail is discussed regarding the position and 
function of Bod1L in the pathway and therefore the implications and future 
direction of the study are hard to gauge. In addition, no replication or DNA 
damage defects could be detected in cells only depleted of Bod1L, indeed all 
phenotypes observed in the study were induced using agents that lead to 
replication stress, particularly MMC. Whilst the use of such agents is useful in 
exacerbating subtle phenotypes, if the principle function of Bod1L was to 
safeguard genome stability following replication stress, one would expect a 
more pronounced phenotype occurring as a result of endogenous replication 
stress. The authors do however demonstrate that Bod1L interacts with a 
number of key components of the DDR, including MRE11 and BRCA2, 
suggestive of a potential additional role of this protein in repair of damaged 
DNA.  
1.9 Aims and objectives 
The maintenance of genomic integrity by DNA repair is of critical importance for 
cell survival. DSBs are among the most adverse forms of DNA damage and 
failure to properly repair these breaks may lead to genomic instability, gene 
deletions and cancer (Bartkova et al., 2005; Ciccia and Elledge, 2010; Jackson 
and Bartek, 2009). The cell therefore maintains several elaborate systems to 
rapidly detect and repair DNA damage, whilst delaying cell cycle progression 
(Lukas et al., 2004b; Melo and Toczyski, 2002; Zhou and Elledge, 2000). As 
such, one of the objectives of this study will be to determine whether Bod1L 
functions to delay the cell cycle upon DNA damage. 
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As outlined above, the recognition and repair of DNA lesions is accomplished 
by the concentration of signalling and repair factors in the vicinity of the 
damage, leading to the formation of DNA damage foci (Lukas et al., 2005). 
ATM-dependent phosphorylation of the histone variant H2AX (γH2AX) is the 
principal and critical step for subsequent down-stream accumulation of 
signalling and repair factors at DNA lesions (Celeste et al., 2003; Paull et al., 
2000; Rogakou et al., 1998). MDC1 directly binds γH2AX (Stucki and Jackson, 
2006), and is the critical recruitment platform for most other proteins involved in 
signalling and repair at sites of damage (Jungmichel and Stucki, 2010; Stucki et 
al., 2005). Analysis of global ATM and ATR substrates, as well as ultradeep 
phosphoproteome mass-spectrometry revealed multiple phosphorylation sites 
on Bod1L (Matsuoka et al., 2000; Sharma et al., 2014). In light of this evidence, 
coupled with the preliminary data from the lab suggesting that Bod1L depletion 
leads to genomic instability and published data on Bod1L (Higgs et al., 2015), 
this study will look to investigate the role of Bod1L in controlling the focal 
assembly of early DNA repair factors at sites of DNA damage. 
 
Multiple protein phosphatases have been implicated in the repair of DNA 
damage, involved in both the formation of DNA damage foci as well as the 
disassembly of foci following repair (Chowdhury et al., 2005; Freeman and 
Monteiro, 2010; Li et al., 2015; Nakada et al., 2008). Specifically, PP2A-B56 
isoforms are required for dephosphorylation of γH2AX (Chowdhury et al., 2005; 
Li et al., 2015) with the loss of PP2A activity resulting in persistent γH2AX foci 
and impaired DNA damage repair. In addition to a role in modulating foci 
formation, PP2A has also been implicated in the inhibition of cell proliferation 
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and the cell cycle following DNA damage (Li et al., 2007). There is also strong 
recent evidence that treatment of cells with chemical inhibitors of PP2A causes 
defects in cell cycle arrest leading to improper DNA damage repair and cell 
death (Lu et al., 2009). Given the already established role of Bod1 as an 
inhibitor of PP2A-B56 function, coupled with the strong degree of homology 
between Bod1 and Bod1L, this study will look to investigate whether Bod1L, like 
Bod1, interacts with the Ser/Thr phosphatase PP2A-B56. There is already 
precedence for the involvement of phosphatase inhibitors during the DNA 
damage response, with the cellular PP2A inhibitor TIPRL having been shown to 
play an important role in DNA damage and repair signalling, opposing 
ATM/ATR-dependent phosphorylation events (McConnell et al., 2007; Smetana 
and Zanchin, 2007) 
 
To summarise, in light of this background information and preliminary data, the 
aims and objectives of this study were:  
 
i. Investigate the role of Bod1L during the DNA damage response 
ii. Identify whether Bod1L, like Bod1, interacts with the Ser/Thr 
phosphatase PP2A-B56 
iii. Understand whether Bod1L plays a role in cell-cycle control following 
DNA damage 
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Chapter 2 - Experimental Procedures 
2.1 Tissue Culture 
2.1.1 Cell Lines and Culture 
All cell lines were maintained in a standard EMEM medium (Lonza) and 
supplemented with 10% v/v foetal bovine serum (FBS)(Lonza), 2 mM L-
glutamine (Life Technologies), 100 U/mL Penicillin and 100 mg/mL 
Streptomycin (Life Technologies). U2OS cells stably expressing a DR-GFP 
cassette construct were maintained in the standard cell culture medium 
supplemented with 2 µg/mL puromycin (Sigma). U2OS cells stably expressing 
GFP-MDC1 were maintained in the standard cell culture medium supplemented 
with 400 µg/mL G-418 (Life Technologies). Individual cell culture details can be 
found in table 2.1. For adherent cells, 0.05% trypsin-EDTA with phenol red (Life 
Technologies) was added to lift cells for passaging. All cell lines were 
maintained at 37°C at 5% CO2 in a humidified incubator. At passage 20, cells 
were disposed of and fresh cells were defrosted from liquid nitrogen storage. 
Liquid nitrogen storage media consisted of 90% FBS and 10% DMSO (Sigma). 
2.1.2 DNA and RNA transfections 
2.1.2.1 siRNA transfection 
Cells were seeded in 6-well tissue culture dishes (TPP) and incubated until 90% 
confluence was reached in culture medium that does not contain penicillin or 
streptomycin. Cells were transfected with 8 – 24 nM siRNA duplexes 
(concentration is optimisation dependant), or equal concentration medium-GC 
control siRNA (Life Technologies) using Lipofectamine 2000 (Life 
 94 
Technologies). Standard manufacturers protocol was followed for transfections. 
After 16-24 hours, cells were split into fresh media. Cells were assessed for 
knockdown 48 hours after transfection. 
2.1.2.2 DNA transfection 
Cells were seeded in 6-well tissue culture dishes and incubated until 70-90% 
confluence was reached. Cells were transfected with 0.3-1 µg DNA per well 
(concentration is optimisation dependant) using Effectene transfection reagent 
(Qiagen) following standard manufacturers protocol. The following day, cells 
were split into fresh culture medium and expression was assessed after 48 
hours. DNA constructs used in this study are listed in table 2.5. 
2.1.2.3 siRNA and DNA co-transfection 
For rescue experiments, endogenous protein was depleted by siRNA and 
exogenous fusion protein was expressed from plasmid DNA. Cells were seeded 
in 6-well tissue culture dishes and incubated until 80% confluence was reached 
in culture medium that does not contain penicillin or streptomycin. Cells were 
transfected with siRNA as described previously. After 16-24 hours, fresh media 
containing penicillin and streptomycin was added and cells were transfected 
with DNA as described previously. After 12 hours, cells were split into fresh 
media. Cells were assessed for knockdown and exogenous protein expression 
24 hours after DNA transfection. 
2.1.3 Generation of stable cell lines 
pDRGFP was a gift from Maria Jasin (Addgene plasmid # 26475) (Pierce et al., 
1999). HeLa DR-GFP cells were generated by transfecting HeLa S3 cells with 
pDRGFP plasmid using Effectene as described above. 2 µg/mL puromycin (Life 
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Technologies) was used to select for cells that had stably integrated the 
plasmid. Single clones were selected, transfected with I-Sce-I plasmid and 
screened for GFP by direct microscope observation. 
 
Full length Homo Sapiens MDC1 (NP_055456.2) (Yin et al., 2012)(A kind gift 
from the Hay group, Dundee) cloned from HeLa Kyoto cDNA was fused to 
eGFP or mCherry generating  pEGFP-MDC1 (pA414) and pmCherry-MDC1 
(pA495). U2OS GFP-MDC1 cells were generated by transfecting U2OS cells 
with GFP-MDC1 plasmid using METAFECTENE PRO (Biontex). After G418 
selection (400µg/ml)(Calbiochem), GFP-MDC1 expression was confirmed by 
direct microscope observation. 
 
pCDNA5-B56γ1-YFP (a kind gift from the Saurin Group, Dundee) was created 
by PCR of B56γ1 from pCEP-4xHA-B56γ1 (Addgene plasmid #14534; 
deposited by D. Virshup, Duke-NUS Graduate Medical School, Singapore) and 
ligation into pCDNA5 vector using Not1 and Apa1 restriction sites. HeLa Flp-in 
cells (a gift from S. Taylor, University of Manchester, UK) were transfected with 
pCDNA5-YFP-B56γ1 and pOG44 (Invitrogen) using Fugene HD (Promega) and 
positive clones were selected using Hygromycin B. PP2A-B56γ1-YFP 
expression was induced with 1 µg/mL of doxycycline for ≥16 h. 
2.1.4 Clonogenic survival assay 
HeLa or U2OS cells were transfected with siRNA and DNA as described above 
and seeded 2000 cells per 10 cm dish. Experiments were carried out in 
triplicate for each condition. Compounds were added for 16 hours before wash-
out and fresh media addition. Cells were left to propagate for 10-12 days before 
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plates were dried and then stained with a 2/1/1 ddH2O/MeOH (VWR)/Crystal 
violet solution (Sigma). Colonies were counted using a GelCount colony counter 
(Oxford Optronix) and percentage survival was calculated. 
2.1.5 DR-GFP Assay 
U2OS cells stably expressing a cassette in which a unique I-Sce-I restriction 
site was placed between tandem mutant copies of GFP were transfected with 
control or Bod1L siRNA. After 48 hours cells were transfected with I-Sce-I 
vector plus DMSO or 10 µM KU59933. After 24 hours cells were fixed in PFA 
and analysed with microscopy for GFP expression. 
2.1.6 Drug treatments and Ionising Radiation 
Chemicals were dissolved in DMSO (Sigma) to a stock concentration of 
between 100 µM – 10 mM. Etoposide (Sigma) was used at a working 
concentration of 10 µM. Monastrol (Tocris) was used at a concentration of 100 
nM. Nocodazole (CalBioChem) was used at a concentration of 100 ng/mL. 
Cisplatin (Sigma), Mitomycin C (SantaCruz), Camptothecin (Donated by Rouse 
group, University of Dundee) and 6-Thioguanine (Sigma) were all used at the 
concentration ranges indicated.  
 
Irradiation of samples was carried out using an IBL 437C Gamma Irradiator with 
a Cesium137 gamma source. The typical dose delivered was 5 Gy unless 
otherwise stated, at an approximate rate of 2 Gy/min. Note that all non-
irradiated samples were treated with a mock-irradiation to mimic any results 
arising as a result of temperature shock. Recovery from irradiation or mock-
irradiation was at 37°C. 
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Table 2.1 Cell culture cell line maintenance 
Cell Line ATCC Number Culture Medium Cell Passaging Notes 
HeLa (S3) CCL-2.2 EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
 
HeLa-DRGFP - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin, 2 µg/ml puromycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
 
HeLa-PP2A-B56alpha-GFP "211C" - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
Gift from Foley Lab 
RPE1-PP2A-B56delta-GFP - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
Gift from Foley Lab 
HeLa-PP2A-A -GFP "204E" - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
Gift from Foley Lab 
HeLa-PP2A-B56 1-YFP - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
Gift from Saurin Lab 
U2OS HTB-96 EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:5 every 4 days.  
Maintained between 
passage number 1 and 
20. 
 
U2OS-MDC1-GFP - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin, 400 µg/ml G418 
Split 1:5 every 4 days.  
Maintained between 
passage number 1 and 
20. 
Gift from Hay Lab 
U2OS-LacO - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:4 every 4 days.  
Maintained between 
passage number 1 and 
20. 
Gift from Saurin Lab 
HeLa (Kyoto)-CENPA-GFP - EMEM, 10% FBS, 2 mM L-Glutamine, 100 U/ml Penicillin, 100 mg/ml Streptomycin 
Split 1:10 every 4 days.  
Maintained between 
passage number 1 and 
20. 
 
Gift from Jaqaman 
Lab 
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2.2 Molecular Biology 
2.2.1 Primer design 
All primers were ordered with a synthesis scale of 25 nmole and pre-purified via 
de-salting. Primers were reconstituted in TE buffer to a stock concentration of 
100 µM and kept at -20°C. 
 
Primers for PCR reactions varied according to application but were generally 
kept between 20-30 nucleotides in length, with a GC content of between 40-
60%. Unique restriction sites were inserted into primer sequence where 
necessary. Primer Tm for PCR reactions was calculated using the following 
calculation: 
Tm=(sum A+T) x 2 + (sum G+C) x 4°C 
 
Primers for sequencing reactions followed similar design guidelines to PCR 
primers, however the Tm was kept close to 60°C. In addition to this, primers 
were designed with at least one G or C at the 3’ end of the primer. 
Homopolmeric (e.g. CCCCC) and sequence repeats were also avoided where 
possible. A list of primers used in this study can be found in table 2.4. 
2.2.2 Polymerase chain reaction (PCR) 
PCR reactions were performed in 25 µL reactions using an Eppendorf 
Mastercycler Gradient Thermal Cycler. 10 ng of template DNA was combined 
with 200 µM dNTPs (Thermo), 500 nM forward and reverse primers, 1 X 
Phusion reaction buffer and 0.4U Phusion HotStart II DNA polymerase 
(Thermo). PCR reactions with Bod1L had the addition of 8% v/v DMSO (Sigma) 
and 1.6 M Bettaine (Sigma) to help reduce secondary structure. PCR cycling 
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program was optimised for each reaction, however in general the programme 
consisted of an initial denaturation at 98°C for 3 minutes, proceeded by 25-30 
cycles of 98°C for 30 seconds, Tm°C for 30 seconds (with Tm the calculated 
melting temperature of primer pair used), 72°C for 30 seconds/Kb followed by 
72°C for product length + 20%. 
2.2.3 DNA sequencing and concentration determination 
DNA sequencing was performed in-house using the Dundee sequencing 
service (http://www.dnaseq.co.uk/, accessed between 09/11 – 05/15) DNA 
concentrations from PCR reactions or restriction digests were measured using a 
Nanodrop 1000 spectrophotometer (Thermo). The Nanodrop was blanked with 
EB Buffer (Qiagen) before 1 µL of DNA in EB buffer was measured and the 
concentration noted. A260/280 was also measured to assess DNA purity. Samples 
with an A260/280 differing from ~1.8 were rejected. 
2.2.4 Agarose gel electrophoresis 
Restriction digested DNA and PCR products were visualised via agarose gel 
electrophoresis. 0.8% w/v Agarose gels were cast using Ultrapure agarose (Life 
Technologies) in TAE buffer. Ethidium bromide (EtBr)(Sigma) was added to the 
partially cooled agarose at a final concentration of 0.5 µg/mL. Samples were 
combined with 10 X loading dye to a final concentration of 1 X and run 
alongside a 0.1-10 Kb DNA ladder (New England Biolabs). Samples were run at 
110V for 45 minutes. Gels were visualised using the Gel-Doc system (BioRad). 
2.2.5 Restriction digests 
Restriction digests were carried out for cloning or verification of DNA fragment 
size. All restriction enzymes were purchased from New England BioLabs and 
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where possible High-Fidelity versions were used. Reactions were performed at 
37°C for 1 hour and consisted of between 0.5 and 4 µg DNA and 10-20 units of 
restriction enzyme. Double digests were performed where necessary in a 
compatible buffer. Where no compatible reaction buffer was available, 
sequential reactions were performed, passing the DNA through a QIAquick 
PCR purification column (Qiagen) for buffer exchange. 
 
For plasmid backbone, where necessary, samples were treated with Calf 
intestinal alkaline phosphatase (CIP)(New England Biolabs) at a final 
concentration of 10U/reaction to dephosphorylate 5’ and 3’ ends and help 
prevent relegation. 
2.2.6 Bacterial Transformation 
2.2.6.1 Bacterial culture medium and plates 
LB broth and LB agar plates were purchased pre-prepared from the in-house 
media kitchen and stored for a maximum of one month at 4°C. Ampicillin was 
added to LB and LB-agar at a final concentration of 100 µg/mL. Kanamycin was 
added to LB and LB-agar at a final concentration of 50 µg/mL. 
2.2.6.2 Bacterial transformation 
Chemically competent DH5α and BL21 E. coli cells were purchased in-house 
(MRC-PPU/DSTT). For circular plasmid DNA, 0.2 µL of DNA or ddH2O as 
control was gently mixed with 50 µL competent E. coli cells. For ligation 
products from molecular cloning, 4 µL of DNA or ddH2O was gently mixed with 
50 µL competent E. coli cells. Cells were incubated on ice for 30 minutes before 
heat-shock at 42°C for 30 seconds and then 2 minutes recovery on ice. 950 µL 
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S.O.C. medium (Life Technologies) was added to the cells and mixture was 
incubated with shaking at 37°C for 1 hour. 100 µL of cells were then plated onto 
antibiotic selection plates. The remaining mixture was spun-down at 7,500 r.c.f. 
for 5 minutes before re-suspending in 100 µL fresh S.O.C. This was then plated 
onto another LB-agar plate containing the selection antibiotic. Colonies were 
allowed to grow overnight at 37°C before colonies were picked and grown in 
liquid culture. 
2.2.7 Molecular cloning 
A list of all DNA constructs used in this study can be found in table 2.5. 
2.2.7.1 Standard cloning 
DNA to be inserted into the plasmid vector was amplified using PCR method 
described above. PCR products were run on 0.8% w/v agarose gel and DNA 
was visualised using EtBr. Bands corresponding the to the correct size were 
excised from the gel and prepared using a QIAquick gel extraction kit (Qiagen). 
Both the PCR amplified insert as well as the target vector were digested with 
two unique cutting restriction enzymes (New England BioLabs/Thermo) in order 
to generate complementary sticky DNA overhangs for ligation. Insert and target 
vector were ligated using T4 DNA ligase (New England BioLabs) using an 
insert:vector ratio of 4:1. Ligation reaction was performed at 16°C overnight or 
at room temperature for 2 hours. 5 µL ligated DNA product was then 
transformed into competent cells. 
 102 
2.2.7.2 Gibson Assembly cloning 
Gibson assembly protocol (New England BioLabs) was used to ligate site 
directed mutagenesis fragments. Standard manufacturers protocol was 
followed. 
 
PCR primers were designed to contain 30 nucleotide homologous overlapping 
regions to ensure full sequence coverage of final product. PCR reactions were 
performed as described above. PCR product was run on 0.8% w/v agarose gel 
and bands were excised and prepared using QIAquick gel extraction kit. As per 
the manufacturers protocol, 0.2 pmol DNA for each fragment was added to the 
reaction mix and an optimal ligation an optimal ligation ratio of 2:1 insert to 
backbone was used. Samples were incubated at 50°C for 60 minutes before 
bacterial transformation was carried out. Positive and negative controls were 
included to ensure specificity and functionality of Gibson assembly master mix. 
2.2.7.3 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the Q5 site-directed 
mutagenesis kit (New England BioLabs). 
 
Non-overlapping primer design allows for exponential amplification of region of 
interest. Mutagenic substitutions are created by incorporating the mutagenic 
nucleotide into the centre of the forward primer, with the reverse primer 
designed so that the 5’ ends of the primers anneal back-to-back. Mutagenic 
primers were designed using the following web-app: 
http://nebasechanger.neb.com/ (Accessed 09/14 – 09/15). PCR reaction was 
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carried out as described above, using the Q5 Hot Start High-Fidelity DNA 
polymerase (New England BioLabs). 
  
1 µL PCR product was run on 0.8% w/v agarose gel to ensure successful PCR. 
PCR product was then treated with KLD enzyme mix (Kinase:Ligase:DpnI) to 
ligate linear DNA and digest methylated DNA template. Ligated DNA was then 
transformed into competent bacteria. 
2.2.8 Preparation of plasmid DNA 
2.2.8.1 Mini-prep of plasmid DNA 
Single bacterial colonies were picked from LB-agar selection plates and spiked 
into pre-warmed LB broth containing the relevant antibiotic. Samples were 
incubated with shaking overnight at 37°C. Once turbid, samples were spun-
down at 6,000 r.c.f. for 5 minutes to pellet bacteria. Preparation of plasmid DNA 
was carried out using a QIAprep kit (Qiagen). Purified plasmid DNA was 
analysed using a Nanodrop 1000 to determine concentration and purity. DNA 
was stored in EB buffer at -20°C. 
2.2.8.2 Maxi-prep of plasmid DNA 
For larger scale production of plasmid DNA, single bacterial colonies were 
picked and spiked into pre-warmed LB broth containing the relevant antibiotic. 
Samples were incubated with shaking for 10-12 hours at 37°C. Starter culture 
was then diluted 1:1000 into 250 mL of LB broth containing antibiotic. Cells 
were then grown at 37°C for 12–16 h with vigorous shaking. Bacterial cells were 
harvested by centrifugation at 6000 r.c.f. for 15 min at 4°C. A Qiagen plasmid 
maxi-prep kit was then used to purify plasmid DNA and standard manufacturers 
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protocol was followed. Air-dried plasmid DNA was re-suspended in EB buffer 
and analysed using a Nanodrop 1000 to determine concentration and purity. 
DNA was aliquoted and stored at -20°C. 
2.2.8.3 Preparation of glycerol stocks 
Bacteria expressing various plasmid DNA constructs were stored as glycerol 
stocks. In short, 750 µL of starter culture was combined with 250 µL 50% v/v 
autoclaved glycerol (VWR) and stored at -80°C. 
2.3 Biochemistry 
2.3.1 Protein concentration determination 
Protein concentration of cellular lysate, recombinant protein and purified 
antibodies were determined using Bradford protein assay (BioRad). A series of 
standards ranging from 0-10 µg/mL were made up using either BSA for protein 
concentration determination, or rabbit IgG for antibody concentration 
determination. Standards were combined with Bradford solution diluted 1:5 in 
ddH2O and a standard curve was generated. Protein or antibody samples were 
added to diluted Bradford solution, incubated for 5 minutes and absorption was 
measured at 595 nm. Protein concentrations were calculated from the standard 
curve using Microsoft Excel. 
2.3.2 Cell lysis and sample preparation 
2.3.2.1 Radioimmunoprecipitation assay (RIPA) buffer 
Fresh RIPA buffer was prepared fresh and kept on ice. Adherent cells were 
grown to the desired confluence before culture medium was aspirated and cells 
were washed once with ice-cold PBS. RIPA buffer was added directly to the 
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cells and left to incubate at 4°C for 10 minutes. After incubation, cells were lifted 
from culture dish using a sterile cell scraper (Greiner) and centrifuged at 
~20,000 r.c.f. at 4°C for 10 minutes to pellet cellular debris. Supernatant was 
snap-frozen in liquid nitrogen and stored short-term at -20°C or long-term at -
80°C. 
2.3.2.2 Fractionation lysis 
Fraction lysis buffers were prepared fresh and kept on ice. Adherent cells were 
grown to the desired confluence before culture medium was aspirated and cells 
were washed once with ice-cold PBS. Buffer A was added to cells and left to 
incubate at 4°C for 20 minutes. After incubation, cells were very gently lifted 
from culture dish using a sterile cell scraper (Greiner) and centrifuged at 1,400 
r.c.f. at 4°C for 10 minutes. Supernatant was carefully aspirated, labelled as 
‘cytoplasmic fraction’ and snap frozen. Pellet was re-suspended in buffer A+ 
and incubated for 1 minute at 37°C. EDTA was immediately added to a final 
concentration of 2 mM and lysate was incubated on ice for 5 minutes. Lysate 
was then centrifuged at 1,400 r.c.f. at 4°C for 5 minutes. Supernatant was 
carefully aspirated, labelled as ‘nucleoplasmic fraction’ and snap frozen. Pellet 
was re-suspended in buffer B and incubated for 1 minute at room temperature. 
Lysate was then centrifuged at 15,000 r.c.f. at 4°C for 10 minutes. Supernatant 
was then aspirated, labelled as ‘chromatin fraction’ and snap frozen. Protein 
lysates were stored short-term at -20°C or long-term at -80°C. 
2.3.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Pre-cast Bolt or NuPAGE SDS-PAGE gels (Life Technologies) were selected 
according to protein of interest. Typically proteins larger than 300 kDa were run 
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using 3-8% Tris-Acetate gels, with most other proteins run using 4-12% Bis-Tris 
gels. Protein concentration of samples was determined by Bradford assay and 
typically 20-40 µg of protein was run per well. Protein samples were prepared 
with LDS NuPAGE sample buffer (Life Technologies), supplemented with 5% 
v/v β-mercaptoethanol (Sigma). Samples were boiled for 5 minutes before 
centrifugation at 2,700 r.c.f. at 4°C for 2 minutes. Samples were run alongside a 
pre-stained high-molecular weight marker (Life Technologies) as well as an un-
stained standard molecular weight marker (BioRad). Gels were run at 90V for 
20 minutes followed by 180V (NuPAGE) or 165V (Bolt) for 50 minutes. Proteins 
were visualised on gels using SimplyBlue Safestain (Life Technologies) 
following manufacturers protocol. 
2.3.4 Immunoblotting 
2.3.4.1 Standard protein immunoblotting 
Proteins were separated by size by SDS-PAGE and then transferred to either 
0.2 µm pore-size nitrocellulose membranes or 0.2 µm pore-size PVDF 
membranes (GE Healthcare). Chilled 20X transfer buffer (Life Technologies) 
was diluted down to working concentration and supplemented with 10% v/v 
methanol (VWR). Transfer was carried out at 80V for 2 hours at room 
temperature. Protein transfer efficiency was determined by staining membranes 
in Ponceau S stain (Sigma) diluted in 1% v/v acetic acid (VWR). Excess 
Ponceau S stain was removed by washing in 1% v/v acetic acid until protein 
bands were visible. Prior to blocking, all Ponceau S stain was removed by 
washing for 5 minutes in TBS-Tween20. 
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To minimise non-specific binding, membranes were blocked by incubation in 
either 5% w/v non-fat milk in TBS-Tween20 (non phospho-antibodies)(Marvel) 
or 10% v/v Roti-Block in TBS-Tween20 (phospho-antibodies)(Carl Roth) at 
room temperature for 1 hour. Blocking solution was removed by a brief wash in 
TBS-Tween20 before addition of primary antibody. Antibodies were diluted in 
AbDil solution. Details of antibody dilution can be found in table 2.3. Following 
primary antibody incubation, membranes were washed 3 x 5 minutes in TBS-
Tween20. Membranes were then incubated with secondary antibody 
conjugated with horseradish peroxidase (HRP) in 5% w/v low-fat milk, according 
to details in table 2.3. Following secondary antibody incubation, membranes 
were washed 3 x 5 minutes in TBS-Tween20. Membranes were incubated in 
Clarity ECL substrate (BioRad) according to manufacturers protocol and signal 
was detected using either X-ray film (Kodak) or the Odyssey CLx infrared 
detection system (LI-COR). 
2.3.4.2 Immunoblotting of large (>300 kDa) proteins 
For large proteins, a modified protocol was used for immunoblotting to ensure 
maximum transfer. Samples were boiled for 2 x 5 minutes with a brief vortex 
between each boil. Standard protein immunoblotting was followed except a 
modified Laemlli buffer was used for transfer, supplemented with 7.5% v/v 
methanol. Transfer was carried out at 4°C for 16-20 hours at 30V. The buffers 
and apparatus used for the blotting were all SDS-free to ensure maximum 
transfer efficiency. 
2.3.4.3 Strip and re-blotting 
When necessary, membranes were stripped of primary and secondary 
antibodies and re-probed with fresh antibody. A modified stripping buffer 
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(Yeung and Stanley, 2009) was added to membranes for 10 minutes at room 
temperature with agitation. After incubation, membranes were washed 3 x 5 
minutes in TBS-Tween20 before blocking and standard immunoblotting protocol 
was followed. 
2.3.5 GFP-Trap Immunoprecipitation 
2.3.5.1 Generation of GFP-trap beads 
Transformed BL21 E. coli expressing LAMA GFP-Trap fused to a GST tag were 
kindly donated by the Lamond Lab, University of Dundee. 
 
A single colony was used to inoculate 5 mL LB broth (containing 100 µg/mL 
ampicillin) and was grown for 12 hours at 37°C with shaking. The starter culture 
was used to inoculate 500 mL of pre-warmed auto-induction media (containing 
100 µg/mL ampicillin). This was incubated for 6 hours at 30°C. The temperature 
was then decreased to 25°C and bacteria were grown for 24 hours with 
shaking. Cells were harvested by centrifugation at 4,500 r.c.f at 4°C for 45 
minutes with slow deceleration. 
  
The cell pellet was re-suspended in 50 µL of PBS for every 1 mL of culture 
volume. Complete-EDTA free protease inhibitors (Roche) were added to the 
PBS prior to re-suspension. Lysozyme (Sigma) was added to a final 
concentration of 1 mg/mL and cells were incubated at 4°C with rotation for 30 
min. Triton X-100 (VWR) was added to a final concentration of 1% v/v rotated 
for 5 minutes at 4°C. 
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Cell lysate was sonicated on ice with the program set to 5 seconds bursts with 5 
second rests at 15% power for 5 minutes. Lysate was incubated at 4°C with 
rotation for 15 minutes before sonication was repeated. Cell lysate was 
centrifuged at 20,000 r.c.f. in a JLA25.50 rotor for 30 minutes at 4°C to pellet 
cellular debris. 
 
Glutathione sepharose 4B slurry (Thermo) was pre-equilibrated by washing in 
50 mL of PBS. Beads were centrifuged at 3000 r.c.f. for 4 minutes at 4°C with 
slow deceleration to preserve bead pellet. The protein lysate was then 
combined with the washed glutathione sepharose 4B and incubated overnight 
on a rotating wheel at 4°C. The bead/lysate solution was centrifuged at 3000 
r.c.f. for 4 minutes at 4°C with slow deceleration and beads were washed twice 
with 50 mL of PBS. After washing, beads were re-suspended in PBS. 
 
A 10 mL plastic column (Thermo) was washed with 30 mL PBS at room 
temperature. Beads in PBS were added to column and washed with 20 mL of 
TBS followed by 20 mL of thrombin cleavage buffer. 20U of thrombin (Sigma) 
was added to approximately 2-3 mL of cleavage buffer in the column. 3 µL of 
0.5% w/v xylene cyanol (Sigma) was added to the column and pipetted to mix 
(added to enable visualisation of mixing and elution). Column was incubated 
overnight at room temp. Thrombin cleavage buffer was added to the column to 
elute cleaved fusion protein. Flow-through was collected until no more xylene 
cyanol was visible in the column. 
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Column flow through containing LAMA GFP-Trap was washed with PBS and 
concentrated using a 5 kDa centrifugal concentrator (Millipore). Protein 
concentration was measured by Bradford assay. 
 
LAMA GFP-Trap protein was coupled to NHS-Activated Magnetic Beads 
(Thermo) following manufacturers instructions. GFP-Trap beads were stored in 
PBS + 0.05% w/v sodium azide (Sigma) for up to one year at 4°C. 
2.3.5.2 GFP-Trap Immunoprecipitation protocol 
Cells stably expressing or transiently expressing GFP fusion proteins were 
lysed using the fractionation lysis protocol and chromatin fractions were used 
for immunoprecipitation reactions. Cells expressing an empty GFP vector were 
used as a control condition. 10% of the sample was retained before the IP to be 
used as input control. GFP-Trap beads were washed 3 X 2 minutes in PBS 
before cell lysate was added to beads and incubated at 4°C for 1 hour with 
rotation. Beads were washed 3 X 5 minutes in IP wash buffer before LDS 
NuPAGE sample buffer was added, supplemented with 5% v/v β-
mercaptoethanol. Samples were boiled for 5 minutes, gently vortexed and then 
boiled for a further 5 minutes. Samples were then spun at 2,700 r.c.f. at 4°C for 
2 minutes and then either run on SDS-PAGE gel or stored at -80°C. 
2.3.6 Generation of Bod1L non-phospho antibody 
Peptide antibodies and non-phospho antibodies were designed and generated 
according to (Field et al., 1998). Bod1L antibody peptide was designed by Iain 
Porter (Swedlow group, University of Dundee) and immunised in rabbit. Full 
antigenic peptide sequence was NH2-CLYSKYYSDSDDELTVEQRRQS-COOH 
(>80% purity)(Pepceuticals). 
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2.3.6.1 Coupling peptides to resin for affinity purification 
Peptide was coupled covalently to resin in order to affinity purify the antigenic 
serum. All steps were carried out in a 5 ml poly-prep chromatography column 
(Biorad). 5 ml of Affigel-10 resin was washed and then activated with 5% v/v 
ethylene diamine (Sigma) in ddH2O to generate Amino-Affigel. Amino groups 
were then converted to iodoacetyl groups via the addition of 7 mg IAA-NHS 
ester (Sigma) per ml of resin. Resin was washed thoroughly using 0.1 M sodium 
phosphate buffer (pH 7.8) before 5 mg of peptide (dissolved in DMSO at 100 
mg/ml) was added to the resin and mixed gently overnight at 4°C. Residual 
iodoacetate groups were blocked by the addition of 0.2 % v/v β-
mercaptoethanol. Resin was then consecutively washed with 0.1 M NaHCO3, 1 
M Na2CO3, ddH2O, 0.2 M glycine-HCl (pH 2.0) and TBS in order to remove non-
covalently bound peptide. Resin was re-equilibrated and stored in TBS + 0.1% 
w/v NaN3. 
2.3.6.1 Purification of anti-peptide antibody 
Serum was diluted 1:1 with TBS and filtered through a 0.2 µm non-cellulose 
filter (Sartorius Stedim). Diluted serum was then loaded 10 times over the 
column and then washed with TBS. Column was washed 10 times with 0.5 M 
NaCl, 20 mM Tris-HCl (pH 7.4) and 0.2% v/v Triton-X100 before a further wash 
with TBS. Antibody was eluted from the column using a low pH buffer consisting 
of 0.15 M NaCl, 0.2 M Glycine-HCl (pH 2.0). 500 µL fractions were collected 
into eppendorf tubes containing 0.1 mL of 2 M Tris-HCl (pH 8.5). Column pH 
was re-equilibrated with a TBS wash and stored in TBS + 0.1% w/v NaN3. 
Individual fractions were spotted onto nitrocellulose and protein content was 
visualised with Ponceau S. Protein containing fractions were pooled and 
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dialysed into TBS overnight. NaN3 concentration was bought up to 0.1% v/v and 
antibodies were stored at either 4°C or -20°C in 50% v/v glycerol. 
2.3.7 Generation of Bod1L pS1145 and pS1710 antibodies 
2.3.7.1 Design of phospho-peptide 
To maximise the likelihood of generating a successful antibody, peptides were 
designed with an overall net charge of -2 (https://www.genscript.com/ssl-
bin/site2/peptide_calculation.cgi - accessed 09/14). A surface accessibility plot 
was generated to ensure that the modified pS residue was likely to be exposed. 
As figure 2.1 shows, the pS residue is exposed in both peptides. 
 
The antigenic phospho-peptide sequence for the pS1145 site was NH2-
CDNRNNN[pS]QQDID-COOH. The antigenic phospho-peptide sequence for 
the pS1710 site was NH2-CEEVDG[pS]QGNMMR-COOH. 
 
 
Figure 2.1 Surface accessibility plot for Bod1L phospho-peptide 
Relative Surface Accessibility (RSA) was calculated using NetSurfP1.1. Residues (Petersen et 
al., 2009). Individual amino acids were classified as exposed or buried based on the cut-off 
value assigned by the algorithm. 
Exposed Exposed
Buried Buried
 113 
2.3.7.2 Thiol coupling of phospho-peptides to KLH 
In order to generate the maximum possible antigenic effect in the sheep, the 
phospho-peptides were coupled with Keyhole Limpet Haemocyanin 
(KLH)(Millipore). Two sheep were used per phospho-peptide to limit any 
possible sheep-to-sheep variation in the immune response to the peptides. For 
the four injections needed to immunise the sheep, 100 mg of KLH was 
dissolved in 2 mL ddH2O and dialysed overnight in 0.1 M sodium phosphate 
(pH 7.8). After dialysis, aggregates were removed from the solution by 
centrifugation. KLH-solution was warmed to room temperature and 1/9th volume 
100 mg/mL IAA-NHS in DMSO was added. In dark, 4°C conditions, the solution 
was loaded into a large gel-filtration column containing Bio-Gel P-10 resin 
(Biorad) and equilibrated with 0.1 M sodium phosphate (pH 7.8). The KLH 
containing fractions (greyish-green colour) were pooled and 10 mg phospho-
peptide was added and incubated for 8 hours at 4°C with gentle rotation. pH 
was checked and adjusted to 7.2-7.8 if necessary. KLH coupled peptide was 
diluted to 5 ml (final concentration 2 mg/mL) with 0.15 M NaCl, aliquoted and 
frozen ready for immunisation. 
2.3.7.3 Immunisation protocol in sheep 
As mentioned previously, two sheep were immunised per phospho-peptide to 
limit any possible sheep-to-sheep variation in the immune response to the 
peptides. The sheep were immunised with the KLH-peptide four times in total, 
and three bleeds were taken according to the immunisation schedule shown in 
table 2.2. 
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Table 2.2 Immunisation schedule for Bod1L phospho-antibody generation 
Immunisation and bleeds were carried out by the Scottish National Blood Transfusion Service 
(Midlothian, Scotland). Terminal bleeds on sheep were not performed. 
 
Sera collected from each donation were run on a western blot on control 
samples and samples depleted of Bod1L by siRNA to assess whether a band 
could be identified. The strongest band was seen in the third bleed for each 
sheep and as such this sera was used for further affinity purification. 
2.3.7.4 Coupling of phospho-peptides and non-phospho-peptides to resin for 
affinity purification 
To generate Bod1L phospho-antibodies, HiTrap NHS activated HP columns 
(GE Healthcare) were used to affinity purify the sera. To prepare the columns 
for affinity purification, columns were first washed with 6 mL ice-cold 1 mM HCl 
before 1 mL peptide-containing solution was loaded into column. Peptide-
containing solution consisted of 5 mg peptide in 1 mL coupling buffer (0.1 M 
NaHCO3, 0.5 M NaCl (pH 8.3)). Column containing peptide was incubated at 
room temperature for 60 minutes. Un-reacted NHS groups were then blocked 
by washing column with 10 mL blocking buffer (0.5 M ethanolamine, 0.5 M NaCl 
(pH 8.3)). Column was then incubated for 30 minutes at room temperature in 
blocking buffer. Column was consecutively washed with 10 mL of 10 mM Tris-
HCl (pH 8.0), 10 mL of 0.1 M glycine (pH 2.0), 10 mL of 10 mM Tris-HCl (pH 
8.0) and 10 mL of 0.1 M triethylamine (pH 11.5). Washes were repeated before 
column was washed with 30 mL PBS. Column was stored at 4°C in a storage 
buffer containing 0.05 M Na2HPO4 and 0.1% w/v NaN3 (pH 7.0). 
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2.3.7.5 Purification of phospho-antibody 
Serum from each of the immunised sheep was purified on a column coupled 
with the non-phospho peptide, followed by a subsequent purification on a 
column coupled with the phospho-peptide. The non-phospho peptide column 
binds any antibodies that are specific to the epitope but not the phospho-
epitope. The eluted antibodies from this column were designated as pan-
specific and were used as an internal control. The column coupled with the 
phospho-specific peptide would therefore only bind the phospho-specific 
antibodies left in the serum, thus acting to enrich this pool of antibody in the 
eluate from the column. 
 
Approximately 15 mL serum was diluted 1:1 with 2 X PBS and filtered through a 
0.2 µm non-cellulose filter. Serum solution was re-circulated through the column 
using a peristaltic pump overnight at 4°C. Column was washed with 
approximately 50 mL wash buffer (0.5 M NaCl, 0.1% v/v Triton-X100 in PBS) 
until no protein could be detected in the flow through by Bradford assay. 
Column was then washed with 50 mL PBS. Antibody was eluted using 0.1 M 
glycine (pH 2.6), collecting 1 mL of eluate into eppendorfs containing 100 µL 2M 
Tris-HCl (pH 8.5). Column was washed with 50 mL of 10 mM Tris-HCl (pH 8.0), 
followed by 50 mL PBS before being stored at 4°C in a storage buffer 
containing 0.05 M Na2HPO4 and 0.1% w/v NaN3 (pH 7.0). 
 
Individual eluates were spotted onto nitrocellulose and protein content was 
visualised with Ponceau S. Protein containing fractions were pooled and 
dialysed into PBS overnight. NaN3 concentration was bought up to 0.1% v/v and 
antibodies were stored at either 4°C or -20°C in 50% v/v glycerol. 
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2.3.8 In vitro kinase assays 
2.3.8.1 GFP-MDC1 in vitro ATM kinase assay 
ATM was immunoprecipitated with anti-ATM antibody (Abcam ab78) from cells 
dosed with 5 Gy IR and allowed to recover for 60 minutes. Cells were lysed in lysis 
buffer containing 20 mM Tris Acetate (pH 7.5), 1 mM EGTA, 1 mM EDTA, 10 mM 
Na-β-glycerophosphate, 5 mM Na-pyrophosphate, 1 mM Na-orthovanadate, 50 mM 
NaF, 1 mM microcystin, 0.27 M sucrose and 1 % v/v Triton-X-100. 
Immunoprecipitates were washed three times with lysis buffer and three times with 
a kinase buffer containing TADB (6.7 mM Tris–HCl (pH 7.5), 13 mM EGTA, 2 mM 
DTT), IB (10 mM Na2HPO4 (pH 7.4), 100 mM KCl, 1 mM MgCl2) and 
magnesium/ATP cocktail (27.5 mM MgCl2, 0.183 mM ATP, 4 mM 3-(N-morpholino) 
propanesulfonic acid (pH 7.2), 9.17 mM β-glycerolphosphate, 1.83 mM EGTA, 0.37 
mM sodium orthovanadate, 0.37 mM DTT). Immunoprecipitated ATM was 
combined with GFP-MDC1 purified using GFP-trap protocol outlined in section 
2.3.5 and incubated at 30°C for 45 minutes. Kinase reactions were stopped with 
SDS−PAGE loading dye and reaction mixtures were separated by SDS−PAGE. 
Transferred ATM and substrates were visualised using anti phospho-ATM (S9181), 
anti-phospho MDC1 (T4) and anti-MDC1 antibodies. 
2.3.8.2 Bod1L-T in vitro DNA-PK kinase assay 
Purified DNA-PKcs, Ku70/80 and Calf-thymus DNA was a kind gift from the 
Lees-Miller lab (Calgary, Canada). In vitro kinase assays were carried out as 
described (Yu et al., 2003). In short, purified DNA-PKcs (30 ng) and Ku70/80 
(10 ng) were incubated in 20 µL of kinase buffer containing 50 mM Tris–HCl 
(pH 8.0), 10 mM MgCl2, 1 mM DTT, 0.2 mM EGTA, 0.1 mM EDTA, 10 µg/ml 
sonicated calf thymus DNA, and 300 ng GST-Bod1L-T or 300 ng GST-Bod1L-
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TS1710A and incubated for 45 minutes at 30°C. Kinase reactions were stopped 
with SDS−PAGE loading dye and reaction mixtures were separated by 
SDS−PAGE. Transferred substrates were visualised using anti phospho-Bod1L 
(S1710A), anti-GST and anti-KU80 antibodies. 
2.3.9 In vitro GFP-MDC1 phosphatase assay 
Phosphatase assay was performed as described in (Porter et al., 2013). In brief, 
PP2A-B56δ-GFP was immunoprecipitated from RPE1 cells stably expressing the 
PP2A-B56δ-GFP construct (Foley et al., 2011). Beads were washed with a 
stringent wash buffer (300 mM NaCl, 1% v/v NP-40). GFP-MDC1 was 
immunoprecipitated from U2OS cells stably expressing GFP-MDC1, treated with 10 
µM etoposide for 16 hours. GFP-MDC1 and PP2A-B56δ-GFP were mixed and 
resuspended in PPase reaction buffer +/- 2 nM Okadaic acid (50 mM HEPES, 1 
mM dithiothreitol (DTT), 1 mM EDTA and 0.1% v/v NP40). Samples were incubated 
for 45 minutes at 30°C before run on SDS-PAGE gel and probed with anti-phospho 
MDC1 (T4), anti-GFP and anti-PP2A-C antibodies. 
2.4 Imaging 
2.4.1 Fixative preparation 
2.4.1.1 3.7% w/v Paraformaldehyde (PFA) 
10 µL 10M KOH (Sigma) was added to 3.5 mL ddH2O. To this, 1.85 g of 
paraformaldehyde was added and agitated in a water bath set to 90°C for 5 
minutes. After solution had cleared, it was passed through a 0.2 µm filter 
(Millipore) and 10 µL 10M HCl was added to neutralise pH. Solution was made 
up to 45 mL with ddH2O to generate a paraformaldehyde solution with a final 
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concentration of 3.7% w/v. PFA solution was warmed to 37°C and used 
immediately. 
2.4.1.2 70% v/v EtOH 
Absolute ethanol (VWR) was diluted with ddH2O until a concentration of 70% 
v/v was achieved. 70% EtoH was stored at -20°C until immediately before use, 
at which point it was transferred to a container containing dry-ice to keep 
temperature of ethanol solution low. 
2.4.2 Immunofluorescence 
2.4.2.1 Standard immunofluorescence staining 
Cells were seeded onto borosilicate glass cover slips, thickness 1.5 (VWR). 
Once desired confluence was reached, media was aspirated and cells were 
fixed in 3.7% v/v PFA for 7 minutes at 37°C at 5% CO2 in a humidified 
incubator. Fixative was aspirated and cells were briefly washed in PBS-T before 
incubation in PBS-T for 5 minutes at 37°C at 5% CO2 in a humidified incubator. 
An additional 5-minute incubation in PBS-T was carried out at room 
temperature before coverslips were blocked with 1% v/v normal donkey serum 
(Sigma) in AbDil for 1 hour at room temperature or overnight at 4°C. Coverslips 
were washed once in TBS-T before primary antibody was added for 1 hour at 
room temperature diluted in AbDil. Details of antibody dilution can be found in 
table 2.3. Coverslips were gently washed twice in TBS-T, before the 
corresponding-species fluorescently labelled secondary antibody diluted 1:150 
in AbDil (Jackon ImmunoResearch) was added for 1 hour. Coverslips were 
washed twice in TBS-T and then twice in TBS before 4',6-diamidino-2-
phenylindole (DAPI)(Sigma) was added to coverslips at a final concentration of 
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1 µg/mL in TBS for 5 minutes. Cells were washed twice in TBS before mounting 
onto microscope slides (VWR) with mounting medium. Coverslip edges were 
sealed with nail-varnish and stored at -20°C in the dark. 
2.4.2.2 Chromosome spreads 
Cells were seeded onto borosilicate glass cover slips, thickness 1.5 and grown 
to desired confluence. 14 hours prior to fixation, nocodazole (CalBioChem) was 
added to a final concentration of 100 ng/mL. After incubation with nocodazole, 
cells were swollen in swelling media for 20 minutes at room temperature (40% 
fresh cell culture media, 60% ddH2O passed through 0.45 µm filter (Millipore) 
and 100 ng/mL nocodazole). Coverslips were then centrifuged at 2,400 r.c.f. for 
4 minutes on blotting paper (GE Healthcare) to spread the chromosomes. 
Standard immunofluorescence staining was then carried out. 
2.4.3 Image acquisition 
2.4.3.1 Fixed wide-field microscopy 
Three-dimensional wide-field image data sets were primarily acquired using a 
DeltaVision Elite imaging system (GE Healthcare) equipped with an Olympus 
IX71 inverted microscope with high precision stage, and light delivery optics. 
Microscope was fitted with solid-state illumination source and CoolSNAP HQ2 
CCD camera. In addition, microscope was fitted with a Quantifiable Laser 
Module (QLM) and environmental chamber for live-cell photo-manipulation. 
Depending on application, imaging was carried out using a 100X/1.4NA Plan-
Apochromat oil immersion objective, 60X/1.42NA Plan-Apochromat oil 
immersion objective, 40X/0.6NA Plan Fluor objective or a 40X/1.2NA Plan-
Apochromat oil immersion objective. 
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Image data sets were acquired in a single sitting and Z-stacks were collected 
using Nyquist sampling. Images were deconvolved using softWoRx software 
(GE Healthcare). 
2.4.3.2 Live cell microscopy 
For live cell microscopy, cells were seeded into glass bottom LabTek imaging 
dishes (Thermo) and incubated until desired cell confluence was reached. Once 
desired confluence was reached, media was aspirated and cells were washed 
with PBS at 37°C. L-15 media (Lonza) with 10% v/v FBS was added to cells 
and dish was moved to pre-warmed environmental chamber of microscope. 
Cells were imaged as described above, with care taken to minimise exposure 
times and prevent temperature fluctuations. 
2.4.3.3 Laser stripe damage 
To generate laser micro-irradiation stripes, cells were seeded into glass bottom 
LabTek imaging dishes (Thermo) and incubated until approximately 60% 
confluent. Media was aspirated and cells were washed with PBS at 37°C. L-15 
media (Lonza) with 10% v/v FBS and 0.5 µg/ml Hoechst 33342 (Sigma) was 
added to cells and dish was incubated for 30 minutes at 37°C at 5% CO2 in a 
humidified incubator. Cells were moved to pre-warmed environmental chamber 
of microscope. Laser micro-irradiation stripes were generated using a 
60X/1.42NA oil immersion objective using a 30 mW 406 nm laser at 20% power 
with exposure time of 0.1 seconds. Striped cells were either imaged as 
described above or incubated for 30 minutes post before being fixed and 
immuno-stained. 
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2.4.3.4 Fluorescence Recovery After Photobleaching (FRAP) 
Cells were prepared for live cell imaging as described previously. For FRAP 
experiments the microscope was set-up to acquire 3 pre-FRAP images and 32 
post images using adaptive timing. Expected half-life was optimised for each 
experimental condition, total imaging ranged between 2-20 minutes. FRAP of 
GFP fusion proteins was performed using 60X/1.42NA oil immersion objective, 
1 second 50 mW 488 nm laser exposure at 100% power. FRAP of 
RFP/mCherry fusion proteins was performed using 60X/1.42NA oil immersion 
objective, 2 second 50 mW 532 nm laser exposure at 100% power. 
2.4.3.5 Förster Resonance Energy Transfer (FRET) 
Cells were prepared for live cell imaging as described above. Fusion proteins 
expression GFP and TagRFP-t were used as an acceptor Photobleaching 
FRET pair. Imaging was carried out using a Zeiss 710 confocal microscope 
fitted with an environmental chamber set to 37°C. Photobleaching was 
performed using 60X/1.42NA oil immersion objective, 1 second 20 mW 543 nm 
laser exposure at 100% power, which reduced TagRFP-t signal by 60-70% of 
maximum. 
2.4.4 Flow cytometry 
Cells were transfected with siRNA as described previously and then incubated 
in 10 µM Etoposide for 14 hours. Cells were harvested by trypsinisation and 
washed twice in PBS. Cells were transferred to FACS tubes (Greiner) and fixed 
in 1 mL ice-cold 70% v/v EtOH. Cells were transferred to -20°C for 24 hours. 
Cells were washed twice in PBS + 1% w/v Bovine Serum Albumin 
(BSA)(Sigma). Cells were then pelleted and re-suspended in 500 µL staining 
buffer and incubated at room temperature protected from light for 20 minutes. 
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Cells were analysed using a FACS Calibur (Becton Dickinson) and data was 
analysed using FlowJo software. 
2.4.5 Data analysis 
2.4.5.1 Image quantification 
Images acquired using a DeltaVision Elite microscope were deconvolved in 
SoftWoRx software and imported into OMERO for processing (Allan et al., 
2012). Regions of interest (ROI) were drawn around cells for processing using 
either the built-in software in OMERO or the “Box-It” tool of the OMERO.mtools 
suite. Using the ‘Intensity Measure’ tool in the OMERO.mtools suite, cells to be 
analysed were segmented using Otsu thresholding and a minimum object size 
was set. The fluorescence signal for multiple channels was measured within the 
segmented mask and background signal was determined using a 2-pixel 
annulus derived from a 1-pixel gap around the mask. Quantified fluorescence 
intensity was expressed as the summed fluorescence intensity for each channel 
within the mask, subtracting the product of the mask size and average 
background intensity calculated from the 2-pixel annulus. 
2.4.5.2 Statistics 
Statistical tests were performed using SigmaPlot 12 (Sysat Software Inc.) or 
SPSS statistics V22 (IBM). A Kolmogorov–Smirnov test was performed to 
determine the distribution of the dataset. For normally distributed data, a 
student t-test was performed. For non-parametric data sets, a Wilcoxon–Mann–
Whitney test was used. Data was a p-value ≥0.05 was determined as non-
significant. A p-value score of between 0.01 and 0.05 was determined as 
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significant (*), between 0.01 and 0.001 as very significant (**) and ≤0.001 as 
extremely significant (***). 
2.4.6 Intra S-phase checkpoint assay 
To determine the integrity of the intra S-phase checkpoint, HeLa cells were 
transfected with control, PP2A-B56, Bod1L or PP2A-B56 + Bod1L siRNA. After 
48 hours, cells were irradiated with 0, 5 or 10 Gy and left to recover for 1 hour at 
37°C. BrdU (Life Technologies) was added incubated for a further 1 hour. Cells 
were fixed in PFA and BrdU intensity was determined by microscopy. 
2.5 Software and bioinformatics 
 
DNA sequence analysis, cloning design and DNA sequencing data was all 
carried out using CLC workbench 6 (CLC Bio). Pair-wise alignments were 
carried out using EMBOSS Needle (EMBL-EBI) and multiple sequence 
alignments were undertaken using Clustal OMEGA (EMBL-EBI). Potential post-
translational modifications on Bod1L were identified using ELM (Dinkel et al., 
2013) and Phosphosite Plus (Cell Signalling). Wide-field microscopy images 
were deconvolved using SoftWoRx software (GE Healthcare). All microscopy 
images and metadata were imported and saved using OMERO. Analysis was 
carried out using OMERO and a MatLab-based plug-in for OMERO, 
OMERO.mtools (Michael Porter, University of Dundee). Statistical tests were 
performed using SigmaPlot 12 and SPSS V22. All figures and diagrams were 
generated using Photoshop CS5.1 (Adobe) and Illustrator CS5.1 (Adobe). 
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2.6 Buffers, Reagents and Chemicals 
2.6.1 Chemicals and Reagents 
Unless otherwise stated, all chemical compounds were dissolved in DMSO 
(Sigma) to a stock concentration of between 100 µM – 10 mM. Etoposide 
(Sigma) was stored at a stock concentration of 10 mM used at a working 
concentration of 10 µM for 16 hours. Monastrol (Tocris) or S-trityl-L-cysteine 
(STLC)(Enzo Life Sciences) were used to induce mitotic arrest overnight at a 
concentration of 100 nM or 5 µM respectively. Nocodazole (CalBioChem) was 
stored at a stock concentration of 1 mM and used at a concentration of 100 
ng/mL for 12 hours. MG132 (CalBioChem) was stored at a stock concentration 
of 10 mM and used at a final concentration of 10 µM for 1 hour. KU59933 
(Selleck) was stored at a stock concentration of 10 mM and used at a working 
concentration of 10 µM for 1 hour. Cisplatin (Sigma), Mitomycin C (in 
EtOH)(SantaCruz), Camptothecin (Donated by Rouse group, University of 
Dundee) and 6-Thioguanine (Sigma) were all used at the concentration ranges 
indicated for clonogenic survival assays.  
 
Dithiothreitol (DTT)(Sigma) was made at a stock concentration of 1 M, aliquoted 
and stored at -20°C. DTT was used at a final concentration of 1 mM 
Microcystin-LR (Carol McIntosh, University of Dundee) was stored at -80°C at a 
stock concentration of 1 mM and used at a final concentration of 1 µM. 
Phenylmethanesulfonylfluoride (PMSF)(Thermo) was stored at a stock 
concentration of 0.2 M at -20°C in 100% EtOH and used at a final concentration 
of 0.1 µM. 
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For bacterial growth, Ampicillin was added to LB and LB-agar at a final 
concentration of 100 µg/mL. Kanamycin was added to LB and LB-agar at a final 
concentration of 50 µg/mL. Chloramphenicol was added to LB and LB-agar at a 
final concentration of 100 µg/mL. Isopropyl β‐D‐1‐thiogalactopyranoside 
(IPTG)(Sigma) was used for protein expression induction at a final 
concentration of 0.1 mM. LPC was prepared by combining a 10 mg/mL solution 
of leupeptin, pepstatin and Aprotinin (Sigma) in DMSO. LPC solution was 
aliquoted and stored at -20°C and used at a final concentration of 10 µg/mL. 
 
Tissue culture medium antibiotics were added at the final concentrations 
indicated in table 2.1. G-418 (SelleckChem) was stored at a stock concentration 
of 100 mg/mL at 4°C for no longer than 1 month. Puromycin (Life Technologies) 
was stored at a stock concentration of 1 mg/mL and stored at -20°C. 
2.6.2 Buffers 
Antibody Dilution Buffer (AbDil) 
0.25% v/v Tween-20 (VWR), 2% w/v BSA (Sigma), 0.1% w/v NaN3 (Sigma) in 1 
X TBS 
 
Electrophoresis loading buffer 
1 X LDS NuPAGE sample buffer (Life Technologies) diluted in ddH2O, 
supplemented with 5% v/v β-mercaptoethanol (Sigma). 
 
Flow cytometry staining buffer 
50 µg/mL Propidium Iodide (PI)(Sigma), 50 µg/mL ribonuclease A (RNase 
A)(Sigma), 1% w/v BSA in 1 X PBS.  
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Fractionation buffer A 
10 mM HEPES (pH7.9)(Sigma), 10 mM KCl (Sigma), 1.5 mM MgCl2 (Sigma), 1 
mM DTT, 10 µg/mL LPC, 0.1 mM PMSF, 0.34 M sucrose (VWR), 10% v/v 
Glycerol (VWR), 0.1% v/v Triton X-100 in 1 X PBS. 
 
Fractionation buffer A+ 
10 mM HEPES (pH7.9)(Sigma), 10 mM KCl (Sigma), 1.5 mM MgCl2 (Sigma), 1 
mM DTT, 10 µg/mL LPC, 0.1 mM PMSF, 0.34 M sucrose (VWR), 10% v/v 
Glycerol (VWR), 0.1% v/v Triton X-100, ~ 50 U benzonase nuclease (Thermo), 
1 mM CaCl2 in 1 X PBS. 
 
Fractionation buffer B 
3 mM EDTA (Sigma), 0.2 mM EGTA (Sigma), 1 mM DTT, 10 µg/mL LPC in 1 X 
PBS. 
 
IP wash buffer 
20 mM Tris-HCl (pH7.4), 200 mM NaCl, 1 mM EGTA, 0.1% v/v Triton X-100 in 1 
X PBS 
 
Laemmli buffer (10 X stock) 
250 mM Tris-Base (Sigma), 2 M Glycine (Sigma) in ddH2O. 
 
LB (Luria-Bertani) liquid medium (ordered in-house) 
10 g/L Tryptone, 10 g/L NaCl, 5g/L Yeast extract in ddH2O 
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LB Agar (ordered in-house) 
20 g/L Agar, 10 g/L Tryptone, 10 g/L NaCl, 5g/L Yeast extract in ddH2O 
 
10 X DNA Loading dye 
25% v/v Ficoll-PM400 (Sigma), 100 mM Tris-HCl (pH 7.4), 100 mM EDTA, ~ 1 
mg Bromophenol blue (SantaCruz) in ddH2O. 
 
Mounting medium 
0.5 % w/v p-Phenylenediamine (Sigma), 20 mM Tris-HCl (pH8.8), 90% v/v 
glycerol in ddH2O and stored at -80°C protected from light. 
 
1 X Phosphate-buffered saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 (Sigma), 1.8 mM KH2PO4 (Sigma) 
in ddH2O. 
 
PBS-Triton X-100 (PBS-T) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.1% v/v Triton 
X-100 in ddH2O. 
 
Radioimmunoprecipitation assay buffer (RIPA) 
1% v/v Triton X-100, 0.1% w/v SDS (Sigma), 50 mM Tris HCl (pH 7.4), 150 mM 
NaCl, 0.5% Sodium Deoxycholate (Sigma), 1 mM EDTA, 1 mM Microcystein-LR 
(Carol McIntosh, University of Dundee), 1% v/v β-mercaptoethanol, 10 µg/mL 
LPC in ddH2O. 
 
SDS-PAGE loading buffer 
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1 X LDS buffer (Life Technologies)(Consists of: 106 mM Tris-HCl, 141 mM Tris 
Base, 2% w/v LDS, 10% Glycerol, 0.51 mM EDTA, 0.22 mM SERVA Blue 
G250, 0.175 mM Phenol Red), 5% v/v β-mercaptoethanol in ddH2O. 
 
SDS-PAGE MOPS running buffer 
50 mM MOPS (Life Technologies), 50 mM Tris Base, 0.1% w/v SDS, 1 mM 
EDTA in ddH2O. Buffer adjusted to pH 7.7 and stored at room temperature. 
 
SDS-PAGE Tris-Acetate running buffer 
50 mM Tricine (Life Technologies), 50 mM Tris Base, 0.1% w/v SDS in ddH2O. 
Buffer adjusted to pH 8.24 and stored at 4°C. 
 
TAE (50 X stock solution) 
2.5 M Tris-Acetate, 50 mM EDTA in ddH2O. 
 
Tris-buffered saline (TBS) 
150 mM NaCl, 50 mM Tris-HCl (pH 7.4) in ddH2O. 
 
TBS-Triton X-100 (TBS-T) 
150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 0.1% v/v Triton X-100 in ddH2O. 
 
TBS-Tween20 
150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 0.1% v/v Tween-20 in ddH2O. 
 
Tris-EDTA (TE) Buffer 
10 mM Tris-HCl (pH 8.0), 1 mM EDTA in ddH2O. 
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Thrombin cleavage buffer 
50 mM Tris-HCl (pH 8.0), 10 mM CaCl2 in ddH2O. 
 
Thrombin storage buffer 
20 mM Tris-HCl (pH8.0), 50% v/v Glycerol in ddH2O. 
 
Transfer buffer 
1 X NuPAGE transfer buffer (Life Technologies), 10% v/v Methanol (VWR) in 
ddH2O. 
 
Western blot stripping buffer (Adapted from (Yeung and Stanley, 2009)) 
6 M GnHCl (Sigma), 0.2% v/v IGEPAL CA630 (NP40)(Sigma), 20 mM Tris-HCl 
(pH 7.5) in ddH2O. Stored at room temperature and used for up to one month. 
 
2.7 Antibodies, Primers, DNA constructs and siRNA 
2.7.1 Antibodies 
Antibodies were aliquoted and stored according to manufacturers instruction at 
either 4°C, -20°C or -80°C in TBS containing 0.1% w/v Na-Azide. Antibodies 
generated in the lab were stored at various temperatures and then tested for 
affinity to determine storage conditions. 
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Table 2.3 Immunoblotting and immunostaining antibodies 
Protein Target Species Manufacturer WB dilution 
IF 
dilution 
MDC1 Mouse Abcam 1:200 1:200 
Bod1L Rabbit Generated by Swedlow Lab 1:250 - 
pBod1L (S1710) Goat Generated by Swedlow Lab 
1:250 
(+1:50 non-
phospho 
peptide) 
1:250 
(+1:50 
non-
phospho 
peptide) 
pBod1L (S1145) Goat Generated by Swedlow Lab 
1:250 
(+1:50 non-
phospho 
peptide) 
1:250 
(+1:50 
non-
phospho 
peptide) 
MDC1 Rabbit Bethyl 1:1000 1:500 
pChk2 (T68) Rabbit Abcam 1:500 - 
Rad51 Rabbit SantaCruz - 1:500 
pMDC1 (S329/T331) Rabbit Gift from Steve Jackson, Cambridge 1:500 1:500 
pMDC1 (T4) 
 
Rabbit 
 
Abcam 
 
1:500 
 
1:500 
 
Phospho-(Ser/Thr) ATM/ATR Substrate 
Antibody 
Rabbit Cell Signalling 1:500 - 
gamma-H2AX (S139) Rabbit Millipore 1:1000 1:500 
GFP Mouse Roche 1:1000 1:1000 
Anti-Centromere Auto-antisera (ACA) Human Gift from Sara Marshall, Dundee - 1:1000 
Histone-H3 Rabbit Cell Signalling 1:1000 - 
FANCD2 Rabbit Abcam 1:1000 - 
ATM Mouse Abcam 1:1000 - 
NBS1 Rabbit Abcam 1:1000 - 
PP2A-B56 (B') Rabbit Millipore 1:1000 - 
pCDC25A (S124) Rabbit Abcam 1:500 - 
pATM (S1981) Rabbit Abcam 1:2000 1:2000 
Chk2 Rabbit Abcam 1:5000 - 
GAPDH Mouse Abcam 1:10000 - 
Vinculin Mouse Sigma 1:20000 - 
Anti-Mouse HRP Donkey GE Healthcare 1:10000  
Anti-Rabbit HRP Donkey Cell Signalling 1:5000  Anti-Sheep HRP Donkey Sigma 1:2500 
 Anti-Mouse FITC/TRITC/Cy5 Donkey Jackson ImmunoResearch - 1:150 
Anti-Rabbit FITC/TRITC/Cy5 Donkey Jackson ImmunoResearch - 1:150 
Anti-Human FITC/TRITC/Cy5 Donkey Jackson ImmunoResearch - 1:150 
Anti-Goat FITC/TRITC/Cy5 Donkey Jackson ImmunoResearch - 1:150 
 
2.7.2 Primer sequences 
The following primers were used during this study. All primers were made up to 
a stock concentration of 100 µmole in TE buffer and stored at -20°C. 
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Table 2.4 Primer sequences 
Primer Name Manufacturer Sequence (5' to 3') Notes 
Bod1L_seq_nt4
08 
Invitrogen 
#E6055F07 TCA GGT TGT GGA CCC AAA G 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt4
96 
Invitrogen 
#E6055F02 CTT TGT GAT TTA GCG TGG CC 
Bod1L gene reverse 
sequencing primer 
Bod1L_seq_nt1
193 
Invitrogen 
#E6055F08 CTG ATG TGG ATG GAC TTA CAG 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt1
999 
Invitrogen 
#E6055F09 GTA CAG GAA GAG ACT GAC AC 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt2
821 
Invitrogen 
#E6055F10 CCA GAC AAG GAG AAG AAC ACA G 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt3
451 
Invitrogen 
#E6055F11 TAT AAG CCA GGC CGT GGA AC 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt4
293 
Invitrogen 
#E6055F12 GAA TGG CAA GAA GGA TGG C 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt5
106 
Invitrogen 
#E6055G01 AAG CAG TGA AGA GGT GGA TG 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt5
898 
Invitrogen 
#E6055G02 TGA AGT GAC ACC AGT TCC AG 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt6
759 
Invitrogen 
#E6055F03 TGG CAT CAT CTC TAC GAG C 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt7
491 
Invitrogen 
#E6055F04 GAA TGC TAA CTC ACC TGC C  
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt8
250 
Invitrogen 
#E6055F05 CGG TCA CAG TGT TGA AGC AG 
Bod1L gene forward 
sequencing primer 
Bod1L_seq_nt9
012 
Invitrogen 
#E6055F06 ATC CAC CAC CAG ATC AGA G 
Bod1L gene forward 
sequencing primer 
Bod1L_Frag1_s
eq_rev In house #69124 CTG TGT TGC CAC TTC CTT 
Bod1L_Frag1 reverse 
sequencing primer 
TagRFP-
t_Seq_End_fwd 
Invitrogen 
#M5015A08 CTG GGG CAC AAA CTT AAT GG 
TagRFP-t  forward 
sequencing primer 
TagRFP-
t_Seq_End_rev 
Invitrogen 
#E2252B01 GAC GTA GGT CTC TTT GTC G 
TagRFP-t  reverse 
sequencing primer 
pCMV5 Fwd Dundee DNA sequencing service CGC AAA TGG GCG GTA GGC GTG 
CMV forward 
sequencing primer 
pCMV5 Rev Dundee DNA sequencing service 
CCT CCA CCC CAT AAT ATT ATA GAA GGA 
CAC 
CMV reverse 
sequencing primer 
CMV_seq_fwd In house #69125 TGG CAT TAT GCC CAG TAC CMV forward sequencing primer 
pEGFP-N1 Dundee DNA sequencing service CATGGTCCTGCTGGAGTTCGTGAC 
eGFP forward 
sequencing primer 
pEGFP-N1R Dundee DNA sequencing service GGC CGT TTA CGT CGC CGT CC 
eGFP reverse 
sequencing primer 
pmCherry-C1-
Fwd 
Dundee DNA 
sequencing service GTT GGA CAT CAC CTC CCA CAA CGA G 
mCherry forward 
sequencing primer 
pmCherry-N1-
Rev 
Dundee DNA 
sequencing service GGG CGG CCC TCG CCC TCG CCC TCG 
mCherry reverse 
sequencing primer 
MBP seq fwd Invitrogen #E6040F03 GAT GAA GCC CTG AAA GAC GCG CAG 
MBP forward 
sequencing primer 
eGFP_fwd_Xho
I 
Invitrogen 
#E9793F08 ATA CTC GAG ATG GTG AGC AAG GGC 
PCR of eGFP for 
Bod1L-GFP 
eGFP_rev_SacI
I 
Invitrogen 
#E9793F09 CGA TAC CGC GGT TAC TTG TAC AGC TC 
PCR of eGFP for 
Bod1L-GFP 
TagRFP-
T_fwd_XhoI 
Invitrogen 
#M2721G11 ATA CTC GAG ATG GTG TCT AAG GGC G 
PCR of TagRFP-t for 
Bod1L-TagRFP-t 
TagRFP-
T_rev_SacII 
Invitrogen 
#M2721G12 ATA CCG CGG TTA CTT GTA CAG CTC G 
PCR of TagRFP-t for 
Bod1L-TagRFP-t 
TagRFP-
t_Seq_End_fwd 
Invitrogen 
#M5015A08 CTG GGG CAC AAA CTT AAT GG 
PCR of TagRFP-T for 
TagRFP-t-Bod1L 
Bod1L_Frag_1_
fwd_new 
Invitrogen 
#M0034E09 CAG AGC TCG TTT AGT GAA CCG TCA G PCR of Bod1L-N 
Bod1L_Frag_1_
rev_new 
Invitrogen 
#M0034E10 
AAA CCG CGG GGA AGT GGA GTC TTT ATC 
ACT CTT A PCR of Bod1L-N 
Bod1L_Frag_2_
fwd_new 
Invitrogen 
#M0144F03 
GCA AGA TCT ATG TCC ACT TCC ACC AGG 
CTT GAG AGA AAG PCR of Bod1L-T 
Bod1L_Frag_2_
rev_new 
Invitrogen 
#M0144F04 
GCA CCG CGG TAC AGA GGT GAT GAT GTC 
CTC A PCR of Bod1L-T 
Bod1L_Frag_3_
fwd 
Invitrogen 
#E8891D04 
GCA AGA TCT ATG GGC CTG GTC GGG GGT 
AGT TAC GAT PCR of Bod1L-C 
Bod1L_Frag_3_
rev 
Invitrogen 
#E8891D05 
GCA CCG CGG TCG CTT CGC TTT TTT CAC 
AG PCR of Bod1L-C 
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Bod1L_2769_3
020_fwd 
 
Sigma #HA05524785 
 
GGG CTG GAG CAG GTC CTA AAA GAA AAA 
GAA AGC AGC ATT ATC TCG CTG GAC CTT 
CTA 
TCA AGC GCA AGA GAG AAG TCA GCG CAG 
GTG CGG CCG CTG CTG GAG CG 
 
Insert for 2769_3020 
NLS 
Bod1L_2769_3
020_rev Sigma #HA05524786 
GAT CCG CTC CAG CAG CGG CCG CAC CTG 
CGC TGA CTT CTC TCT TGC GCT TGA TAG 
AAG GTC 
CAG CGA GAT AAT GCT GCT TTC TTT TTC 
TTT TAG GAC CTG CTC CAG CCC GC 
Insert for 2769_3020 
NLS 
LacI_Bod1L_ins
ert_fwd 
Invitrogen 
#Q1276G07 
GGC CGC GCT GCT AGA TCT GCT  GCT CTC 
GAG ATA AGC TCT GCA 
PCR of Bod1L into 
LacI-GFP vector 
LacI_Bod1L_ins
ert_rev 
Invitrogen 
#Q1276G08 
GAG CTT ATC TCG AGA GCA GCA GAT CTA 
GCA GCG C 
PCR of Bod1L into 
LacI-GFP vector 
LacI_Frag1_fwd Invitrogen #Q7805A09 
GAA TTC GTC GAC TGG ATC CGG TAC CGA 
GGA G 
PCR of Bod1L-N into 
LacI Vector 
LacI_Frag1_rev Invitrogen #Q7805A10 
CAA CTT TCT CTC AAG CCT GGT GGA AGT 
GGA 
PCR of Bod1L-N into 
LacI Vector 
LacI_Frag2_fwd Invitrogen #Q7805A11 
TCC ACT TCC ACC AGG CTT GAG AGA AAG 
TTG 
PCR of Bod1L-T into 
LacI vector 
LacI_Frag2_rev Invitrogen #Q7805A12 
AAG AAC ATC GTA ACT ACC CCC GAC CAG 
GCC 
PCR of Bod1L-T into 
LacI vector 
LacI_Frag3_fwd Invitrogen #Q7805B01 
GGC CTG GTC GGG GGT AGT TAC GAT GTT 
CTT 
PCR of Bod1L-C into 
LacI vector 
LacI_Frag3_rev Invitrogen #Q7805B02 
TCG CTT CGC TTT TTT CAC AGG GGC TTC 
CTC 
PCR of Bod1L-C into 
LacI vector 
Bod1L_S1145E
_fwd 
Invitrogen 
#Q8633B12 
CAA TAA TAA TGA GCA GCA AGA CAT TGA 
CTC 
Bod1L S1145A 
mutation primer 
Bod1L_S1145E
_rev 
Invitrogen 
#Q8633B10 CGG TTG TCT TGG GTT TTA G 
Bod1L S1145A 
mutation primer 
Bod1L_S1710E
_fwd 
Invitrogen 
#Q8633C01 GGT GGA TGG CGA GCA GGG AAA TAT G 
Bod1L S1710A 
mutation primer 
Bod1L_S1710E
_rev 
Invitrogen 
#Q8633B11 TCT TCA CTG CTT ATA GAT CC 
Bod1L S1710A 
mutation primer 
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2.7.3 DNA constructs 
All DNA constructs were stored in TE buffer at -20°C at a concentration of 
between 200-1000 ng/µL.  
 
Table 2.5 DNA constructs 
Name Description Notes 
Bod1L-GFP Full length Bod1L, labelled at C-terminus with eGFP 
Bod1L-tGFP purchased fom 
Origene (NM_148894). tGFP 
substituted for eGFP 
GFP-Bod1L Full length Bod1L, labelled at N-terminus with eGFP - 
Bod1L-TagRFPt Full length Bod1L, labelled at C-terminus with TagRFP-t - 
TagRFPt-Bod1L Full length Bod1L, labelled at N-terminus with TagRFP-t - 
Bod1L-
N_2769_3020 Bod1L amino acid 1-1009, labelled at C-terminus with eGFP - 
Bod1L-
T_2769_3020 
Bod1L amino acid 1007-2038, labelled at C-terminus with 
eGFP - 
Bod1L-
C_2769_3020 
Bod1L amino acid 2002-3051, labelled at C-terminus with 
eGFP - 
LacI_GFP LacI fused to eGFP with MCS intact Gift from Saurin Group, Dundee 
LacI_GFP_Bod1L LacI_GFP fused to full length Bod1L - 
LacI_GFP_Bod1L-
N LacI_GFP fused to full length Bod1L-N - 
LacI_GFP_Bod1L-
T LacI_GFP fused to full length Bod1L-T - 
LacI_GFP_Bod1L-
C LacI_GFP fused to full length Bod1L-C - 
Bod1L-
GFP_S1145A 
Full length Bod1L with an S to A mutation at position 1145, 
labelled at C-terminus with eGFP - 
Bod1L-
GFP_S1710A 
Full length Bod1L with an S to A mutation at position 1710, 
labelled at C-terminus with eGFP - 
mCherry-MDC1 Full length MDC1, labelled at N-terminus with mCherry Gift from Hay Group, Dundee 
PP4C-GFP Full length PP4C, labelled at C-terminus with eGFP Purchased from DSTT (#DU19835), Dundee 
H2B-RFP Full-length Histone H2B labelled at C-terminus with RFP Gift from M. Posch (Swedlow Group) 
pCBASceI I-SceI endonuclease expression vector with mammalian promoter to introduce a DSB at a genomic I-SceI site.  
pCBASceI was a gift from Maria 
Jasin (Addgene plasmid # 
26477)  
Bod1L_T_ 
GST_WT 
Bod1L amino acid 1007-2038, labelled at C-terminus with 
GST - 
Bod1L_T_ 
GST_S1710A 
Bod1L amino acid 1007-2038, labelled at C-terminus with 
GST with S1710A point mutation - 
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2.8.4 siRNA sequences  
A table containing details of siRNA used in this study is shown below. siRNA 
oligos were resuspended and stored in TE buffer at -20°C. 
 
Table 2.6 siRNA sequences 
 
 
 
 
 
 
 
Protein Target Sense sequence Manufacturer + Chemistry Notes 
Bod1L 5'-CAGUGCUGCUAGGGCUUCAACAGAA-3' LifeTechnologies - Stealth 
This siRNA 
was used 
throughout 
the study 
Bod1L_Cterm 5'-CAUCUAGCAGCAAACUGAAAGUAAU-3' LifeTechnologies - Stealth (HSS177930) 
Used to 
assess on 
target activity 
Bod1L_3'UTR  5'-UGGGAUUUCCCAAUGUGACACAUCA-3' LifeTechnologies - Stealth  - 
FANCD2 Unknown - Pool of 3-5  target-specific 19-25 nt siRNAs  SantaCruz (sc-35356)  - 
PP4-Catalytic 
(PPP4C) 5'-GGCCAGAGAGAUCUUGGUAUU-3' Dharmacon 
(Chowdhury 
et al., 2008) 
PP2A-B56α 
(PPP2R5A) 5’‐GCUCAAAGAUGCCACUUCA‐3’ Eurofins-MWG 
(Foley et al., 
2011) 
PP2A-B56β 
(PPP2R5B) 5’‐CGCAUGAUCUCAGUGAAUA‐3’ Eurofins-MWG 
(Foley et al., 
2011) 
PP2A-B56γ 
(PPP2R5C) 5’‐GGAUUUGCCUUACCACUAA‐3’ Eurofins-MWG 
(Foley et al., 
2011) 
PP2A-B56δ 
(PPP2R5D) 5′‐UCCAUGGACUGAUCUAUAA‐3′ Eurofins-MWG 
(Foley et al., 
2011) 
PP2A-B56ε 
(PPP2R5E) 5’‐UUAAUGAACUGGUGGACUA‐3’ Eurofins-MWG 
(Foley et al., 
2011) 
Control Stealth RNAi siRNA Control, Medium GC Content LifeTechnologies - Stealth  -  
BRCA2 5′-GAAACGGACUUGCUAUUUA-3′ Dharmacon (Edwards et al., 2008) 
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Chapter 3  - Bod1L is required for a robust DNA damage 
response 
 
This chapter seeks to explore the novel protein, Biorientation Of Chromosomes 
In Cell Division Protein 1-Like (Bod1L), a member of the same protein family as 
Bod1, the mitotic PP2A-B56 inhibitor (Porter et al., 2007; 2013). The 
experiments described in the following chapter aim to explore the functional and 
molecular characterisation of Bod1L. 
Results 
Bod1L is a conserved chromatin protein 
Our group has previously identified and characterised the PP2A-B56α/δ-specific 
inhibitor Bod1, which is required for the establishment of proper bi-orientated 
kinetochore-microtubule attachment during mammalian cell mitosis (Porter et 
al., 2007; 2013). We identified an uncharacterised protein, 
Bod1L/FAM44A/KIAA1327 (referred to forthwith as Bod1L) in the human 
sequence databases which contained a region of ~80% homology with Bod1 
(Figure 3.1A, B). This region of Bod1 homology with Bod1L is well conserved 
throughout higher eukaryotic species, but no evidence of Bod1L at a protein 
level can be detected in lower eukaryotes (Figure 3.1C). Despite the similarity of 
this region of sequence, loss of Bod1L did not affect normal mitotic progression 
(Porter et al., 2007). 
 
1 3051
Bod1 
homology
NLS
2769
NLS
3020
A-T 
Hook
Pro-
rich
A
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Mouse        LKSQGLFDQFRRDCLADVDTKPAYQNLRQRVDNFVANHLATHTWSPHLNKNQLRNNIRQQ 
Rat          ---------------------PAYQNLRQRVDNFVANHLATHTWSPHLNKNQLRNNIRQQ 
Chicken      LKSQGLFDQFRRDCLADVDTKPAYQNLRQRVDNFVCNHLATHTWSPHLNKNQLRNNIRQQ 
Xenopus      LKSQGLFDQFRRDCLADVDTKPAYQNLRQRVDNFVASHLASHTWSPHLNKNQLRNNIRQQ 
Bovine       LKSQGLFDQFRRDCLADVDTKPAYQNLRQRVDNFVANHLATHTWSPHLNKNQLRNNIRQQ 
Human        LKSQGLFDQFRRDCLADVDTKPAYQNLRQRVDNFVANHLATHTWSPHLNKNQLRNNIRQQ 
Macaque      LKSQGLFDQFRRDCLADVDTKPAYQNLRQRVDNFVANHLATHTWSPHLNKNQLRNNIRQQ                                   
 
Mouse        VLKSGMLESGIDRIISQVVDPKINHTFRPQVEKAVHEFLATLNHKEEAAGSTAPDDEKPE 
Rat          VLKSGMLESGIDRIISQVVDPKINHTFRPQVEKAVHEFLATLNHKEETAGSTAPDDEKLE 
Chicken      VLKSGMLESGIDRIISQVVDPKINHTFRPQVEKAVHEFLATLNHKEEAGPSTAPSEEKMD 
Xenopus      VLKSGMLESGIDRIISQVVDPKINHLFRPQVEKVVKEYLAMMNNKEDGNVNTEQNEERSE 
Bovine       VLKSGMLESGIDRIISQVVDPKINHTFRPQVEKAVHEFLATLSHKEDTSGSTAPEDEKPD 
Human        VLKSGMLESGIDRIISQVVDPKINHTFRPQVEKAVHEFLATLNHKEEGSGNTAPDDEKPD 
Macaque      VLKSGMLESGIDRIISQVVDPKINHTFRPQVEKAVHEFLATLNHKEEASGNTAPDDEKPD 
 
Mouse        SSV-ITQGAPAPGPSANVASDAMSILETITSLNQEANAARASTEMSNAKVSERTSRKLSS 
Rat          SSV-ITQGAPAPGPSANVASDAMSILETITSLNQEANAARASTEMSNAKASERISRKLSS 
Chicken      ASV-AVQGVSTTAPSGNVASDAMSILETITSLNQEASAARASTDNSSSKNSDKAAKRLLS 
Xenopus      ASISVPGSLPAVGPSTNVASDAMSILETISSLNQEATAARAFIETPNNKNSDKVSKRTIQ 
Bovine       SST-ITQGVPAPGPSANVASDAMSILETITSLNQEASAARASTETSNAKTSERMSKKTPS 
Human        TSL-ITQGVPTPGPSANVANDAMSILETITSLNQEASAARASTETSNAKTSERASKKLPS 
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Figure 3.1: Bod1L is a conserved chromatin associated protein 
(A) Schematic representation of the domain architecture of Bod1L. Proline rich region, Bod1 
homology domain, putative ATM phosphorylation sites, a C-terminal pair of nuclear localisation 
signals and an A-T hook domain are indicated. 
(B) Alignment of the Bod1L N-terminus to Bod1. Identical residues are coloured red and similar 
residues are coloured in blue. The red box highlights a non-conserved proline rich region in 
Bod1L. 
(C) Multiple species alignment of the Bod1 homology region of Bod1L. Identical residues are 
coloured red and similar residues are coloured in blue. 
(D) Graphic representation of Bod1L-GFP labelled fragments, containing Bod1L NLS sequence. 
Bod1L-N corresponds to aa1 to aa1009. Bod1L-T corresponds to aa1007 to aa2038. Bod1L-C 
corresponds to aa2002 to aa3051. HeLa cells were transfected with plasmid DNA for the central 
trunk fragment of Bod1L (Bod1L-T)(clock-wise from top left): lacking either NLS sequence, 
containing only the 2769 sequence, containing only the 3020 sequence, containing both 2769 
and 3020 sequence. Representative images show maximum intensity projections of GFP signal. 
NLS insertion site between ORF and GFP fluorescent protein. Scale bars, 10 microns. 
(E) Immunoblots of sub-cellular fractionated HeLa cell lysates were probed with antibodies to 
Bod1L, GAPDH and histone H3. 
(F) Representative maximum intensity projections of a HeLa cell transfected with a Bod1L-GFP 
construct during G2 phase, mitosis and in early G1 phase of the cell cycle. Scale bars, 10 
microns. 
(G) Schematic representation of experimentally determined ATM phosphorylation sites on 
Bod1L (http://www.phosphosite.org/ - accessed May 2015). Residues indicated by black arrow 
(S1145 and S1710) identified in (Matsuoka et al., 2007). 
(H) Immunoblots of HeLa cell lysates treated with 10 µM Etoposide and probed with antibodies 
to GAPDH and Phospho-(Ser/Thr) ATM/ATR substrate. 
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In addition to a region of Bod1 homology, bioinformatic analysis also revealed a 
highly-proline rich region at the extreme N-terminus of Bod1L (Figure 3.1B, red 
box). This region contains 69% proline residues, but importantly contains 
consecutive sequences of 6 or more prolines which have been shown to be 
involved in DNA binding (Morgan and Rubenstein, 2013). Although the precise 
function of such proline-rich domains remains poorly understood, these 
domains have been extensively shown to promote key protein-protein 
interactions (Kay et al., 2000; Williamson, 1994). These domains are a target of 
the SH3-domain containing proteins. SH3 domains are 50–70 amino acids in 
length and are often present in eukaryotic signal transduction proteins such as 
CDC25 (Musacchio et al., 1992; Pawson, 1995). In addition, SH3-Proline 
domain signalling has shown to play an important role in a number of cellular 
process, such as the response to DNA damage (Shafman et al., 1997). 
 
Given a protein of its size, the amino acid sequence of Bod1L contains few 
other annotated domains to indicate function (Figure 3.1A). I identified the 
presence of an A-T hook domain at the C-terminus of Bod1L, flanked by 
predicted nuclear localisation signals (NLS)(Figure 3.1A) (Brameier et al., 
2007). The AT-hook is a short DNA-binding motif which is prevalent in many 
eukaryotic chromatin binding proteins (Aravind and Landsman, 1998). I 
demonstrated that both predicted NLS sequences (aa2769 and aa3020) are 
needed for proper nuclear localisation of synthetic Bod1L fragments (Figure 
3.1D). Loss of either NLS leads to cytoplasmic expression of Bod1L protein 
fragments, suggesting that Bod1L is no longer chromatin bound. 
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To verify the effect of the AT-hook domain and multiple NLS on Bod1L cellular 
localisation, a rabbit antibody was raised against an N-terminal peptide of 
Bod1L corresponding to amino acid 476-496. Biochemical analysis of 
fractionated HeLa cell lysates using this antibody unsurprisingly showed 
localisation of Bod1L in the nucleoplasmic and chromatin fraction (Figure 3.1E). 
I generated a full-length Bod1L-eGFP construct to determine Bod1L localisation 
throughout the cell cycle (Figure 3.1F). Live-cell analysis of HeLa cells 
transfected with Bod1L-GFP revealed nuclear/chromatin localisation during all 
cell cycle phases except mitosis, during which Bod1L-GFP appears to 
dissociate from chromatin before rapidly re-associating during early 
cytokinesis/G1-phase. Whilst the data in figure 3.1F suggests that Bod1L is 
cytoplasmic during mitosis, it cannot be ruled out that a pool of Bod1L may still 
bind chromatin during this mitotic phase. 
 
Bod1L is highly phosphorylated, particularly in response to DNA damage 
Bioinformatic analysis revealed Bod1L as a highly modified protein using data 
collated from multiple phospho-proteomic studies 
(http://www.phosphosite.org/proteinAction.do?id=20501 - accessed 09/2011 – 
09/2015). One such proteomic screen identified multiple ATM (Ataxia 
Telangiectasia Mutated)/ATR (ATM and Rad3-related) dependent 
phosphorylation sites on Bod1L, with the most prevalent sites at pS1145 and 
pS1710 (Matsuoka et al., 2007) (Figure 3.1G, S1145 and S1710 highlighted 
with arrow). Other subsequent studies have also confirmed the modification at 
these specific sites, further validating their probability (Sharma et al., 2014). To 
confirm whether these ATM/ATR phosphorylations on Bod1L were damage 
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dependent, I probed Bod1L-GFP immunoprecipitates treated with the Topo II 
isomerase inhibitor, etoposide, with an antibody against phosphorylated SQ/TQ 
(Figure 3.1H). I observed increased signal in the upper band of damaged lysate 
which aligned with the Bod1L-GFP signal, suggestive that Bod1L is 
phosphorylated by ATM/ATR is response to DNA damage. 
Loss of Bod1L leads to severe genomic instability 
The bioinformatic data regarding annotated Bod1L domains and modifications 
suggested a role for Bod1L in the maintenance of genomic stability. In order 
probe this potential role further; we designed siRNA targeting the N-terminal 
region of Bod1L (siRNA designed by Iain Porter, Swedlow Group). The siRNA 
led to a significant reduction of Bod1L protein levels after 48 hours (Figure 
3.2A). I performed fluorescence microscopy on fixed HeLa cells treated with 
Bod1L siRNA, staining for DNA using DAPI (Figure 3.2B). Loss of Bod1L from 
HeLa cells led to severe genomic instability including the formation of 
micronuclei, anaphase bridging and abnormal nuclear morphology changes, 
suggestive of defective DNA repair (Constantinescu et al., 2010). 
 
In response to DNA damage, multiple signalling cascades are initiated which 
lead to the recruitment of DDR factors to DNA lesions. In addition, multiple 
pathways are activated to arrest the cell-cycle whilst DNA is repaired (Sancar et 
al., 2004). To determine if Bod1L played a role in cell cycle progression, HeLa 
cells were depleted of Bod1L and cell cycle analysis was performed using flow 
cytometry, which revealed no change in normal cell cycle progression (Figure 
3.2C). HeLa cells treated with etoposide arrested correctly during S-phase both 
in the presence and absence of Bod1L (Figure 3.2C). These results taken 
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Figure 3.2: Loss of Bod1L from human cells leads to genomic instability 
and fragmented, acentric chromatin during mitosis 
(A) Immunoblot of HeLa cell lysates transfected with control or Bod1L siRNA and probed with 
antibodies to Bod1L and GAPDH. 
(B) Morphological analysis of HeLa cells transfected with control or Bod1L siRNA. Cells were 
fixed with PFA and stained with DAPI to detect DNA. 
(C) Flow cytometry analysis of HeLa cells 48 hours post transfection with control or Bod1L 
siRNA plus 10 µM etoposide. Representative graph of 3 independent experiments. 2.5% cells 
were excluded as apoptotic/debris. Error bars represent 1 S.D. 
(D) Representative images of chromosome spreads of nocodazole-arrested HeLa-CENPA-GFP 
cells 48 hours after transfection with control or Bod1L siRNA. MDC1, CENPA-GFP, and DNA 
are shown in red, white and green, respectively. Insets show examples of acentric chromatin 
fragments after Bod1L depletion. Mean number of chromosome fragments were determined (10 
cells/condition, two independent experiments). Scale bar, 5 microns. 
(E, F) Morphological analysis of U2OS cells transfected with control or Bod1L siRNA. Cells 
were fixed with PFA and stained with DAPI to detect DNA. Scale bar, 5 microns. 
(G) U2OS cells were transfected with siBod1L. After 48 hours, cells were fixed in PFA and 
immunostained. MDC1, CENPA-GFP, and DNA are shown in red, white and green, 
respectively. Arrow indicates fragmented, acentric chromatin. Scale bar, 5 microns. 
(H, I) HeLa cells stably expressing CENPA-GFP were transfected with control (H) or Bod1L (I) 
siRNA. After 24 hours, cells were transfected with an H2B-RFP construct. Cells were imaged 
during mitosis with single z-section images acquired at 4 minute time intervals. CENPA-GFP is 
shown in green and H2B-RFP is shown in red. Arrow in (I) top row shows fragment of chromatin 
containing centromere, arrow in (I) lower row shows acentric chromatin fragment. 
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together indicate that Bod1L is unlikely to play a critical role in cell cycle 
checkpoint control during the DNA damage response. 
Bod1L depletion results in formation of fragmented, acentric chromatin 
during mitosis 
Figure 3.2B revealed that loss of Bod1L led to micronuclei formation, most likely 
due to fragmented and acentric chromatin present during mitosis occurring as a 
result of unrepaired DNA damage. To examine this further, I performed 
chromosome spreads of HeLa cells treated with siBod1L. Micrographs once 
again revealed the presence of fragmented chromatin upon Bod1L depletion. 
Quantification of micrographs revealed an increased frequency of acentric 
chromatin fragments in cells depleted of Bod1L (Figure 3.2D), again indicative 
of defective DNA damage repair. All of the chromatin fragments detected after 
Bod1L depletion lacked CENPA-GFP staining, indicating that these fragments 
were acentric and were not misaligned chromosomes (Figure 3.2D, inset). 
Depletion of Bod1 from cells produces elongated mitotic spindles with severe 
bi-orientation defects, resulting in mitotic catastrophe and cell death (Porter et 
al., 2007). The lack of centromeric-positive misaligned chromosomes during 
mitosis, suggests that Bod1L and Bod1 are functionally distinct. In addition, 
many of the fragments are also positive for the DNA damage repair protein 
MDC1, suggesting that these fragments originate from unrepaired DNA 
damage. Importantly, the presence of fragmented, acentric chromatin, in 
addition to micronuclei and multi-lobed nuclei, were recapitulated in multiple cell 
lines (HeLa, U2OS), strengthening the hypothesis that these changes are 
directly due to loss of Bod1L and these phenotypes are not cell line specific 
(Figure 3.2E-G).  
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To verify that the fragmented chromatin seen in figure 3.2D was due to loss of 
Bod1L and not due to experimental process, live cell analysis was performed on 
HeLa cells stably expressing CENPA-GFP and transiently expressing H2B-RFP 
(Figure 3.2H-I). Although mitotic timing was unaffected following Bod1L 
depletion; lagging chromosomes and more importantly, fragmented chromatin, 
could be detected in cells following Bod1L depletion (white arrows). 
Cells display hypersensitivity to specific genotoxic stresses in the 
absence of Bod1L 
Defective DNA repair leads to hypersensitivity to agents that induce DNA 
damage. Induction of different forms of DNA lesion can help identify the 
pathways in which unknown proteins play a role.  
 
Depletion of Bod1L with siRNA caused U2OS cells to become hypersensitive to 
a range of different DNA damaging agents. Cells depleted of Bod1L displayed 
severe hypersensitivity to the Topoisomerase II inhibitor etoposide, which 
causes DSBs by forming a ternary complex with topoisomerase II and DNA, 
preventing religation of DNA ends during an intermediary step, thus forming 
DSBs (Figure 3.3A). Loss of Bod1L also lead to mild sensitivity to ionising 
radiation, a treatment that also generates double-strand breaks (Figure 3.3B). 
These data collectively suggest that Bod1L is required for cell survival.  
 
Depletion of Bod1L resulted in no added sensitivity to the Topoisomerase I 
inhibitor, camptothecin (Figure 3.3C). Treatment with camptothecin results in 
the conversion of single-strand breaks to double-strand breaks during S-phase. 
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Figure 3.3: Bod1L depletion results in sensitivity to selective genotoxic 
stresses 
(A-F) Clonogenic survival assays of U2OS cells transfected with Control, Bod1L or BRCA2 
(Etoposide/MMC) siRNA. Etoposide, MMC, Cisplatin, Camptothecin and 6-Thioguanine were 
added 48 hours after transfection at the indicated concentrations and cells propagated for 10 - 
12 days. Cells were treated with IR 48 hours after transfection at the indicated dose and cells 
propagated for 10 - 12 days. For each siRNA, cell viability of untreated cells is defined as 100%. 
3 repeats/condition, two independent experiments. Data represented as mean ± SEM. 
(G) Clonogenic survival assay of HeLa cells transfected with control siRNA, 3’UTR-Bod1L 
siRNA or 3’UTR-Bod1L siRNA plus Bod1L-GFP. 48 hours post transfection MMC was added at 
the indicated concentration. 3 repeats/condition, two independent experiments. Data 
represented as mean ± SEM. 
(H) Immunoblots of cells transfected as in (G) and probed for Bod1L and GAPDH. 
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The absence of camptothecin sensitivity could be explained by the low 
concentration of camptothecin used, thus not highlighting any sensitivity that 
may occur following loss of Bod1L. 
 
In addition to displaying sensitivity to the DSB-inducing stresses, depletion of 
Bod1L also resulted in hypersensitivity to the intra-strand cross linker cisplatin, 
as well as the inter-strand cross linker Mitomycin-C (MMC)(Figure 3.3D, E). 
This severe hypersensitivity to such genotoxic stress suggests a role for Bod1L 
in the repair pathways associated with such lesions. Treatment of BRCA2 
depleted cells with either MMC or etoposide also led to a hypersensitivity 
phenotype as previously reported (Yuan et al., 1999). Comparison of cell 
survival following both Bod1L or BRCA2 depletion and treatment with MMC or 
etoposide revealed that BRCA2 loss led to greater sensitivity than depletion of 
Bod1L (Figure 3.3A, E). This suggests that BRCA2 may play a more important 
role in the repair of DNA damage than Bod1L, or alternatively is involved in 
multiple repair or signalling pathways associated with the DDR. 
 
Cells deficient in mismatch repair have previously been shown to display 
resistance to treatment with 6-thioguanine (Swann et al., 1996). Figure 3.3F 
demonstrates that treatment of Bod1L depleted cells with 6-thioguanine led to 
no additional sensitivity above control treated cells. The lack of resistance to 6-
thioguanine treatments in siBod1L cells suggests that Bod1L is unlikely to be 
involved in mismatch repair.  
 
In order to determine whether the hypersensitivity phenotypes were specifically 
due to loss of Bod1L, siRNA was designed to target the endogenous Bod1L 3’ 
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untranscribed region (UTR), thus depleting endogenous Bod1L but not 
exogenously expressed Bod1L. To demonstrate that the hypersensitivity 
phenotypes were specific to Bod1L depletion, HeLa cells expressing Bod1L-
GFP (expression levels of Bod1L-GFP were >70%) were treated with MMC and 
siRNA targeting the Bod1L 3’-UTR. As figure 3.3G shows, treatment of cells 
with Bod1L 3’UTR led to severe sensitivity to MMC, recapitulating the results 
seen using U2OS cells. Expression of exogenous Bod1L-GFP to approximately 
endogenous protein levels, (Figure 3.3H) led to a complete recovery of 
sensitivity, confirming that the observed phenotypes were directly due to a loss 
of Bod1L. 
A fluorescence reporter assay reveals compromised repair by 
homologous recombination following Bod1L depletion 
Given the hypersensitivity displayed by Bod1L depleted cells to genotoxic 
agents which lead to double-strand break formation, I wanted to determine 
whether Bod1L depleted cells were defective for homologous repair of these 
breaks. I utilised the recombination substrate DR-GFP, to fluorescently assay a 
gene conversion event that replicates repair of a double strand break in cells 
treated with siBod1L (Pierce et al., 1999). In short, the DR-GFP cassette 
contains a modified GFP gene (SceGFP) that contains a unique I-SceI 
restriction site. When I-SceI is expressed in cells containing a stably integrated 
DR-GFP cassette, a single double-strand break is formed. An additional GFP 
fragment in the cassette (iGFP) can repair the DSB by HR, resulting in full-
length, fluorescent GFP that is assessed by fluorescence microscopy (Figure 
3.4A). 
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Figure 3.4: DNA repair by homologous recombination is compromised in 
the absence of Bod1L 
(A) Schematic representation of the DR-GFP homologous recombination (HR) reporter assay. 
Cassette contains a modified GFP gene (SceGFP) that contains an I-SceI unique restriction 
site. An additional GFP fragment in the cassette (iGFP) can repair the DSB by HR, resulting in 
full-length, fluorescent GFP. Adapted from (Schumacher et al., 2012). 
(B) Immunoblot of HeLa whole cell lysates treated with a titration of the ATM inhibitor KU59933. 
DMSO only was used as control. Concentrations of KU59933 used were 1, 5, 10, 20 and 50 
µM. Blots were probed with pATM (S1981), pChk2 (T68) and GAPDH. 
(C) HeLa DR-GFP cells were transfected with control or Bod1L siRNA. After 48 hours, cells 
were transfected with a plasmid expressing the I-SceI endonuclease plus DMSO or the ATM 
kinase inhibitor KU59933. 24 hours later cells were imaged to assess HR dependent GFP 
expression. Data represented as mean ± 1SD. n=>20 for each condition. **P<0.01. 
(D) Immunoblotting of HeLa DR-GFP cell lysates treated as in (G) and probed for pATM 
(S1981), Bod1L and GAPDH. 
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The ATM specific inhibitor KU59933 was used as a positive control in the DR-
GFP assay. Figure 3.4B shows a titration of KU59933 leading to dose-
dependent inhibition of the activating auto-phosphorylation of ATM at S1981, 
providing a robust read-out of ATM activity. A downstream target of ATM, 
pChk2 (T68) is also shown to verify the inhibition of the kinase. 
 
Depletion of Bod1L in HeLa cells stably expressing the DR-GFP cassette 
reduced the efficiency of HR in a manner similar to inhibition of the ATM kinase, 
indicating a critical role for Bod1L in the HR response to DNA damage (Figure 
3.4C). Figure 3.4D confirms the depletion of Bod1L and the KU59933 
dependent inhibition of ATM signalling, as determined by western blot of HeLa 
cell lysates. These data combined with the clonogenic hypersensitivity to DSB 
inducing agents suggest that Bod1L plays a key role in maintaining a robust 
cellular response to DNA damage, with loss of the protein leading to genomic 
instability. 
Bod1L depleted cells contain radial chromosomes that are formed 
independently of FANC complex assembly failure 
The micrograph data in figure 3.2B showed multiple nuclear and chromatin 
aberrations occurring as a direct result of Bod1L knockdown. In addition to the 
aberrations shown in the figure, Bod1L depletion also led to the formation of 
radial chromosomes (Figure 3.5A). Although it is well acknowledged that DNA 
damage associated with high-levels of interstrand cross-linking leads to the 
formation of radial chromosomes; the precise mechanism of radial formation 
remains poorly understood (Hanlon Newell et al., 2008). It is known that in the 
absence of efficient or functional HR-mediated repair, double-strand breaks that 
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have occurred as a result of DNA cross-links do give rise to radial 
chromosomes (Huen et al., 2009). 
 
In HeLa cells treated with siBod1L, I observed an increased number of radial 
chromosomes, even in the absence of genotoxic stress (Figure 3.5A, B). 
Addition of a high concentration of MMC further increased the number of radials 
observed, significantly higher than that seen in siCTR treated cells treated with 
the same dose of MMC. Increased radial chromosome formation is a common 
cytogenetic marker of Fanconi Anaemia (FA), a condition characterised by a 
defective interstrand cross-link repair pathway. Given the similarity between the 
defects caused by Bod1L depletion and FA, I wanted to interrogate the 
robustness of the FA pathway following Bod1L depletion. The 
monoubiquitination of FANCD2 upon DNA damage is a critical event in the FA 
pathway, with the loss of this protein (or ubiquitin-modification) resulting in a 
compromised pathway (Andreassen et al., 2004). I designed an siRNA to target 
FANCD2, which significantly depleted protein levels compared with control 
treated cells (Figure 3.5C). Depletion of FANCD2 led to hypersensitivity to MMC 
as previously reported, however this sensitivity was significantly less than that 
seen following Bod1L depletion, suggestive that these two proteins operate in 
functionally distinct pathways (Figure 3.5D) (Taniguchi et al., 2002). In addition, 
Figure 3.5E shows that depletion of Bod1L had no effect on the MMC induced 
monoubiquitination of FANCD2, further suggesting that Bod1L does not function 
within the Fanconi Anaemia pathway. 
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Figure 3.5: Loss of Bod1L leads to radial chromosome formation, but no 
change to FANCD2 mono-ubiquitination. 
(A) HeLa cells were transfected with either control or Bod1L siRNA. After 24 hours, MMC was 
added to cells at a final concentration of 250 ng/ml, 3 hours later nocodazole was added to a 
final concentration of 100 ng/ml and cells were incubated for 16 hours. Chromosome spreads 
were performed and cells were fixed in PFA and stained with DAPI. Representative maximum 
intensity projections are shown, arrows indicate radial chromosome. 
(B) Quantification of (A). Data represented as mean ± SEM. n=>15 for each condition. *P<0.05. 
(C) Immunoblots of HeLa cells treated with either control or FANCD2 siRNA. 6 nM and 12 nM 
concentration of FANCD2 were used. Immunoblots were probed with antibodies against 
FANCD2 and GAPDH. 
(D) Clonogenic survival assays of U2OS cells transfected with control, Bod1L or FANCD2 
siRNA. MMC was added 48 hours after transfection at the indicated concentrations and cells 
propagated for 10 - 12 days. For each siRNA, cell viability of untreated cells is defined as 100%. 
3 repeats/condition, two independent experiments. Data represented as mean ± SEM. 
(E) HeLa cells were transfected with either control or Bod1L siRNA. After 24 hours, MMC was 
added at the concentration indicated for 16 hours and then lysed. Whole cell lysate 
immunoblots were probed with antibodies against FANCD2, Bod1L and vinculin.
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Bod1L is phosphorylated at S1710 by ATM in response to ionising 
radiation 
To examine the recruitment of Bod1L itself to sites of DNA damage, HeLa cells 
transiently expressing Bod1L-GFP were irradiated and stained for gamma-
H2AX to mark sites of damage. Micrograph images and associated 
quantification (Figure 3.6A, B) detected no recruitment of Bod1L-GFP to IRIF. 
To explore this further, U2OS cells stably expressing GFP-MDC1 were 
transfected with cDNA driving the expression of TagRFP-t fused to Bod1L and 
subjected to our laser micro-irradiation assay. I detected no Bod1L-TagRFP-t at 
DNA damage sites, despite the strong accumulation of GFP-MDC1 (Figure 
3.6C). Switching the location of TagRFP-t to the N-terminus of Bod1L or 
repeating the experiment using fixed cell immunofluorescence resulted in no 
detectable concentration of Bod1L to sites of DNA damage. 
 
Whilst the lack of recruitment to damage sites is surprising, given the likely role 
of Bod1L in the DDR, it is consistent with the behaviour of other chromatin-
associated proteins involved in the response to DNA damage. Other immobile 
proteins involved in the DNA damage response, such as the histone variant 
H2AX, are instead modified at damage sites, often resulting in complex down-
stream signalling cascades (Paull et al., 2000). Previous analysis of global ATM 
and ATR substrates indicated two major phosphorylation sites on Bod1L at 
pS1145 and pS1710 (Figure 3.1G) (Matsuoka et al., 2007). Therefore, I 
immunised sheep with a peptide containing phospho-S1710. The affinity 
purified anti-pS1710 Bod1L antibody (anti-pBod1L) showed strong specificity to 
the phosphorylated peptide compared to the unmodified peptide (Figure 3.7A). 
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Figure 3.6: Bod1L is not re-localised to sites of damage but is 
phosphorylated at ionising radiation induced foci (IRIF) 
(A) HeLa cells were transfected with Bod1L-GFP. 48 hours late, cells were treated with 5 Gy IR, 
allowed to recover for 1 hour and immunostained for γH2AX (S139). Projections of 
representative images are shown. 
(B) Protein accumulation at the damage foci from (A) indicated (inset) was determined by 
quantifying the fluorescent intensity of each channel along the indicated line. 
(C) U2OS cells stably expressing GFP-MDC1 (green) were transfected with Bod1LTagRFPt 
(red). Cells were pretreated with Hoescht and striped with a 405 nm laser. Accumulation of 
GFP-MDC1 and Bod1L-TagRFPt was quantified along the line of the laser stripe. U2OS cells 
stably expressing GFP-MDC1 (green) were transfected with Bod1LTagRFPt (red). Cells were 
pretreated with Hoescht and striped with a 405 nm laser. Accumulation of GFP-MDC1 and 
Bod1L-TagRFPt was quantified along the line of the laser stripe. 
(D) Immunostaining of mock or IR treated HeLa cells transfected with control or 
Bod1L siRNA. Cells were exposed to 5 Gy IR 48 hours after transfection. Cells were fixed two 
hours post IR treatment and immuno-stained for MDC1 (green), γH2AX(pS139) (red) or Bod1L 
(pS1710) (cyan). 
(E) HeLa cells were treated with 5 Gy IR and immunostained for MDC1 (green), 
γH2AX (pS139) (red) or Bod1L (pS1710) (cyan). Protein accumulation at the damage foci 
indicated (inset) was determined by quantifying the fluorescent intensity of each channel along 
the indicated line. 
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In addition, incubation of anti-pBod1L with the phospho-peptide antigen, but not 
with the non-phospho-peptide, led to a marked reduction in signal (Figure 3.7B, 
C).  
 
After treatment with IR, anti-pBod1L accumulated at ionising radiation-induced 
foci (IRIF), co-localising with the phosphorylated H2AX (γH2AX) and 
endogenous MDC1 (Figure 3.6D). Anti-pBod1L (S1710) staining was largely 
eliminated when Bod1L expression was ablated by siRNA, confirming the 
specificity of this antibody (Figure 3.6D, lower row). Quantification of signal 
intensity at individual foci revealed peak distribution of anti-pBod1L similar to 
that of γH2AX and MDC1 (Figure 3.6E). To further examine the modification of 
Bod1L at sites of DNA damage, U2OS cells stably expressing GFP-MDC1 were 
once again sensitised with Hoechst 33342 and subjected to laser micro-
irradiation (Figure 3.8A). Anti-pBod1L (S1710) co-localised with MDC1 and 
γH2AX along the laser-stripe, which was confirmed by quantification of 
micrographs (Figure 3.8B).  
 
ATM phosphorylation of H2AX and the subsequent recruitment of MDC1 to 
sites of DNA damage, is a rapid process, occurring within 1-5 minutes of the 
initial DNA lesion (Lou et al., 2003; Paull et al., 2000; Stewart et al., 2003). To 
determine whether the phospho-Bod1L (S1710) modification occurred rapidly 
following the DNA lesion or whether Bod1L phosphorylation was dependent on 
recruitment of additional factors to DNA lesions, I performed a time-course 
immunostaining post-IR (Figure 3.8C). Low levels of anti-pBod1L (S1710) signal 
were present from the earliest time point measured (5 minutes), and signal 
intensity increased in line with γH2AX and MDC1 accumulation at damage sites. 
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Figure 3.7: Production of a phospho-Bod1L S1710 antibody 
(A) Dot blot of pBod1L S1710 antibody with a dilution series of the non-phosphorylated (upper 
row) and phosphorylated (lower row) antigenic peptide NH2-CEEVDG[pS]QGNMMR-COOH 
corresponding to E1705-R1716 of human Bod1L. 
(B) pBod1L S1710 antibody was incubated with phosphorylated antigenic peptide at an 
equimolar ratio of 50:1. A dot blot of the incubated antibody with a dilution series of the non-
phosphorylated (upper row) and phosphorylated (lower row) antigenic peptide was performed.  
(C) pBod1L S1710 antibody was incubated with non-phosphorylated antigenic peptide at an 
1:50 ratio to saturate the antibody. A dot blot of the incubated antibody with a dilution series of 
the non-phosphorylated (upper row) and phosphorylated (lower row) antigenic peptide was 
performed. Scale bars, 5 microns. 
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Indeed, it is clear that γH2AX is phosphorylated initially at 5-15 minutes and is 
then followed by strong MDC and phospho-Bod1L (S1710) response (Figure 
3.8C-D). These data suggest that phospho-Bod1L (S1710) phosphorylation is 
an early event in the DNA damage-signalling pathway and is unlikely to be 
reliant on downstream protein recruitment. 
 
Bod1L S1710 conforms to the ATM phosphorylation motif, S/T-Q-X, and as 
mentioned previously, has been identified in several ATM/ATR substrate 
specific phospho-proteomic screens (Kim et al., 1999; Matsuoka et al., 2007; 
Traven and Heierhorst, 2005). Immunoblot analysis of HeLa cell lysates dosed 
with IR and treated with the ATM inhibitor KU59933 revealed that phospho-
Bod1L S1710 signal was lost upon inhibition of ATM (Figure 3.9A). Additional 
immunofluorescence analysis confirmed that treatment of irradiated cells with 
KU59933 led to a significant reduction in phospho-Bod1L S1710 signal, in 
addition to another ATM target, γH2AX (S139), thus preventing the timely 
recruitment of MDC1 to sites of damage (Figure 3.9B). Treatment of cells with 
caffeine, a pan-specific ATM/ATR inhibitor also led to a loss in signal, albeit to a 
slightly lesser extent (Figure 3.9B, lower panels). Although these data suggest 
that it is highly likely that ATM phosphorylates Bod1L, since pBod1L (1710) 
signal decreases once total ATM kinase activity is inhibited, it is possible that 
the loss of phospho-Bod1L S1710 signal could solely be due to loss of γH2AX 
phosphorylation. As such, if Bod1L phosphorylation were dependent on γH2AX 
phosphorylation by ATM, this could also explain the loss of phospho-Bod1L 
S1710 signal.  
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Figure 3.8: Bod1L phosphorylation at IRIF or micro-irradiation stripes 
occurs rapidly following damage 
(A) U2OS cells stably expressing GFP-MDC1 (green) were pre-treated with Hoechst 33342 and 
striped with a 405 nm laser. Cells were fixed in PFA and stained for MDC1 (green), H2AX 
(pS139) (red) or Bod1L (pS1710) (cyan).  
(B) Quantification of fluorescence signal (from (A)) for each channel along the indicated line 
profile. 
(C) HeLa cells were treated with 5 Gy IR and allowed to recover for 5, 15 or 30 minutes prior to 
PFA fixation. Cells were immunostained for MDC1 (green), 
H2AX (pS139) (red) or Bod1L (pS1710) (cyan). Representative maximum intensity projections 
are shown. 
(D) Quantification of (C). >10 cells per condition, Data represented as mean ± SEM.  
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To test further whether Bod1L is directly phosphorylated by ATM upon DNA 
damage, we generated a ~160 kDa GST labelled fragment of Bod1L, 
corresponding to amino acids aa1007 to aa2038 (Bod1L-T), containing the 
S1710 phosphorylation site (Figure 3.9C)(Fragments generated by Michael 
Porter, Swedlow group). We utilised recombinant DNA-PK, which shares 
identical specificity to ATM in vitro (Kim et al., 1999; O'Neill et al., 2000), to 
confirm that phospho-Bod1L S1710 is phosphorylated by ATM in response to 
DNA damage in vitro and most likely in vivo (DNA-PK a kind gift from Susan 
Lees-Miller, Calgary). Mutation of S1710A ablated phosphorylation by DNA-PK 
at this site, confirming antibody specificity (Figure 3.9D). 
 
I have demonstrated that Bod1L, at one or more sites, is rapidly and specifically 
phosphorylated at sites of DNA by ATM, however the functional significance of 
this modification remains unclear. To assess the function of this modification I 
generated full-length Bod1L constructs containing S1710A phospho-dead 
mutants and performed clonogenic survival assays, depleting endogenous 
Bod1L and rescuing with the mutant construct (Figure 3.9E). Bod1L containing 
S1710A appeared to rescue the MMC hypersensitivity equally as well as wild-
type Bod1L, suggesting that upon DNA damage, loss of Bod1L S1710 
phosphorylation alone does not affect overall cell survival. 
Bod1L is phosphorylated at S1145 in response to ionising radiation 
As mentioned previously, analysis of global ATM and ATR substrates, as well 
as ultradeep phosphoproteome mass-spectrometry, revealed an additional 
phosphorylation sites on Bod1L at position S1145 (Figure 3.1G) (Matsuoka et 
al., 2007; Sharma et al., 2014).  To determine whether phosphorylation at this 
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Figure 3.9: Bod1L is phosphorylated at S1710 by ATM in vitro 
 
(A) HeLa cells were transfected with either control or Bod1L siRNA. After 48 hours, cells were 
treated with 10 µM KU59933 where indicated, before treatment with 10 Gy IR. Immuno-blots 
were probed with pBod1L (S1710), pATM (S1981) and histone H3. 
(B) HeLa cells were treated with DMSO control, 10 µM KU59933 or 5 mM Caffeine and then 
treated with 5 Gy IR. Cells were fixed in PFA and stained for endogenous MDC1 (green), 
γH2AX (pS139) (red) or Bod1L (pS1710) (cyan). Lower panels show quantification of signal for 
each channel. Data represented as mean ± SEM. n=>20 for each condition. ***P<0.001. Scale 
bar, 5 microns. 
(C) Purified WT or S1710A GST-Bod1L-T were separated by SDS-PAGE and subjected to 
colloidal Coomassie staining. Purified WT and S1710A protein is indicated by arrow (GST 
fragments generated by Michael Porter, Swedlow Group). 
(D) Purified WT or S1710A GST-Bod1L-T were incubated in a kinase buffer containing 
recombinant DNA-PK. SDS–polyacrylamide gel electrophoresis-separated proteins were 
transferred and probed with antibodies against phospho- phospho-Bod1L (S1710) and GST. 
(E) HeLa cells were transfected with control or 3’UTR-Bod1L siRNA. To assess rescue of 
phenotype, cells were then transfected with either Bod1L-GFP, Bod1L-GFP_S1710A, Bod1L-
GFP_S1145A or Bod1L-GFP_S1710A/S145A and clonogenic survival assays were carried out 
with Mitomycin-C. For each treatment, cell viability of untreated cells is defined as 100%.
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site was a damage dependent event, I immunised sheep with a peptide 
containing phospho-S1145. The affinity purified anti-pBod1L (S1145) antibody 
showed strong specificity to the phosphorylated peptide compared to the 
unmodified peptide (Figure 3.10A). In a manner analogous to modification of 
Bod1L at S1710, after treatment with IR, anti-pBod1L (S1145) accumulated at 
ionising radiation-induced foci (IRIF), co-localising with the phosphorylated 
H2AX (γH2AX) and endogenous MDC1 (Figure 3.10B). Anti-pBod1L (S1145) 
staining was largely eliminated when Bod1L expression was ablated by siRNA, 
once again confirming the specificity of this antibody (Figure 3.10, lower row). 
Quantification of signal intensity at individual IRIF revealed peak distribution of 
anti-pBod1L (S1145) similar to that of γH2AX and MDC1 (Figure 3.10C) 
 
Like modification of Bod1L at S1710, phosphorylation of Bod1L at S1145 
appears to only occur at DNA lesions. Once again, to determine the function of 
this modification I generated additional full-length Bod1L constructs containing 
S1145A phospho-dead mutants as well as double S1145A/S1710A mutants 
and performed clonogenic survival assays, depleting endogenous Bod1L and 
rescuing with the mutant construct (Figure 3.9E). Bod1L containing the S1145A 
appeared to rescue the MMC hypersensitivity equally as well as wild-type 
Bod1L, suggesting that similar to S1710, loss of Bod1L S1145 phosphorylation 
alone upon DNA damage does not affect overall cell survival. The double 
mutant, S1145A/S1710 also appeared to have no affect on the survival of 
Bod1L depleted cells treated with MMC, suggesting that there are multiple, 
redundant sites, that are phosphorylated by ATM in the response to damage. 
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Figure 3.10: Bod1L is phosphorylated at S1145 at IRIF 
(A) Dot blot of pBod1L S1145 antibody with a dilution series of the non-phosphorylated (upper 
row) and phosphorylated (lower row) antigenic peptide NH2-CDNRNNN[pS]QQDID-COOH 
corresponding to D1138-D1150 of human Bod1L. 
(B) Immunostaining of mock or IR treated HeLa cells transfected with control or Bod1L siRNA. 
Cells were exposed to 5 Gy IR 48 hours after transfection. Cells were fixed two hours post IR 
treatment and immuno-stained for MDC1 (green), γH2AX (pS139) (red) or Bod1L (pS1145) 
(cyan). 
(C) HeLa cells were treated with 5 Gy IR and immunostained for MDC1 (green), γH2AX (pS139) 
(red) or Bod1L (pS1145) (cyan). Protein accumulation at the damage foci indicated (inset) was 
determined by quantifying the fluorescent intensity of each channel along the indicated line. 
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ATM activation and down-stream signalling is unaffected by depletion of 
Bod1L 
The DNA damage kinase ATM has been shown to physically interact with a 
number of critical DNA damage signalling and effector proteins including Nbs1 
(Gatei et al., 2000b), Rad51 (Chen et al., 1999), BRCA1 (Gatei et al., 2000a) 
and Chk2 (Paz et al., 2010). These interactions have proven to be critical for 
mediating correct phosphorylation of target proteins and the subsequent down 
stream signalling and protein recruitment to sites of damage. To assess any 
potential interaction between ATM and Bod1L, I immunoprecipitated Bod1L 
from HeLa cells expressing Bod1L-GFP and observed no evidence of active 
ATM binding in a chromatin cell fraction, above that of control levels (Figure 
3.11A). 
 
Although Bod1L and ATM do not interact, the data in figure 3.9 strongly 
suggests that Bod1L is an ATM target following DNA damage. It has previously 
been shown that loss of some ATM targets, such as the MRN complex, can 
lead to changes in ATM activation and activity (Uziel et al., 2003). To determine 
whether loss of Bod1L from cells had a similar effect on ATM activity, HeLa 
cells were depleted of Bod1L, treated with a low dose of IR and allowed to 
recover (Figure 3.11B). No loss of ATM auto-phosphorylation could be detected 
in the absence of Bod1L, suggesting that sustained ATM activation was 
unaffected. Moreover, when cells were allowed to fully recover from IR induced 
DNA lesions, siBod1L treatment did not prevent proper inactivation of ATM 
following damage resolution (Figure 3.11C). To probe the activation and 
signalling of ATM following Bod1L depletion further, HeLa cells were depleted 
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of Bod1L, treated with a titration of the ATM inhibitor KU59933 and then dosed 
with IR and lysed immediately (Figure 3.11D). Loss of Bod1L from cells once 
again had no effect on ATM auto-phosphorylation, nor did it affect the 
phosphorylation of downstream targets of ATM such as Chk2. Bod1L knock-
down also had no effect on the potency of KU59933 ATM inhibition. These data 
from figure 3.9 and figure 3.11 taken together suggest that although Bod1L is a 
phosphorylation target of ATM, loss of Bod1L from cells has no observable 
effect on ATM kinase activity following DNA damage. 
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Figure 3.11: Loss of Bod1L does not affect ATM kinase activity 
(A) GFP-Trap Immunoprecipitation (IP) of Bod1L-GFP from the chromatin fraction of HeLa cells 
was performed. Prior to lysis, cells were treated +/- 10 µM Etoposide for 24 hours. IPs were 
analysed by western blotting using antibodies against GFP and pATM (S1981). 
(B) Immunoblots of HeLa cells treated with control or Bod1L siRNA and 1 Gy IR. Cell lysates 
were collected at the time points indicated and analysed using antibodies against pATM 
(S1981), Bod1L and GAPDH. 
(C) Immunoblots of HeLa cells treated with control or Bod1L siRNA and 0.5 Gy IR. Control cells 
were mock irradiated. Cell lysates were collected at 0, 24 and 48 hours and analysed using 
antibodies against pATM (S1981), ATM and GAPDH. 
(D) Immunoblots of HeLa cells treated with control or Bod1L siRNA. Prior to treatment with 5 Gy 
IR, cells were incubated for 1 hour in an increasing concentration of KU59933. Cell lysates were 
collected after 1 hour and analysed using antibodies against pATM (S1981), ATM, pChk2 (T68), 
Chk2, Bod1L and GAPDH. 
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Discussion  
The data presented in this chapter reveal Bod1L as a novel component of the 
DNA damage repair machinery. Bioinformatic analysis reveals Bod1L to contain 
few annotated regions that would suggest the function of this protein. Whilst not 
as detrimental as a loss of BRCA2, depletion of Bod1L led to hypersensitivity to 
a range of DNA lesions and fixed cell immunofluorescence analysis revealed 
that Bod1L depletion resulted in severe genomic instability. ATM signalling is 
unaffected in the absence of Bod1L and these two proteins do not physically 
interact in the presence or absence of DNA damage. Unlike the vast majority of 
DNA damage repair proteins, I found no evidence that Bod1L is specifically re-
localised or recruited in excess to DNA lesions. Instead, phospho-proteomic 
analysis of ATM/ATR substrates identified Bod1L as an ATM target upon DNA 
damage, which was confirmed using phospho-specific antibodies raised against 
these sites (Matsuoka et al., 2007). Bod1L S1710 is rapidly phosphorylated at 
sites of DNA damage in a manner analogous with the phosphorylation of γH2AX 
and the γH2AX dependent recruitment of MDC1. Treatment of cells with ATM 
specific inhibitors, demonstrated that Bod1L is phosphorylated by ATM, which 
was confirmed by in vitro phosphorylation of Bod1L-T at S1710 using 
recombinant DNA-PK. 
 
Although the phosphorylation of Bod1L by ATM at S1710/S1145 in response to 
DNA damage is clear, the functional significance of these likely ATM sites on 
Bod1L remains unclear. Functional rescues of Bod1L depletion revealed that 
mutation of either site individually, or together, had no effect on the ability of 
Bod1L-GFP to rescue clonogenic sensitivity to MMC. Recent literature has 
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highlighted evidence for multiple ATM phosphorylation sites on a key DNA 
damage repair component, which can display a degree of redundancy (Cheng 
et al., 2009). These multiple ATM target sites near a key domain of the MDM2 
protein, function in a redundant manner to provide robust DNA damage 
signalling. The additional ATM phosphorylation sites on Bod1L identified from 
bioinformatic analysis as well as ultradeep phosphoproteome studies (Sharma 
et al., 2014)(Figure 3.1G), suggest that in the event of single or even double 
mutations at these key sites, other phosphorylation sites on Bod1L could still 
elicit a cellular effect. An alternative PIKK kinase, DNA-dependent protein 
kinase (DNA-PK) is able to phosphorylate key ATM targets, such as H2AX, in 
cells depleted of ATM (Stiff et al., 2004). Given that ATM and DNA-PK are able 
to function in a redundant, overlapping manner, it is possible that when key 
ATM phosphorylation sites are modified on Bod1L, other previously redundant 
sites are modified via alterative kinases. More detailed phospho-proteomic 
analysis specifically of Bod1L phosphorylation before and after DNA damage is 
needed to verify these additional sites.  
 
Bod1L sequence analysis reveals a highly conserved, proline-rich region at the 
N-terminus of the protein, located prior to the Bod1 homologous region (Figure 
3.1A). Such proline-rich repeats have been shown to facilitate a range of 
protein-protein interactions with a variety of proteins containing SH3, WW and 
EVH1 domains (Kay et al., 2000). SH3-Proline domain signalling has shown to 
play an important role in a number of cellular process, such as the response to 
DNA damage (Shafman et al., 1997), with the crystal structure having been 
recently solved for the SH3 domain of the phosphoinositide 3-kinases (Chen et 
al., 2011). Whilst the necessity of this proline-rich region of Bod1L was not 
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investigated during this study, it presents an interesting future target for 
modulating the signalling pathways associated with Bod1L. 
 
Assessment of common cancer cell mutations revealed that Bod1L has been 
identified with over 400 unique mutations in tumour samples analysed (Forbes 
et al., 2015). A large majority of these mutations (>75%) resulted in missense 
mutation. Whilst tissue distribution of these mutations appears varied, the 
presence of so many mutations in cancer tissue reveals an interesting target for 
future investigation and suggests that mutations in Bod1L may act as drivers for 
cancer development. 
 
The data presented in figure 3.5 implies that genomic instability associated with 
Bod1L depletion does not arise due to a failure in the FA pathway. Yet one 
open question that remains is how depletion of Bod1L leads to the failure of 
DNA repair by homologous recombination (Figure 3.4).  Previous papers have 
demonstrated that the mislocalisation of the key DNA damage repair proteins 
BRCA2 and Rad51, via depletion or deletion of interacting proteins, can lead to 
a failure of DNA repair and subsequent genomic instability (Davies et al., 2001; 
Moynahan et al., 2001; Saitoh et al., 2002). Given the data in figure 3.11, 
demonstrating that ATM activation and downstream signalling is unaffected 
following Bod1L depletion, one hypothesis could be that phosphorylation of 
Bod1L by ATM controls recruitment or retention of other proteins at DNA 
lesions. Thus, loss of Bod1L would affect any associated binding of such 
proteins. 
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Another consideration of why HR may be compromised in Bod1L depletion cells 
is that phosphorylation of other ATM or casein kinase 2 (CK2) targets may be 
affected as a result of Bod1L loss. I have already demonstrated that ATM 
function is normal following Bod1L depletion, so if phosphorylation of other DNA 
repair proteins is affected then is this may be due to compromised or 
uncontrolled phosphatase activity. Figure 1.7 expresses the complexity of 
Serine/Threonine phosphatase activity associated with DNA damage repair. As 
such it is highly likely that any factor that altered the careful kinase/phosphatase 
balance would have a dramatic effect on maintaining robust DNA repair. 
Indeed, several recent studies have demonstrated that depletion of either a 
phosphatase directly (PP6) or a controlling/regulatory protein (TIPRL/PP2A, 
PNUTS/PP1) can lead to hypersensitivity to genotoxic stress, decreased 
clonogenic survival, changes in protein phosphorylation and protein 
mislocalisation (Douglas et al., 2010; Landsverk et al., 2010; McConnell et al., 
2007). Figure 3.1 showed that Bod1L contains a region of homology with the 
mitotic PP2A-B56 inhibitor, Bod1. Given the sequence similarity of this region 
between Bod1 and Bod1L and the high degree of conservation of this site in 
Bod1L, investigation is needed to understand whether Bod1L also acts as a 
PP2A interacting protein at sites of DNA damage. The following chapter is 
dedicated to exploring the role of Bod1L in controlling PP2A activity at DNA 
lesions. 
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Chapter 4 - Bod1L controls MDC1 and PP2A-56 recruitment to 
sites of DNA damage 
 
The data in Chapter 3 revealed Bod1L as a novel component of the DNA 
damage repair machinery, with loss of Bod1L resulting in compromised damage 
repair and genomic instability. Unlike other DDR proteins, Bod1L associates 
with chromatin during all non-mitotic phases of the cell cycle and is not actively 
recruited to DNA lesions. Instead, I showed that upon DNA damage, ATM 
rapidly phosphorylates Bod1L at multiple sites, suggesting Bod1L may act as 
some form of signalling platform. 
 
Whilst I have evidence of ATM phosphorylation of Bod1L occurring specifically 
at DNA lesions, the functional consequence of such a modification remains 
unclear. Indeed, the mechanism by which Bod1L plays a role in the normal 
DNA damage response still remains uncertain. The data and evidence 
presented in this chapter aims to establish the functional role of Bod1L, both 
before and after DNA damage has occurred, and attempt to elucidate the 
mechanism by which Bod1L depletion leads to the observed genomic instability. 
Results 
Depletion of Bod1L results in changes in the dynamics of DNA repair 
proteins at sites of DNA damage 
Phosphorylation of the histone H2A variant H2AX at Ser139 by ATM 
establishes a binding site onto which regulators of DNA damage repair are able 
to accumulate (Burma et al., 2001; Rogakou et al., 1998; Stiff et al., 2004). 
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MDC1 is recruited via this phospho-epitope and acts as a crucial scaffold for 
further protein recruitment and signal amplification (Lou et al., 2006; Stewart et 
al., 2003; Stucki and Jackson, 2006). I assessed the formation of γH2AX foci 
formation following etoposide treatment (Figure 4.1A), which determined that 
peak foci intensity was achieved between 16-24 hours of 10 µM etoposide 
treatment. Incubation with etoposide in excess of 24 hours led to apoptosis and 
nuclear morphology changes. Following 16 hours of etoposide treatment I 
observed that phosphorylation of H2AX was unaffected after Bod1L depletion 
(Figure 4.1B). Whilst I saw no change in γH2AX phosphorylation following 
Bod1L depletion, MDC1 recruitment to damage sites after etoposide treatment 
was significantly increased in the absence of Bod1L (Figure 4.1B).  
 
To determine whether the increase in MDC1 accumulation following Bod1L 
depletion was due to increased DNA damage or failure to repair existing 
damage, I treated HeLa cells with etoposide, before washout of the drug and 
assessment of MDC1 accumulation. Under these conditions, no additional 
etoposide-associated DNA damage could occur following washout. I observed 
that when siBod1L cells were allowed to recover from DNA damage, MDC1 
accumulation on chromatin continued to increase, in contrast to siCTR treated 
cells where MDC1 chromatin recruitment remained stable or decreased as 
damage was repaired (Figure 4.1C, D). This result suggests that rather than 
etoposide exhibiting an increased damaging effect in the absence of Bod1L, 
MDC1 was hyper-recruited to existing damage sites in the absence of Bod1L. 
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Figure 4.1: Changes in the dynamics of DNA repair proteins at sites of 
damage in Bod1L depleted cells 
(A) HeLa cells were transfected with control siRNA. After 48 hours cells were treated with 10 µM 
etoposide for the time indicated then immediately fixed in PFA and stained for γH2AX (pS139). 
DMSO only was used for 0 µM control. Projections of representative images are shown 
underneath. Graph shows quantification of fluorescence signal for γH2AX. >10 cells per 
condition. Data represented as mean ± SEM. Scale bar, 5 microns. 
(B) HeLa cells were transfected with control or Bod1L siRNA. After 48 hours cells were treated 
with 10 µM etoposide for 16 hours then immediately fixed in PFA and stained for MDC1 (red) 
and γH2AX (pS139)(green). Projections of representative images are shown. Right hand panels 
show quantification of fluorescence signal for each channel. >10 cells per condition, two 
independent experiments. Data represented as mean ± SEM. ***P<0.001. Scale bar, 5 microns. 
(C) HeLa cells were transfected with control or Bod1L siRNA. 48 hours post transfection cells 
were treated with 10 µM etoposide for 24 hours before washout and fixation in PFA at 0 and 8 
hours post washout. Endogenous MDC1 was immunostained. Upper panel shows 
representative projections of MDC1 signal. Lower panel shows quantification of MDC1 signal. 
20 cells per condition, representative images and quantitation of 2 independent experiments. 
Data represented as mean ± SEM. ***P<0.001. Scale bar, 5 microns. 
(D) HeLa cells transfected with control or Bod1L siRNA were treated with etoposide before 
wash-out of the drug and subcellular fractionation lysis at 0, 4 and 8 hours post wash-out. 
Chromatin, nucleoplasmic and cytoplasmic fraction immunoblot of MDC1 is shown along with 
γH2AX chromatin immunoblot.  
(E) HeLa cells transfected with control or Bod1L siRNA were treated with etoposide before 
wash-out of the drug and subcellular fractionation lysis at 0, 4 and 8 hours post wash-out. 
Chromatin fraction immunoblot of MDC1 is shown. Rescue experiments were performed by 
transfecting HeLa cells with Bod1L siRNA targeting the 3’UTR of Bod1L. Cells were then 
transfected with Bod1L-GF before treatment. Histone H3 was used as a loading control. 
(F) HeLa cells were transfected with control or Bod1L siRNA. After 48 hours cells were treated 
with 5 Gy IR and samples were fixed in PFA after 2 hours. Cells were immuno-stained for and 
quantified for endogenous γH2AX (S139) and Rad51. Data shows mean number of foci per cell 
and is represented as mean ± SEM. n=20 for each condition. **P<0.01. 
(G) Representative images from (H). Images show maximum intensity projections of cells 
stained immuno-stained for endogenous γH2AX (S139)(red) and Rad51 (green). Scale bar, 5 
microns. 
(H, I) HeLa cells were transfected with control or Bod1L siRNA. 48 hours post transfection, cells 
were dosed with 5 Gy IR, incubated for 1 hour at 37°C before being PFA fixed and stained with 
antibodies against γH2AX (S139), 53BP1 and ACA. Interphase (H) and mitotic cells (I) were 
identified by ACA and DAPI staining. 20 cells per condition were imaged, quantitation of 2 
independent experiments. Data represented as mean ± SEM. 
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Figure 4.1D demonstrates that the over-accumulation of MDC1 in the absence 
of Bod1L occurs only in the chromatin fraction of the cell lysate. To verify that 
this increased recruitment of MDC1 to sites of DNA damage is a Bod1L specific 
effect, cells were treated with siRNA targeting the 3’UTR of Bod1L and 
exogenous Bod1L-GFP was expressed in these cells (Figure 4.1E). Expression 
of Bod1L-GFP in si3’UTR treated cells rescued the accumulation of MDC1 at 
damage sites. 
 
As mentioned previously, MDC1 acts as a crucial scaffold whose activity is 
regulated by phosphorylation. MDC1 controls further protein recruitment and 
signal amplification in response to DNA damage. Whilst loss of MDC1 is known 
to lead to genomic instability and compromised DNA repair by HR in both cell 
lines and knockout mice; very little is understood regarding the effect of MDC1 
over accumulation at DNA lesions (Lou et al., 2003; 2006; Stewart et al., 2003; 
Zhang et al., 2005). To understand the downstream effect of excessive MDC1 
accumulation, I assayed the formation of Rad51 foci in the presence and 
absence of Bod1L (Figure 4.1F, G). Rad51 is a protein recruited to damaged 
DNA further downstream of MDC1 that plays a major role in the repair of DSBs 
by HR, a process shown to be affected by Bod1L depletion (Figure 3.4) 
(Baumann and West, 1998). As the quantification and representative 
micrographs show, loss of Bod1L led to a small, but reproducible decrease in 
the number of Rad51 foci in damaged cells, whilst the number of γH2AX foci 
remained unaffected. This Bod1L knockdown mediated decrease in the critical 
HR protein, responsible for promoting homologous pairing and strand 
exchange, could explain the compromised HR repair demonstrated in figure 
3.4C. 
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The importance of timely and regulated recruitment and signalling at DNA 
lesions was further highlighted in two recent papers, describing the role of 
53BP1 in DNA damage repair during interphase and mitosis (Lee et al., 2014; 
Orthwein et al., 2014). Here the authors describe that the reversal of 53BP1 
inactivation during mitosis, allowing 53BP1 recruitment to DNA lesions, is 
dependent on targeted phosphatase activity. Given the possible phosphatase 
interaction with Bod1L, I wanted to investigate whether this defined process 
was functional following Bod1L depletion. siCTR or siBod1L cells were treated 
with ionising radiation and intensity of γH2AX and 53BP1 signal was measured 
in an interphase population (Figure 4.1H) and a mitotic population (Figure 4.1I). 
The data revealed that 53BP1 recruitment to DNA lesions was unaffected by 
Bod1L depletion during interphase (Figure 4.1H) and that 53BP1 recruitment 
was inhibited correctly during mitosis (Figure 4.1I), suggesting no role for Bod1L 
in this pathway. 
Depletion of Bod1L leads to changes in MDC1 localisation and dynamics 
at sites of DNA damage 
Data from figure 4.1 suggested that loss of Bod1L led to a failure in correctly 
localising MDC1 to sites of DNA damage. This data generally assessed the 
increase of MDC1 at chromatin on a population-basis. To assess recruitment of 
MDC1 to sites of damage on a single-cell basis, I performed a live cell GFP-
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Figure 4.2: Depletion of Bod1L leads to changes in MDC1 localisation to 
sites of DNA damage 
(A) U2OS cells stably expressing GFP-MDC1 were transfected with control siRNA or Bod1L 
siRNA and pre-treated with Hoechst 33342. Cells were striped or spotted with 405 nm laser and 
GFP-MDC1 fluorescent intensity accumulation was measured within a narrow temporal window. 
Upper panel shows representative images for each time-point. Bod1L depletion was assessed 
by immunoblotting (inset), GAPDH was used as loading control. Time from onset of laser stripe 
is shown underneath. Data represented as mean ± SEM. n=>20 for each condition. Scale bars, 
5 microns. 
(B) U2OS cells stably expressing GFP-MDC1 were transfected with control siRNA or Bod1L 
siRNA and pre-treated with Hoechst 33342. Cells were striped or spotted with 405 nm laser and 
GFP-MDC1 fluorescent intensity accumulation was measured over a longer period of time. 
Green box represents time-period of (A). Left hand panel shows representative images for 
selected time-points. Bod1L depletion was assessed by immunoblotting (inset), GAPDH was 
used as loading control. Data represented as mean ± SEM. n=>20 for each condition. Scale 
bars, 5 microns. 
(C) U2OS cells stably expressing GFP-MDC1 were transfected with control siRNA or Bod1L 
siRNA. DNA Damage was generated by pre-treating cells with Hoechst 33342 and 405 nm laser 
striping. GFP-MDC1 fluorescence at the damage stripe was assessed, with the plateau of re-
localisation indicated by the arrow 
(D) U2OS cells stably expressing GFP-MDC1 were transfected with control siRNA or Bod1L 
siRNA and FRAP was performed at sites of non-damage sites. Bod1L depletion was assessed 
by immunoblotting (inset). GAPDH was used as a loading control. 
(E) U2OS cells stably expressing GFP-MDC1 were transfected with control siRNA or Bod1L 
siRNA and FRAP was performed at sites of damage. Damage was generated by pre-treating 
with Hoechst 33342 and 405 nm laser striping. FRAP was performed once GFP-MDC1 levels 
had plateaued (Indicated by arrow in (B)). Bod1L depletion was assessed by immunoblotting 
(inset). GAPDH was used as a loading control. 
(F) HeLa cells were transfected with Bod1L-GFP. After 48 hours, FRAP was performed at a 
non-damaged nuclear site and recovery was assessed over time period indicated. 
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MDC1 recruitment assay (Figure 4.2A and 4.2B). U2OS cells stably expressing 
GFP-MDC1 were sensitised with Hoechst 33342 and subjected to laser micro-
irradiation (Dinant et al., 2007; Luijsterburg et al., 2009). The increase of GFP-
MDC1 associated fluorescence became discernable after 10-20 seconds, after 
which a rapid accumulation occurred at the damage site in line with previous 
observation (Lukas et al., 2004a). Loss of Bod1L appeared to impede the initial 
rapid recruitment of MDC1 to damage sites, yet over a longer period of time 
post-damage, Bod1L depletion led to a continued accumulation of GFP-MDC1 
at laser spots, complementing data from Figure 4.1B and E. 
 
To confirm these results, I measured the binding of MDC1 to sites of DNA 
damage in live cells stably expressing GFP-MDC1 in a fluorescence recovery 
after photobleaching (FRAP) assay. GFP-MDC1 is actively recruited to sites of 
DNA damage, reaching a plateau level after approximately 10 minutes. To 
ensure that GFP-MDC1 localisation to damage foci had stabilised prior to 
FRAP, I performed laser micro-irradiation and measured the accumulation of 
GFP-MDC1 to damage sites (Figure 4.2C). Failure to allow for plateau to be 
reached could result in a skewed FRAP measurement, occurring due to the 
additive effect of damage-dependent accumulation of MDC1, in addition to 
fluorescence recovery at the FRAP spot. I also confirmed that the FRAP 488nm 
laser did not generate DNA damage within the cell. FRAP assays were 
performed at the time point indicated by the arrow once GFP-MDC1 
fluorescence had plateaued. At sites of DNA damage, following Bod1L 
depletion, I observed a delayed initial recovery of GFP-MDC1 (t1/2: siCTR=50.3s 
± 3.2s; siBod1L=76.6s ± 5.4s), suggesting impairment in MDC1 recruitment 
(Figure 4.2E). I also detected a smaller impairment in MDC1 recruitment to non-
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damaged sites (t1/2: siCTR=22.9s ± 2.3s; siBod1L=26.4s ± 3.0s) (Figure 4.2D), 
suggesting that Bod1L may also affect association of MDC1 at undamaged 
DNA and chromatin. FRAP of GFP labelled Bod1L revealed a very slow 
turnover of the protein, indicative of robust chromatin binding as revealed in 
figure 3.1E. Together these data suggest that Bod1L is associated with 
chromatin throughout the nucleus and provides a binding platform for MDC1. In 
the absence of Bod1L, MDC1 turnover and recovery is slower, both at non-
damage and damage sites, possibly as this recovery is now more reliant upon 
passive diffusion. 
The C-terminal fragment of Bod1L interacts in vivo with components of 
the DNA damage machinery 
Figures 4.1 and 4.2 demonstrated a clear functional link between the unknown 
function of Bod1L, and the correct localisation of key DNA damage repair 
components, particularly the phospho-scaffold MDC1. Given this functional 
relationship between Bod1L and normal MDC1 function, I wanted to investigate 
whether these two proteins shared a physical interaction. Immunoprecipitation 
of GFP-MDC1 stably expressed in U2OS cells revealed that GFP-MDC1 and 
Bod1L bind both in the presence and absence of DNA damage, primarily at 
chromatin (Figure 4.3A). Bod1L immunoprecipitated from HeLa cells expressing 
Bod1L-GFP confirmed this interaction, demonstrating damage-independent 
binding to MDC1 in a chromatin cell fraction (Figure 4.3B). NBS1, a component 
of the MRN complex known to interact with MDC1 at sites of damage 
(Chapman and Jackson, 2008; Lou et al., 2003; Wu et al., 2008), also co-
immunoprecipitated with Bod1L (Figure 4.3C). In both the Bod1L-MDC1 IPs as  
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Figure 4.3: Bod1L interacts in vivo with components of the DNA damage 
repair machinery 
(A) GFP-Trap Immunoprecipitation (IP) of GFP-MDC1 from the nucleoplasmic and chromatin 
fraction of U2OS cells stably expressing GFP-MDC1 and treated with 10 µM etoposide. IPs 
were analysed by western blotting using antibodies against Bod1L. 
(B) GFP-Trap Immunoprecipitation (IP) of Bod1L-GFP from the chromatin fraction of HeLa cells 
transiently expressing Bod1L-GFP. IPs were analysed by western blotting using antibodies 
against GFP and MDC1. 
(C) GFP-Trap Immunoprecipitation (IP) of Bod1L-GFP from the chromatin fraction of HeLa cells 
transiently expressing Bod1L-GFP. IPs were analysed by western blotting using antibodies 
against GFP and NBS1. 
(D) Schematic representation of the LacO single cell interaction assay. A construct containing 
LacI sequence fused to GFP and full length Bod1L is transiently expressed in a U2OS cell line 
stably expressing a LacO tandem repeat on a chromosome arm. This local cluster of 
fluorescently tagged Bod1L is visualised as a single nuclear focus. 
(E) U2OS cells containing a stably integrated lacO tandem repeat were transfected with either 
LacI-GFP or LacI-Bod1L-GFP fusion and treated with 10 µM Etoposide for 24 hours. Protein 
accumulation at the Lac foci was determined by quantifying the fluorescent intensity of each 
channel along the indicated line. Scale bar, 5 microns. 
(F) U2OS cells stably expressing GFP-MDC1 were transfected with either TagRFP-t-Bod1L (left 
panel) or Bod1L-TagRFP-t (right panel). After 48 hours, acceptor photobleaching was 
performed at a non-damaged nuclear site. 10 cells per condition, 2 independent experiments. 
Data represented as mean ± SEM. 
(G) HeLa cells were transfected with mCherry-MDC1 and Bod1L-GFP. After 48 hours, acceptor 
photobleaching was performed at a non-damaged nuclear site. 10 cells per condition, 2 
independent experiments. Data represented as mean ± SEM. 
(H) Upper panel: U2OS cells containing a stably integrated lacO tandem repeat were 
transfected with the various LacI-Bod1L-GFP fusions indicated. The recruitment of MDC1 to 
LacI-GFP foci was determined for each of the Bod1L fusions. 10 cells per condition, 
representative images and quantitation of 2 independent experiments. Data represented as 
mean ± SEM. Lower panel shows graphic representation of Bod1L-GFP labelled fragments, 
containing Bod1L NLS sequence. Bod1L-N corresponds to aa1 to aa1009. Bod1L-T 
corresponds to aa1007 to aa2038. Bod1L-C corresponds to aa2002 to aa3051. Scale bar, 5 
microns. 
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well as the Bod1L-NBS1 IPs, I detected a small, but reproducible, decrease in 
binding between Bod1L and both MDC1 and NBS1 after treatment with 
 etoposide (Figure 4.3A, B and C). This small decrease in binding suggests that 
a small population of Bod1L/MDC1/NBS1 dissociates upon DNA damage, 
whilst the majority of the cellular pool of Bod1L/MDC1/NBS1 remain associated 
in complex. 
 
To investigate the interaction between Bod1L and MDC1 further, single-cell 
binding assays were performed utilising the LacO-LacI system (Janicki et al., 
2004)(Figure 4.3D). Full-length Bod1L was fused to a LacI repressor and 
coupled with GFP. This construct was transiently expressed in a U2OS cell line 
stably expressing a LacO tandem repeat in a euchromatic region of 
chromosome 1p36 (Janicki et al., 2004). This local cluster of fluorescently 
tagged Bod1L was visualised as a single nuclear focus. Immunofluorescent 
staining of cells with anti-MDC1 antibodies confirmed the damage-independent 
interaction between Bod1L and MDC1, with no recruitment of MDC1 to the 
GFP-only focus (Figure 4.3E). 
 
To further explore the in vivo interaction between Bod1L and MDC1, a FRET-
based approach was employed to interrogate whether interaction between 
Bod1L and MDC1, labelled with fluorescent tags, could be detected. Using 
either GFP-MDC1 and TagRFP-T-Bod1L/Bod1L-TagRFP-T (Figure 4.3F) or 
Bod1L-GFP and mCherry-MDC1 (Figure 4.3G), FRET could not be detected 
between these two proteins. 
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Finally, I sought to further interrogate the specific domain or region of Bod1L 
that interacted with MDC1. I expressed either full-length LacI-Bod1L-GFP or 
fragments of LacI-Bod1L-GFP and assessed recruitment of MDC1 when 
targeted to a non-damaged nuclear focus. These LacI constructs (Figure 4.3H, 
lower panel) were targeted to a LacO array to assess MDC1 co-localisation. 
Targeting of either full-length Bod1L or the C-terminal fragment (Bod1L-C) to 
the lacO array caused recruitment of endogenous MDC1 (Figure 4.3H, upper 
panel). Taken together with the complementary results in this section, these 
data suggest that Bod1L and MDC1 interact directly or indirectly through the C-
terminal domain of Bod1L at chromatin. It appears that this interaction is 
constitutive throughout the nucleus and not damage-dependent.  
Phosphorylation of MDC1 by ATM in response to DNA damage is 
increased in the absence of Bod1L 
The function of MDC1 as a scaffold at sites of damage is dependent on its 
dimerisation/oligomerisation (Jungmichel et al., 2012). Phosphorylation of the 
MDC1 FHA domain at T4, primarily by ATM, stimulates the dimerisation of 
MDC1 and accumulation of downstream DDR factors at sites of DNA damage 
(Jungmichel et al., 2012; Liu et al., 2012; Luo et al., 2011). In addition, 
increased local density of MDC1 at DNA lesions promotes accumulation of 
activated ATM at sites flanking DNA damage, further facilitating ATM-
dependent phosphorylation of H2AX and the amplification of DNA damage 
signals (Lou et al., 2006). I used ATM immunoprecipitated from damaged cells 
to phosphorylate GFP-MDC1 pulled down from undamaged cells (Figure 4.4A-
B). GFP-MDC1 pulled down from cells incubated in kinase buffer alone showed 
little to no phosphorylation at T4. GFP-MDC1 incubated with active ATM  
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Figure 4.4: Phospho-MDC1 T4 phosphorylation is increased following 
Bod1L depletion 
(A) Immunoprecipitation (IP) of ATM or rabbit IgG from HeLa cells was performed. Prior to lysis, 
cells were treated with 5 Gy IR and allowed to recover for 60 minutes. IPs were analysed by 
western blotting using antibodies against ATM. 
(B) GFP-trap purified GFP-MDC1 was incubated in a kinase buffer containing ATM precipitated 
from cells dosed with 5 Gy IR. SDS–polyacrylamide gel electrophoresis-separated proteins 
were transferred and probed with antibodies against phospho-ATM (S1981), phospho-MDC1 
(T4) or MDC1. 
(C) HeLa cells were transfected with either control or Bod1L siRNA. After 24 hours, cells were 
treated with 10 µM etoposide for 16 hours. Cells were lysed by fractionation. Immunoblot was 
probed with antibodies against pMDC1 T4, MDC1, Bod1L, GAPDH and H3. 
(D) HeLa cells were transfected with control or Bod1L siRNA. After 48 hours cells were treated 
with 5 Gy IR to generate IRIF. Cells were fixed in PFA after 2 hours and stained for endogenous 
MDC1 (pT4) (green) or γH2AX (pS139) (red). Scale bar, 5 microns. 
(E) Quantification of MDC1 (pT4) signal (B). >50 cells per condition, representative images and 
quantitation of 3 independent experiments. 
(F) HeLa cells were transfected with control or Bod1L siRNA. After 48 hours cells were treated 
with 5 Gy IR and samples were fixed in PFA at 1, 4 and 8 hours. Cells were immuno-stained for 
endogenous MDC1 (pT4) and quantified for MDC1 (pT4) signal. Data represented as mean ± 
SEM. ***P<0.001. 
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showed strong phosphorylation at T4, confirming that MDC1 is phosphorylated 
at this site by ATM following activation of the kinase (Figure 4.4B).  
 
In figure 4.1B I observed that depletion of Bod1L resulted in increased MDC1 at 
DNA lesions that was independent of additional DNA damage. As such, I 
hypothesised that this increase of MDC1 at sites of damage could be as a result 
of increased dimerisation/oligomerisation. Following depletion of Bod1L and 
treatment with IR, I assessed the phosphorylation of phospho-MDC1 T4, using 
an antibody specific for this modification. I depleted Bod1L from HeLa cells and 
assessed phospho-MDC1 T4 signal by immunofluorescence observing that loss 
of Bod1L led to a significant increase in the ratio of phospho-MDC1 T4/total 
MDC1 (Figure 4.4C, D).  Furthermore, phospho-MDC1 T4 in Bod1L-depleted 
cells remained elevated relative to control cells for several hours after damage 
(Figure 4.4E). This result is in agreement with the data showing increased 
MDC1 recruitment to DNA lesions at these time points (Figure 4.1C-E). As 
demonstrated previously, I detected no specific interaction between ATM and 
Bod1L above GFP-only control levels, with activation of ATM following DNA 
damage appearing normal (Figure 3.11A-C). Immediate phosphorylation of 
downstream targets of ATM such as the checkpoint kinase Chk2 (Ahn et al., 
2000) also appeared normally phosphorylated after Bod1L depletion (Figure 
3.11D).  
Additional MDC1 phosphorylation sites are affected by loss of Bod1L, 
leading to loss of critical DNA damage repair interactions 
MDC1 functions as a phospho-scaffold required for recruitment of downstream 
effectors to sites of damage (Lou et al., 2003; Stewart et al., 2003). One such 
 205 
interaction, with the NBS1-containing MRN complex, is dependent on 
phosphorylation of the SDT-rich N-terminus of MDC1 by casein kinase 2 (CK2) 
(Chapman and Jackson, 2008; Melander et al., 2008; Spycher et al., 2008). 
Upon DNA damage, the CK2-phosphorylated modification of MDC1 is stabilised 
relative to the total MDC1 pool. I used an MDC1 pSDpTD antibody (phospho-
S329/T331-MDC1)(a kind gift from Jackson group, Cambridge) to determine the 
role of Bod1L in control of this modification. Depletion of Bod1L from HeLa cells 
treated with etoposide led to a damage-independent decrease in the phospho-
S329/T331-MDC1 signal (Figure 4.5A). In cells treated with a moderate dose of 
IR and then fixed and immunostained for phospho-S329/T331-MDC1, Bod1L 
depletion led to a significant reduction in the presence of this modification 
following IR (Figure 4.5B). Quantification of this data revealed that Bod1L 
depletion reduced the presence of this modification only in the presence of DNA 
damage, with no reduction seen in undamaged cells (Figure 4.5C). 
 
As mentioned above, sustained phosphorylation of MDC1 at this cluster of 
SDTD repeats (highlighted in figure 1.5B) is critical for establishing MDC1 
interaction with NBS1 and the MRN complex. Failure to maintain this key 
interaction at DNA lesions abrogates the accumulation of the MRN complex at 
such lesions and leads to compromised damaged repair and checkpoint 
signalling (Spycher et al., 2008). To examine whether the decrease in phospho-
S329/T331-MDC1 signal led to a functional consequence, I depleted Bod1L and 
immunoprecipitated MDC1 from U2OS cells stably expressing GFP-MDC1, 
observing damage dependent decrease in MDC1 binding to NBS1 in the 
absence of Bod1L (Figure 4.5D). 
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Figure 4.5: Phospho-MDC1 S329/T331 signalling is reduced following 
Bod1L depletion leading to a loss of MDC1-NBS1 binding 
(A) HeLa cells were transfected with either control or Bod1L siRNA. After 24 hours, cells were 
treated with 10 µM etoposide for 16 hours. Immunoblots were probed with antibodies against 
pMDC1 (S329/T331), MDC1 and H3. 
(B) HeLa cells were transfected with control or Bod1L siRNA. After 48 hours cells were treated 
with 5 Gy IR to generate IRIF. After 2 hours, cells were fixed in PFA and stained for 
endogenous MDC1 (pS329/pT331) (green) or γH2AX (pS139) (red). Representative maximum 
intensity projections shown. Scale bar, 5 microns 
(C) Panel shows quantification of MDC1 (pS329/pT331) signal. Data shows background 
corrected mean signal intensity per cell and is represented as mean ± SEM. n=10 for each 
condition. **P<0.01. 
(D) GFP-Trap Immunoprecipitation (IP) of GFP-MDC1 from the chromatin fraction of U2OS cells 
transfected with control or Bod1L siRNA for 48 hours. Prior to lysis, cells were treated +/- 10 µM 
Etoposide for 24 hours. Immunoblots were analysed by western blotting using antibodies 
against GFP, NBS1 and Bod1L. 
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Together with the results from figure 4.4, these data suggest that Bod1L 
depletion leads to a significant change in the phosphorylation dynamics of 
MDC1 sites of DNA damage, resulting in an overall increase of MDC1 at 
damaged DNA and a decrease in binding to known interaction partners. 
Increased phospho-MDC1 T4 should increase the MDC1 accumulation, exactly 
as observed in biochemical and live cell analyses (Figure 4.1B-E, Figure 4.2A-
B). I hypothesise that this uncontrolled dimerisation/oligomerisation causes 
steric hindrance, which could explain the loss of phosphorylation within the SDT 
domain and thus interaction with key down-stream protein complexes, such as 
the MRN complex. 
Bod1L and the B56 regulatory subunit of PP2A interact in vivo 
As described above, I had observed changes in multiple phosphorylation sites 
on MDC1 in Bod1L-depleted cells, but had not detected any change in ATM 
activity (Figure 3.11). I therefore focused on determining whether changes to 
antagonising phosphatases were the cause of the Bod1L-depletion phenotype. 
Several groups of Ser/Thr phosphatases have been implicated in the control of 
the DNA damage response (Heideker et al., 2014), including PP2A (Chowdhury 
et al., 2005; Li et al., 2007; 2015; Shouse et al., 2011)  and PP4 (Chowdhury et 
al., 2008; Nakada et al., 2008). As described in figure 3.1, Bod1L contains a 
region of highly conserved homology with Bod1, which has been shown to 
functionally interact with the regulatory B56 subunit of the PP2A holocomplex 
(Porter et al., 2013). I immunoprecipitated Bod1L-GFP from HeLa cells 
transiently expressing Bod1L-GFP and observed specific binding of the B56 
regulatory subunit upon DNA damage (Figure 4.6A). No specific interaction 
could be detected between Bod1L and the α-subunit of the PP2A catalytic 
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subunit, most likely due to the very high expression of this subunit and the 
associated promiscuous binding in immunoprecipitation assays. I also 
immunoprecipitated stably expressed PP2A-B56-GFP and observed a 
chromatin specific co-immunoprecipitation of endogenous Bod1L (Figure 4.6B).  
Depletion of the B56 regulatory subunit of the PP2A holocomplex 
phenocopies Bod1L depletion 
To assess whether the interaction between Bod1L and PP2A-B56 had a 
functional effect on maintaining a robust response to DNA damage, I sought to 
evaluate the effect of B56 depletion on DNA repair. To test this, I depleted all 
five PP2A-B56 isoforms from HeLa cells and carried out clonogenic survival 
assays using MMC (Figure 4.6C). Whilst depletion of the B56 pool led to a 
degree of mitotic arrest, a shorter siRNA incubation (24 hours) allowed the large 
majority of cells to continue to cycle for the duration of the assay. Loss of Bod1L 
led to severe hypersensitivity to MMC as described previously (Figure 3.3E). 
Depletion of B56 from cells led to an equally pronounced sensitivity to MMC, 
whilst co-depletion of both Bod1L and PP2A led to no additional sensitivity to 
MMC. These data suggest that Bod1L and PP2A-B56 function in a non-epistatic 
manner and likely function in the same pathway. 
 
I demonstrated previously that depletion of Bod1L led to slower accumulation of 
GFP-MDC1 at sites of DNA damage (Figure 4.2A). Assessment of GFP-MDC1 
localisation following B56 depletion revealed that loss of the PP2A regulatory 
subunit phenocopied this effect (Figure 4.6D). Since depletion of Bod1L led to 
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Figure 4.6: Bod1L interacts in vivo with PP2A-B56 with PP2A-B56 
depletion phenocopying loss of Bod1L 
(A) GFP-Trap immunoprecipitation of Bod1L-GFP from chromatin fraction of HeLa cells 
transiently expressing Bod1L-GFP and mock treated or treated with 10 µM etoposide for 24 
hours. IPs were analysed by immuno-blotting using antibodies against GFP, PP2A-B56 (pan-
specific) and PP2A-Cα. Upper band of PP2A-B56 blot shows PP2A-B56δ, lower band is all 
other PP2A-B56 isoforms. 
(B) Immunoprecipitation (IP) of PP2A-B56-GFP from the nucleoplasmic and 
chromatin fraction of HeLa cells stably expressing PP2A-B56-GFP and treated with 10 µM 
etoposide. IPs were analysed by western blotting using antibodies against Bod1L and GFP. 
(C) HeLa cells were transfected with control, Bod1L, or B56 pool siRNA or combinations as 
indicated. Clonogenic survival assays were carried out with MMC. For each siRNA, cell viability 
of untreated cells is defined as 100%. To assess rescue of phenotype, HeLa cells were 
transfected with Bod1L siRNA targeting the 3’UTR repeat of Bod1L. Cells were then transfected 
with Bod1L GFP and clonogenic survival assays were carried out with Mitomycin-C. 
(D) Accumulation of GFP-MDC1 at sites of DNA damage. U2OS cells stably expressing GFP-
MDC1 were transfected with control siRNA, Bod1L siRNA or siRNA targeting the B56 pool of 
PP2A and pre-treated with Hoechst 33342. Cells were striped with 405 nm laser and GFP-
MDC1 fluorescent intensity accumulation was measured. Time from onset of laser stripe is 
shown underneath. Data represented as mean ± SEM. n=10 for each condition. 
(E) HeLa cells were transfected with control siRNA, Bod1L siRNA or siRNA targeting the B56 
pool of PP2A. After 24/48 hours cells were treated with 5 Gy IR to generate IRIF. Cells were 
fixed in PFA after 2 hours and stained for endogenous MDC1 (pT4) (green). Quantification of 
MDC1 (pT4) fluorescence signal is shown. 
(F, G) HeLa cells stably expressing PP2A-A-GFP (F) or PP2A-B56α-GFP (G) were transfected 
with mCherry-MDC1. Cells were pre-treated with Hoescht and striped with a 405 nm laser. 
Accumulation of GFP-MDC1 and PP2A were quantified along the line of the laser stripe (right-
hand panel). 
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no change in the activation or activity of ATM (Figure 3.11), I hypothesised that 
Bod1L may bind PP2A-B56 specifically at sites of DNA damage and 
subsequently control the modification of phospho-MDC1 T4.  If this hypothesis 
was correct, then a deletion of PP2A-B56 in the presence of Bod1L should 
mimic the Bod1L phenotype. To test this, I depleted all five PP2A-B56 isoforms 
from HeLa cells and assessed phospho-MDC1 T4 after treatment with IR 
(Figure 4.6E). As predicted, loss of PP2A-B56 led to an increase in phospho-
MDC1 T4 signal, even in the presence of Bod1L. Once again, depletion of 
either PP2A-B56 alone, or co-depletion of Bod1L and PP2A-B56, phenocopied 
this increase in phospho-MDC1 T4 signal at DNA lesions. Taken together these 
data suggest that PP2A-B56 is required in the same functional pathway as 
Bod1L.  
Localisation of PP2A-B56γ1 to sites of damage is lost upon Bod1L 
depletion 
I have demonstrated so far that loss of either Bod1L or the B56 regulatory 
subunit of PP2A leads to hypersensitivity to MMC and changes in the 
localisation and control of MDC1 at sites of DNA damage (Figure 4.6). Evidence 
from figure 4.6C and E suggest that PP2A-B56 and Bod1L act in a non-epistatic 
manner, most likely functioning in the same pathway upon DNA damage. I 
demonstrated that although Bod1L is not re-localised to DNA lesions, ATM 
phosphorylates Bod1L at sites of DNA damage (Figure 3.7-9). Using either GFP 
labelled PP2A structural ‘Aα’ subunit, or GFP labelled B56α I detected no 
localisation of PP2A to sites of laser micro-irradiation DNA damage (Figure 4.6 
F, G), despite strong mCherry-MDC1 accumulation at these stripes. 
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It has previously been reported that the catalytic (C) PP2A subunit, co-localised 
and co-immunoprecipitated with γH2AX; an interaction important for the 
dephosphorylation of γH2AX upon resolution of DNA damage (Chowdhury et 
al., 2005). More recent studies have identified an additional DNA damage role 
for the specific B56-gamma subunit, identifying functional association of p53 
and PP2A-B56γ at sites of DNA damage (Li et al., 2007; Shouse et al., 2011). 
To assess and determine whether Bod1L specifically regulates this DNA 
damage specific PP2A-B56γ function, I applied the laser damage assay to a 
HeLa cell line stably expressing PP2A-B56γ1-YFP and observed PP2A-B56 
rapidly localising to sites of laser damage (Figure 4.7A). To verify the 
localisation of PP2A-B56 in damaged cells, I transfected PP2A-B56γ1-YFP cells 
with mCherry-MDC1 and detected co-localisation of YFP and mCherry 
fluorescence at laser stripes (Figure 4.7A). PP2A-B56γ1-YFP fluorescence 
could be detected and quantified at the laser stripe track as early as 5 minutes 
post-irradiation (Figure 4.7B).  This rapid recruitment to DNA lesions is on a 
similar timescale to the phosphorylation of Bod1L at damage sites (Figure 
3.8D). Depletion of Bod1L prevented any detectable accumulation of PP2A-
B56γ1-YFP at damage sites (Figure 4.7C).  
 
Given that depletion of PP2A-B56 phenocopied Bod1L depletion (Figure 4.6C-
E), I hypothesised that Bod1L may control the delivery of MDC1 to sites of DNA 
damage, buffering the ATM-mediated oligomerisation of MDC1 through 
recruitment of PP2A-B56 to sites of DNA damage. To test this hypothesis, I 
employed In vitro phosphatase assays consisting of GFP-MDC1 and PP2A-B56δ-
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Figure 4.7: PP2A-B56γ1-YFP localisation to sites of laser DNA damage is 
ablated upon Bod1L depletion and mediates phospho-MDC1 T4 
dephosphorylation 
(A) Inducible HeLa cells stably expressing PP2A-B56γ1-YFP were transfected with mCherry-
MDC1. After 24 hours cells were induced with 1 µg/ml doxycycline for 16 hours. Cells were pre-
treated with Hoescht and striped with a 405 nm laser. Representative maximum intensity 
projections are shown. Data represented as mean ± SEM. n=>20 for each condition. *P<0.05, 
**P<0.01, ***P<0.001. Scale bar, 5 microns. 
(B) Quantification of PP2A-B56γ1-YFP signal along the 10 µm (90 pixel) indicated line profile. 
Fluorescence values subtracted against background signal. 
(C) Inducible HeLa cells stably expressing PP2A-B56γ1-YFP were transfected with control or 
Bod1L siRNA. After 24 hours cells were induced with 1 µg/ml doxycycline for 16 hours. Cells 
were pre-treated with Hoescht and striped with a 405 nm laser. Images were acquired every 1 
minute. 
(D) GFP-MDC1 was pulled down using GFP-Trap, from stably expressing U2OS cells treated 
with 10 µM etoposide. PP2A-B56δ-GFP was pulled down from stably expressing RPE1 cells. In 
vitro phosphatase assay was performed in the presence or absence of 2 nM Okadaic acid. 
Immunoblots were stained for phospho-MDC1 T4, GFP and PP2A-C (Experiment performed by 
Iain Porter, Swedlow Group). 
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GFP pulled down from damaged cell lysates, which revealed that PP2A-B56δ-GFP 
could dephosphorylate phospho-MDC1 T4 in vitro. This specific dephosphorylation 
event was inhibited following a dose of Okadaic acid that only targets PP2A (Figure 
4.7D).  
Bod1L does not interact with the Ser/Thr phosphatase PP4 in vivo 
As shown in figure 1.7, multiple Ser/Thr phosphatases have been shown to play 
a role in regulation of DNA damage repair. One of the better studied Ser/Thr 
phosphatases in the response to DNA damage is PP4, which has been shown 
to dephosphorylate γH2AX following resolution of DNA damage, allowing 
recovery from the G2/M checkpoint arrest as a result of replication stress 
(Chowdhury et al., 2008; Nakada et al., 2008). In addition, PP4 has been shown 
to dephosphorylate replication protein A (RPA) subunit RPA2 at DNA lesions, 
promoting efficient loading of the essential HR factor RAD51 (Lee et al., 2010). I 
demonstrated above that PP2A-B56 is involved in controlling the 
phosphorylation of MDC1 following DNA damage. Given the multiple roles 
previously described for PP4 in maintaining robust HR mediated repair, I 
wanted to establish whether Bod1L and PP4C also functionally interact during 
DNA repair. 
 
I used siRNA to target the catalytic subunit of PP4 (PP4C) (Chowdhury et al., 
2008) and probed depleted lysates with an antibody specific for the PP4C 
subunit. This siRNA significantly depleted PP4C protein levels compared with 
control treatment, and had no effect on Bod1L expression (Figure 4.8A). 
Fractionation of HeLa cell lysates revealed PP4C expression almost exclusively 
in the nucleoplasm, with a small amount associated with chromatin as reported 
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in the literature (Shimada and Nakanishi, 2013)(Figure 4.8B). Depletion of 
PP4C from HeLa cells led to hypersensitivity to MMC in a manner similar to loss 
of Bod1L (Figure 4.8C), which is unsurprising given the literature describing the 
role of PP4C in HR-mediated repair (Lee et al., 2010). To assess any 
interaction of Bod1L with PP4C, I generated a full-length GFP labelled PP4C 
construct, which was transiently expressed in HeLa cells. Immunoprecipitation 
of PP4C-GFP from HeLa cells expressing the construct revealed that PP4C-
GFP and Bod1L did not bind either in the presence or absence of DNA damage 
in the nucleoplasmic fraction of cell lysates (Figure 4.8D). Reciprocal 
experiments performed using HeLa cells transiently expressing Bod1L-GFP 
also failed to immunoprecipitate PP4C suggesting that it is unlikely that these 
two proteins interact in the nucleus in vivo. Using the PP4C-GFP construct, I 
could detect PP4C signal in the nucleus which was unaffected by depletion of 
Bod1L or the induction of DNA lesions by gamma-irradiation (Figure 4.8E). 
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Figure 4.8: Bod1L does not interact in vivo with PP4C 
(A) Immunoblots of HeLa cells treated with either control or PP4C siRNA. 6, 8 and 12 nM 
concentration of siPP4C were used. Immunoblots were probed with antibodies against PP4C, 
Bod1L and GAPDH 
(B) Subcellular fractionation of HeLa cell lysate. Immunoblots were probed with antibodies 
against vinculin, PP4C, Bod1L and H3. 
(C) Clonogenic survival assays of HeLa cells transfected with control, Bod1L or PP4C siRNA. 
MMC was added 48 hours after transfection at the indicated concentrations and cells 
propagated for 10 - 12 days. For each siRNA, cell viability of untreated cells is defined as 100%. 
3 repeats/condition, two independent experiments. Data represented as mean ± SEM. 
(D) Immunoprecipitation (IP) of PP4C-GFP using GFP-Trap from the chromatin fraction of HeLa 
cells transiently expressing PP4C-GFP. IPs were analysed by western blotting using antibodies 
against GFP and Bod1L. 
(E) U2OS cells stably expressing MDC1-GFP (green) were transfected with control or Bod1L 
siRNA. After 48 hours cells were treated with 5 Gy IR to generate IRIF. Cells were allowed to 
recover for 1 hour, fixed in PFA and stained for endogenous γH2AX (pS139) (red) and PP4C 
(cyan). Representative maximum intensity projections shown. Scale bar, 5 microns.
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Discussion 
I have shown in the previous chapter that Bod1L acts as a chromatin-bound 
component of the repair machinery. Bod1L localises throughout the nucleus but 
is specifically phosphorylated at damage sites by ATM, with phosphorylated 
Bod1L co-localizing with γH2AX and MDC1. Here I expand my previous findings 
and show that Bod1L makes two critical contributions to the DNA damage 
response: it promotes the initial targeting of MDC1 to sites of DNA damage and 
limits MDC1 accumulation by targeting PP2A-B56 to dephosphorylate ATM 
phosphorylated MDC1-T4. 
 
I demonstrate that the depletion of Bod1L results in two defects that occur at 
different timescales; first, the delivery of MDC1 to sites of DNA damage is 
impaired in the first few minutes after damage, which also compromises the 
targeting of downstream repair factors (Figure 4.5D). Secondly at longer 
timescales, control of MDC1 accumulation is lost, leading to MDC1 over-
recruitment which results in deficient repair at sites of DNA damage. Previous 
literature has demonstrated using a budding-yeast system that over-recruitment 
of DNA damage factors to sites, sequesters HR proteins and can prevent 
proper repair at bona fide DSB (Lin et al., 2009). In human cells, other studies 
investigating the functional dependence of key HR components, observe that 
suppression of 53BP1 expression led to increased recruitment of NFBD1/MDC1 
and Nbs1 to sites of DNA DSBs (Mochan et al., 2003). Given this precedent of 
improper protein recruitment resulting in repair defects, the Bod1L mediated 
control of MDC1 levels is very credible.  
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I have shown that Bod1L binds to MDC1 both in the presence and absence of 
DNA damage, with a small but reproducible decrease in binding between the 
proteins observed upon damage. Despite clear evidence of interaction between 
Bod1L and MDC1, no FRET could be detected between the two proteins 
(Figure 4.3F-G). Given the large size of the protein pair, achieving Förster 
distance between C- or N-terminally tagged fluorophores is challenging. As 
figure 4.3H showed that only the C-terminal fragment of Bod1L is necessary for 
MDC1 binding, repeating these FRET assays with a smaller Bod1L fragment 
may increase the chance of achieving the Förster distance between the two 
fluorophores and thus detecting FRET. 
 
In addition to strong evidence of an interaction with MDC1, I show that Bod1L 
interacts with the MRN complex via NBS1. Given that this interaction is only 
detectable using immunoprecipitation from fractionated HeLa cell lysate, and 
not using the single-cell binding LacO-LacI system, I suggest that the 
interaction between Bod1L and NBS1 is likely mediated through MDC1 (Figure 
4.3C). I also observe that the interactions between Bod1L and MDC1/NBS1 are 
constitutive but are slightly, although reproducibly reduced, after damage 
(Figure 4.3A, B and C). Given that these immunoprecipitation reactions pull-
down total cellular Bod1L, I hypothesise that whilst most cellular Bod1L 
interacts with MDC1/NBS1 in the absence of damage, this interaction is lost at 
DNA lesions, explaining the small, but reproducible, reduction in interaction 
after damage. 
 
I also show that Bod1L binds PP2A-B56 exclusively in damaged cells and 
together these factors moderate the proper level of MDC1 phosphorylation. 
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Previous studies have highlighted the role of the Bod1L family member, Bod1, 
as a PP2A-B56 inhibitor during mammalian cell mitosis. Although Bod1L and 
Bod1 share a strong degree of homology, key residues identified within Bod1 
which are critical for PP2A-B56 inhibition, are not conserved in Bod1L (Porter et 
al., 2013). This evidence, coupled with the loss of PP2A-B56 localisation to 
DNA lesions upon Bod1L depletion, leads us to hypothesise that the Bod1L-
PP2A-B56 interaction mediates localisation of the phosphatase holocomplex 
rather than its inhibition. The data suggest that only specific PP2A 
holocomplexes are associated with DNA lesions, the specifics of which are 
unclear. I observed PP2A-B56γ1 localising to laser stripes, however I saw no 
evidence of the B56α subunit also localising to such stripes, consistent with the 
recruitment of specific B56 holocomplexes (Figure 4.6G). Given the hypothesis 
that Bod1L recruits PP2A-B56 holocomplexes to sites of DNA damage, it is 
surprising that I could not detect localisation of the PP2A-Aα scaffold subunit to 
micro-irradiation stripes (Figure 4.6F). Whilst this could be due to the high-
fluorescence background caused by reagent choice and experimental design, it 
could be that Bod1L recruited complexes contain the PP2A-Aβ isoform instead 
of the PP2A-Aα isoform. More investigation is needed to explore the subunit 
composition of PP2A-B56 complexes recruited to damage sites by Bod1L. 
Previous studies have detected the catalytic subunit of PP2A at IRIF, however I 
was unable to reproduce this observation (Chowdhury et al., 2005). Once 
again, it is possible that different PP2A holocomplexes localise to DNA lesions 
under differing temporal conditions; perhaps related to their function, hence the 
differences in localisation observed. 
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I have demonstrated that a loss of Bod1L prevents the proper recruitment of 
PP2A-B56 to sites of damage, affecting the delicate balance of kinase and 
phosphatase at DNA lesions. This data suggests that the resulting unbalanced 
hyper-phosphorylation of MDC1 results in the excessive accumulation of MDC1. 
Literature data suggests that this excessive accumulation may be mediated 
through the unregulated oligomerisation of this critical DNA repair scaffold 
(Jungmichel et al., 2012; Liu et al., 2012; Luo et al., 2011). I hypothesise that in 
the absence of Bod1L, the resulting high phospho-MDC1 T4, which persists 
even 8 hours after damage compared with control, could explain the continued 
accumulation of MDC1 at sites of damage even in the absence of the damaging 
agent. The hyper-phosphorylation leads to further oligomerisation thus 
increasing local concentrations of MDC1 at these sites as seen in figure 4.1B-E. 
The data are in agreement with studies showing that disruption of MDC1 
dimerisation/oligomerisation at DSBs can lead to disruption of proper DDR 
(Jungmichel et al., 2012; Liu et al., 2012; Luo et al., 2011). I show that in the 
absence of Bod1L, PP2A-B56 function at sites of damage is perturbed, leading 
to hyper-phosphorylation of MDC1 T4. The resulting uncontrolled increase of 
MDC1 at damaged sites possibly sterically hinders CKII phosphorylation of 
MDC1 (Figure 4.5B, C), preventing interaction with NBS1, which is critical for 
downstream break processing (Chapman and Jackson, 2008; Melander et al., 
2008; Spycher et al., 2008).  
 
The role of kinases such as ATM and ATR have long been established as 
critical for repair (Sancar et al., 2004), however the role of antagonising 
phosphatases is poorly understood, especially during early DNA damage 
protein complex formation. This study reveals Bod1L as a key modulator of 
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early phosphatase activity at sites of DNA damage and begins to shed light on 
the complex role of phosphatases in the control of DDR. Here I show an 
important role for the direct recruitment of PP2A to the sites of DNA damage, 
early in the repair process, an observation previously unreported. The data 
presented here are complementary to recent studies which highlight the 
function of phosphatase activity earlier in the repair process both in activating 
cell cycle checkpoints in response to damage (Yan et al., 2010) and in 
preventing incorrect DDR complex formation at specific cell cycle stages (Lee et 
al., 2014; Orthwein et al., 2014).  
 
Despite emerging evidence for the important role of phosphatases in the 
damage response, several questions remain to be investigated (Shimada and 
Nakanishi, 2013). Primarily, it is not clear how the activity of each phosphatase 
is regulated to induce dynamic dephosphorylation events following DNA 
damage, as outlined in figure 1.7. In the case of PP1, DNA damage triggers 
dissociation of PP1 from its inhibitory subunits which results in its activation 
(Tang et al., 2008). Yet, the role of cellular PP2A inhibitory proteins in DNA 
damage repair, shown to be crucially important during other cellular processes, 
remains poorly understood (Haesen et al., 2014). One inhibitor identified to be 
involved in damage repair, TIPRL, has been shown to interact with both PP2A 
and PP4C to inhibit ATM/ATR signalling, with loss of the protein leading to 
cisplatin sensitivity (Gingras et al., 2005; McConnell et al., 2007). Indeed, 
multiple PP2A inhibitors in phase I clinical trials have been shown to 
hypersensitise tumour cells to DNA damaging agents, identifying this pathway 
as a promising combination therapy in cancer treatment (Chang et al., 2015; Lv 
et al., 2014; Wei et al., 2013). The function of chromatin associated proteins 
 226 
such as Bod1L, located and modified close to DNA lesions, may be key in 
maintaining the correct localisation and activity of these dynamically regulated 
protein phosphatases. 
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Chapter 5 - The role of Bod1L in control of DNA damage 
checkpoints 
 
In the previous two chapters, I have established that Bod1L is a critical player in 
the maintenance of genomic stability. Whilst it is likely that Bod1L plays many 
roles in the repair process, I have specifically shown that Bod1L functionally 
interacts with the B56 regulatory subunit of PP2A to regulate the 
phosphorylation of the critical phospho-scaffold MDC1. Depletion of Bod1L 
initially results in a loss of rapid MDC1 recruitment to DNA lesions. In addition to 
this, Bod1L depletion leads to a loss of PP2A-B56 recruitment to sites of 
damage, resulting in a failure of cells to control further MDC1 localisation to 
DNA lesions, eventually culminating in defective HR repair. 
 
As outlined in figure 1.2, Chk2 is a cell-cycle specific kinase that is necessary in 
activating cell-cycle checkpoints upon genotoxic stress (Ahn et al., 2004). Chk2 
phosphorylates a number of downstream targets that results in the arrest of the 
cell cycle at various different stages (Figure 1.6). Chk2 has been shown to 
physically interact with a number of critical DNA damage repair components 
including the phospho-scaffold MDC1 (Lou et al., 2003). Upon DNA damage, 
the FHA domain of MDC1 is able to bind to the phospho-T68 Chk2 protein (Wu 
et al., 2012). Interestingly, Chk2 does not co-localise with MDC1 at DNA 
lesions, instead remaining diffusely localised in the nucleus, implying a transient 
interaction between the two proteins (Jungmichel and Stucki, 2010). 
Furthermore, forced localisation of Chk2 to MDC1 containing IRIF, impaired the 
downstream signal transduction associated with the kinase, suggesting that 
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although the interaction with MDC1 is important, the dynamic mobilisation of 
Chk2 is critical for proper kinase function (Lukas et al., 2003). 
 
In addition to interacting with core components of the DNA repair machinery, 
Chk2 has also been shown to physically interact with the Ser/Thr phosphatase 
PP2A-B56 (Dozier et al., 2004; Freeman et al., 2010). Studies have 
demonstrated a damage-dependent, direct interaction with both the B56γ and 
B56α subunits of the PP2A holocomplex. Although the precise functional 
consequence of such interactions remains unclear, subsequent studies have 
hypothesised that PP2A-B56 (in association with other phosphatases) 
counteracts the low basal kinase activity of ATM in the absence of DNA 
damage (Figure 1.7). Activation of ATM in response to genotoxic stress 
deactivates this negative feedback loop allowing the phosphorylation of Chk2 
by ATM and subsequent downstream signalling (Carlessi et al., 2010). Inhibition 
of PP2A with Okadaic acid (OA) or depletion by siRNA, induced accumulation 
of phospho-T68 Chk2 (as well as auto- and trans-phosphorylations involved in 
its full activation), highlighting the importance of the phosphatases in the Chk2 
pathway. 
 
Given that I have demonstrated a damage dependent interaction of Bod1L with 
PP2A-B56γ, I wanted to investigate whether Bod1L was involved in the ATM-
Chk2-CDC25A pathway. The following chapter outlines the findings showing 
that loss of Bod1L leads to compromised T68 phosphorylation of Chk2 following 
DNA damage, resulting in defective checkpoint control. 
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Results 
The activation and role of the checkpoint kinase Chk2 in response to DNA 
damage 
DNA damage dependent activation of the critical checkpoint kinase Chk2, is a 
complex but well understood process (Figure 5.1A) (Cai et al., 2009). In 
undamaged cells, Chk2 exists as an inactive monomer, predominantly localised 
in the nucleus during interphase (Chouinard et al., 2013). Upon activation of 
ATM occurring at DNA lesions, the inactive Chk2 monomer is phosphorylated at 
the SQ/TQ cluster domain, specifically at T68 (Ahn et al., 2000; Matsuoka et al., 
2000), with mutation of T68 resulting in failure to activate the kinase. The 
phosphorylated Chk2 monomer then binds to another inactive phospho-Chk2 
monomer via the FHA domain, forming an inactive dimer (Ahn et al., 2002). The 
kinase domain of Chk2 is then activated via a series of auto- and trans-
phosphorylations through the kinase activation loop (Schwarz et al., 2003). 
Once activated, the kinase exists as an active dimer or monomer, with the T68 
modification no longer required for sustained activation of the kinase (Ahn and 
Prives, 2002). 
 
The activated Chk2 kinase plays many roles in response to DNA damage, 
including signal propagation, cell-cycle arrest and apoptosis (Figure 5.1B) (Ahn 
et al., 2004). The first characterised, and arguably best validated, Chk2 
substrates are the CDC25 phosphatase family, consisting of CDC25A and 
CDC25C. The primary role of these two phosphatases is promoting cell-cycle 
progression via activation of CDK1/2 through the dephosphorylation of inhibitory 
phosphorylation at T14/15 (Falck et al., 2001). Chk2 phosphorylation of 
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Figure 5.1: The role of Chk2 kinase in DNA damage repair 
(A) Schematic representation of Chk2 activation upon DNA damage. Active ATM 
phosphorylates Chk2 at T68 resulting in dimerisation. Trans- and auto-phosphorylation at T383 
and T387 results in the formation of an active dimer which splits to form an active monomeric 
kinase. Adapted from (Ahn et al., 2004). 
(B) Schematic representation of the role of Chk2 during the DNA damage response. Activated 
ATM phosphorylates and activates Chk2 as described (A). Chk2 can then phosphorylate 
CDC25A resulting in proteosomal degradation of the phosphatase. Active Chk2 can also 
phosphorylate BRCA1 at S988, promoting repair by HR. Adapted from (Zhou and Bartek, 2004). 
(C) HeLa cells were dosed with 10 Gy IR and lysed at time-points indicated. Immunoblots were 
probed with antibodies targeting pChk2 (T68), Bod1L and GAPDH. To determine phospho-
specificity of antibody, lambda phosphatase (λ) was included as a control. 
(D) HeLa cells were dosed with 10 Gy IR and lysed at time-points indicated. Immunoblots were 
probed with antibodies targeting pATM (1981), pChk2 (T68), Bod1L and GAPDH.  
(E) HeLa cells were dosed with 10 Gy IR and lysed at time-points indicated. Immunoblots were 
probed with antibodies targeting pATM (1981), pChk2 (T68), γH2AX (S139) and GAPDH.
 232 
CDC25A at S124 leads to proteosomal degradation of the phosphatase, thus 
maintaining the inhibition of CDK2 and preventing cell cycle progression (Bartek 
and Lukas, 2001). Chk2 phosphorylation of CDC25C leads to interaction of the 
phosphatase with 14-3-3 scaffold proteins, inhibiting interaction with CDK1, thus 
halting cell-cycle progression (Peng et al., 1997). In addition to a role in 
regulating cell-cycle progression upon damage, Chk2 also mediates DNA repair 
through the phosphorylation of Breast cancer type 1 susceptibility protein 
(BRCA1) (Zhang et al., 2004). Chk2 mediated phosphorylation of BRCA1 at 
S988 promotes repair via HR, thus inhibiting the more error-prone NHEJ 
(Zannini et al., 2014). Knock-in of an equivalent S988 mutation in mice revealed 
that the BRCA1S971A/S971A mice displayed increased instance of spontaneous 
tumour formation and were hypersensitive to DNA damaging agents (Kim et al., 
2004), indicating the importance of Chk2 phosphorylation of BRCA1 in 
maintaining robust DNA repair. 
 
I observed that HeLa cells treated with 10 Gy IR displayed a rapid induction of 
phospho-T68 Chk2, with phosphorylation peaking immediately after damage 
and rapidly decreasing after 30 minutes (Figure 5.1C). Treatment of cellular 
lysates, damaged with IR, with lambda phosphatase revealed that the antibody 
was specific for the phosphorylated form of the kinase. Assessing a much 
narrower window post-IR treatment revealed that phospho-T68 Chk2 levels 
decrease as soon as 15 minutes post damage, returning to almost basal levels 
after 60 minutes (Figure 5.1D, E). The increase in phospho-T68 Chk2 
phosphorylation directly correlates with ATM activation, with ATM remaining 
active throughout the time course examined (Ward et al., 2001; Zhao et al., 
2008). I detected γH2AX phosphorylation at later time-points compared with 
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Chk2 (Figure 5.1E), suggesting that these two components of the damage 
repair machinery act in separate pathways. 
 
Sustained IR-induced phospho-T68 Chk2 phosphorylation is lost 
following Bod1L depletion 
The rapid and transient nature of the phospho-T68 Chk2 modification is clearly 
important in establishing an active Chk2 kinase, which is then able to 
phosphorylate a number of downstream substrates. Given that I have shown 
that Bod1L interacts with a number of proteins that have also been shown to 
interact with Chk2, such as MDC1 and PP2A-B56 (Dozier et al., 2004; Liang et 
al., 2006; Lou et al., 2003), I wanted to understand whether loss of Bod1L led to 
a change in Chk2 activation or normal activity upon DNA damage. I depleted 
Bod1L from HeLa cells and dosed with 10 Gy IR. 30 minutes after IR treatment I 
lysed the cells and probed the immunoblots for phospho-T68 Chk2. Upon 
Bod1L depletion, Chk2 is not phosphorylated at T68, despite active ATM as 
denoted by phospho-S1981 (Figure 5.2A). 
 
Failure of Chk2 phosphorylation at phospho-T68 would result in the kinase 
remaining inactive, as previously described (Ahn et al., 2000). To assess 
whether Chk2 kinase was active in the absence of Bod1L, I treated HeLa cells 
with siBod1L and 10 Gy IR before probing immunoblots with antibodies against 
phospho-S124 CDC25A. In the absence of Bod1L, initial phosphorylation of 
phospho-T68 Chk2 was normal but this phosphorylation was not maintained 
compared with control (Figure 5.1C). The lack of sustained phosphorylation of 
Chk2 led to a decrease in the phosphorylation of CDC25A, a major downstream 
pChk2 (T68)
Bod1L
GAPDH
pATM (S1989)
pCDC25A (S124)
350
420
59
62
37
- 0 60 120
siCTR
- 0 60 120
siBod1L
Time post-
10 Gy IR (min)
pATM (S1981)
pChk2 (T68)
Bod1L
GAPDH
350
62
420
37
10 Gy IR - + - +
siCTR siBod1L
Bod1L
GAPDH37
420
siC
TR
siB
od
1L
si3
’U
TR si3
’U
TR
 +
Bo
d1
L-G
FP
- 0 15 30
siCTR
- 0 15
si3’UTR
Time post-
10 Gy IR (min) 30 - 0 15
si3’UTR + 
Bod1L-GFP
30
pChk2 (T68)
GAPDH
Bod1L420
62
37
A
B
C
D
234
 235 
Figure 5.2: Sustained Chk2 phosphorylation post-damage is lost in the 
absence of Bod1L 
(A) HeLa cells were transfected with either control or Bod1L siRNA. After 48 hours, cells were 
dosed with 10 Gy IR or mock irradiated and lysed immediately. Immunoblots were probed with 
antibodies targeting pATM (S1981), pChk2 (T68), Bod1L and GAPDH. 
(B) HeLa cells were transfected with control, Bod1L or 3’UTR-Bod1L siRNA. After 24 hours, 
3’UTR-Bod1L treated cells were transfected with Bod1L-GFP. Immunoblots were probed with 
antibodies against Bod1L and GAPDH. 
(C) HeLa cells were transfected with either control or Bod1L siRNA. After 48 hours, cells were 
dosed with 10 Gy IR or mock irradiated and lysed at the time point indicated. Immunoblots were 
probed with antibodies targeting pATM (S1981), Bod1L, pChk2 (T68), pCDC25A (S124) and 
GAPDH. 
(D) HeLa cells were transfected with control, Bod1L or 3’UTR-Bod1L siRNA. After 24 hours, 
3’UTR-Bod1L treated cells were transfected with Bod1L-GFP (>70% expression). After 24 
hours, cells were dosed with 10 Gy IR or mock irradiated and lysed at the time point indicated. 
Immunoblots were probed with antibodies against pChk2 (T68) Bod1L and GAPDH. 
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target of Chk2. This suggests that loss of Bod1L leads to less robust activation 
of Chk2 and a subsequent reduction in the down stream phosphorylation of 
Chk2 substrates. 
 
To further explore the loss of sustained phosphorylation of phospho-T68 Chk2 
further, I performed repeat experiments utilising a much narrower temporal 
window. In addition I incorporated a rescue experiment to determine whether 
depletion of Bod1L was the cause of the changes in Chk2 phosphorylation 
(Figure 5.2D). Figure 5.2B demonstrates that using a siRNA targeting the 
3’UTR of Bod1L whist transiently expressing Bod1L-GFP, I was able to re-
express Bod1L to endogenous protein levels. Using this system, I observed that 
Bod1L depletion has two main effects on phospho-T68 Chk2: firstly initial 
phosphorylation immediately after damage is slightly lower than control and 
secondly, this reduced phosphorylation is not sustained for the same duration at 
siCTR treated cells (Figure 5.1D). Exogenous expression of siRNA resistant 
Bod1L in such treated cells recovers to phospho-T68 phosphorylation to levels 
comparable with control treated cells. 
Depletion of PP2A-B56 also leads to the loss of sustained phospho-T68 
Chk2 
Chk2 physically interacts with MDC1 in the presence of DNA damage, an 
interaction mediated via the MDC1 FHA domain and phosphorylated-T68 of 
Chk2 (Lou et al., 2003). This interaction has been shown to be critical for the 
maintenance of Chk2-mediated DNA damage responses. Chk2 also interacts 
with the B56-gamma regulatory subunit of PP2A (Dozier et al., 2004; Liang et 
al., 2006). Although the functional impact of this interaction remains unclear, it 
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appears that the Chk2-PP2A interaction may control the activity of the kinase at 
sites of DNA damage. Given the evidence that Chk2 and Bod1L share key 
functional interactions upon DNA damage, I wanted to determine whether 
Bod1L and Chk2 physically interact in the presence or absence of genotoxic 
stress. I immunoprecipitated Bod1L-GFP from HeLa cells stably expressing 
Bod1L-GFP but observed no specific binding of Chk2 in the presence or 
absence of DNA damage (Figure 5.3A).  
 
I demonstrated in figure 5.1D that initial phosphorylation of Chk2 immediately 
after damage is marginally lower than in control treated cells and secondly, that 
this reduced phosphorylation is not sustained for the same duration compared 
with control. Co-depletion of Bod1L and the B56 regulatory subunit of PP2A 
phenocopied this effect (Figure 5.3B). Depletion of Bod1L or PP2A-B56 had no 
effect on Chk2 protein expression as demonstrated by immunoblotting 
unmodified Chk2. Assessment of phospho-T68 Chk2 modification on a more 
narrow temporal window reveals that the loss of phosphorylation upon DNA 
damage is more severe upon PP2A-B56 depletion than Bod1L (Figure 5.3C), 
suggestive that these two proteins may be possibly acting in an epistatic 
manner.  
Loss of either Bod1L or PP2A-B56 results in compromised intra-S-phase 
checkpoint control 
To help preserve genomic integrity, cells exposed to DNA damage activate the 
ATM kinase which results in a complex signalling pathway, leading to S-phase 
checkpoint arrests, thus delaying DNA replication (Falck et al., 2002). Defects in 
any components of this pathway, such as phospho-T68 Chk2 modification or 
Bod1L-GFP
Chk262
447
10 μM 
Etoposide - + - + - + - +
Input IP Input IP
GFP Bod1L-GFP
pATM (S1981)
pChk2 (T68)
Bod1L
GAPDH
Chk2
420
350
62
62
37
Time post-
10 Gy IR (min) - 0 30 60 - 0 30 60 - 0 30 60
siBod1LsiCTR siBod1L + siB56
pChk2 (T68)62
62 Chk2
GAPDH37
350 pATM (S1989)
- 0 15 30
siCTR
- 0 15 30
siBod1L
- 0 15 30
siB56
Time post-
10 Gy IR (min)
A
B
C
238
 239 
Figure 5.3: Depletion of PP2A-B56 also results in the loss of Chk2 T68 
phosphorylation post-damage 
(A) GFP-Trap Immunoprecipitation (IP) of Bod1L-GFP from the chromatin and nuclear fraction 
of HeLa cells transiently expressing Bod1L-GFP. IPs were analysed by western blotting using 
antibodies against GFP and Chk2. 
(B) HeLa cells were transfected with control, Bod1L or Bod1L + PP2A-B56 siRNA. After 48 
hours, cells were dosed with 10 Gy IR or mock irradiated and lysed at the time point indicated. 
Immunoblots were probed with antibodies targeting Bod1L, pATM (S1981), pChk2 (T68), Chk2 
or GAPDH. 
(C) HeLa cells were transfected with control, Bod1L or PP2A-B56 siRNA. After 48 hours, cells 
were dosed with 10 Gy IR or mock irradiated and lysed at the time point indicated. Immunoblots 
were probed with antibodies targeting pATM (S1981), pChk2 (T68), Chk2 or GAPDH. 
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ATM inhibition, lead to radio-resistant DNA synthesis (RDS) (Falck et al., 2001). 
This inability of a cell to reduce the rate or inhibit DNA replication post-DNA 
damage, leads to replication stress ultimately resulting in mutagenesis or cell 
death. 
 
Figure 5.4A shows a schematic representation of the ATM-Chk2-CDC25A 
signalling pathway that acts to protect against such DNA synthesis post-
damage. At DNA lesions ATM is activated which leads to the phosphorylation 
and activation of Chk2 demonstrated in figure 5.1A. Activated Chk2 is then able 
to phosphorylate CDC25A, resulting in proteolytic degradation of the protein. 
The loss of CDC25A phosphatase prevents the dephosphorylation of the 
CDK2/CyclinE complex, thus locking this S-phase promoting complex in the 
inactive state, preventing Cdc45 loading at replication origins (Bartek and 
Lukas, 2001). I have already demonstrated that loss of Bod1L, or the B56 
regulatory subunit of PP2A, leads to a decrease in the phosphorylation of Chk2, 
resulting in a loss of downstream CDC25A phosphorylation (Figure 5.1C). The 
model for S-phase checkpoint inhibition would predict that this loss of CDC25A 
phosphorylation would result in an activated CDK2/CyclinE complex, leading to 
radio-resistant DNA synthesis. To test this prediction, I performed an intra s-
phase checkpoint assay, using DNA labelled with BrdU to assess for any DNA 
replication following ionising radiation. I observed that depletion of either Bod1L 
or PP2A-B56 alone led to a significant amount of RDS at 5 Gy IR compared 
with control treated cells (Figure 5.4B). Co-depletion of these two proteins 
interestingly did not lead to RDS, despite knockdown of PP2A-B56 almost 
completely ablating Chk2 phosphorylation (Figure 5.3C). At higher doses of IR, 
only Bod1L depletion sustained this significant RDS. 
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Figure 5.4: Loss of Bod1L or PP2A-B56 leads to a compromised intra-S-
phase checkpoint 
(A) Schematic representation of the intra-S-phase checkpoint in response to DNA damage 
during S-phase. Active Chk2 phosphorylates CDC25A resultingtargetting the phosphatase for 
proteosomal degradation. CDK2/CycE remains phosphorylated at T14/Y15 which prevents 
CDC45 loading at replication origins. Adapted from (Bartek and Lukas, 2001) 
(B) HeLa cells were transfected with control, PP2A-B56, Bod1L or PP2A-B56 + Bod1L siRNA. 
After 48 hours, cells were irradiated with 0, 5 or 10 Gy and left to recover for 1 hour 37°C. BrdU 
was added incubated for a further 1 hour. Cells were fixed and BrdU intensity was determined 
by microscopy. Data represented as mean ± SEM. n=>20 for each condition. *P<0.05, 
**P<0.01. 
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Discussion 
I have demonstrated that loss of either Bod1L or PP2A-B56 prevents the 
sustained phosphorylation of phospho-T68 Chk2 in response to DNA damage. 
The initial phosphorylation of Chk2 immediately upon DNA damage seems only 
marginally affected by Bod1L depletion, compared with the rapid decrease in 
phosphorylation at later time points. This data, coupled with evidence from 
figure 3.11B-D which suggests that ATM kinase activity is unaffected by Bod1L 
depletion, highlight the probable involvement of phosphatases in this process. 
 
I demonstrate in figure 4.6A-B that Bod1L interacts with PP2A-B56 specifically 
in the presence of DNA damage, with this interaction critical for proper PP2A-
B56γ localisation to DNA lesions (Figure 4.7). I mentioned previously that 
activation of ATM in response to genotoxic stress deactivates the PP2A-
B56/Chk2 negative feedback loop, allowing the phosphorylation of Chk2 by 
ATM and subsequent downstream signalling (Carlessi et al., 2010). The data 
presented in this chapter, suggests that Bod1L could possibly act as an 
additional level of control over this step, acting to release Chk2 from this 
inhibitory phosphatase complex upon DNA damage, thus allowing it to 
phosphorylate downstream substrates. Based on the evidence presented in 
figures 5.1-3, I hypothesise that loss of Bod1L from cells leads to ‘uncontrolled’ 
PP2A-B56 that is able to promiscuously dephosphorylate Chk2 irrespective of 
the presence or absence of DNA damage. The data showed that depletion of 
PP2A-B56 also led to a loss of sustained phosphorylation of Chk2 following 
DNA damage. This suggests that an additional phosphatase must also be able 
to promiscuously dephosphorylate phospho-Chk2 T68 in the absence of PP2A-
B56 activity (Figure 6.2). Wip1 is known to target T68 phosphorylation (Oliva-
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Trastoy et al., 2006), therefore it would be interesting to investigate the effect of 
Bod1L and/or PP2A-B56 depletion on the activity of this potentially unregulated 
phosphatase.  
 
The activation process of the Chk2 kinase is well documented, with the reliance 
on sustained T68 phosphorylation demonstrated as being important during the 
early activation phase, but not once the kinase is active (Ahn and Prives, 2002). 
The hypothesis suggests that the failure to maintain phospho-T68 Chk2 during 
the initial activation of the kinase renders the downstream signalling 
compromised as a result of an inactive, or partially inactive, kinase. Further 
investigation using phosphorylation specific mass-spectrometry, or use of 
phospho-specific antibodies, is needed to determine whether the auto- and 
trans-phosphorylations associated with active Chk2 are present in the absence 
of Bod1L. A reduction in the presence of these ‘activating’ phosphorylations 
would verify my hypothesis that Chk2 is less active in the absence of Bod1L. 
 
In chapter 4, I demonstrated that co-depletion of Bod1L and PP2A-B56 
phenocopied the Bod1L knockdown with regard to elevated phosphorylation of 
phospho-T4 MDC1 and the subsequent hypersensitivity to genotoxic stress. 
Here I show that depletion of Bod1L and PP2A-B56 appears to generate an 
additive effect in loss of phospho-T68 Chk2 phosphorylation, suggesting that 
these proteins are acting in epistatic pathways. Alternatively, loss of PP2A-B56 
is affecting additional pathways involved in checkpoint arrest, which is resulting 
in this additive effect. Indeed, I observe that co-depletion of Bod1L and PP2A-
B56 rescue RDS at low doses of IR, further suggesting that knockdown of both 
genes simultaneously, may affect more than one pathway (Figure 5.4B). One 
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such additional pathway that may be affected by Bod1L depletion with regard to 
checkpoint control, is ATM mediated phosphorylation of phospho-S343 NBS1 
and subsequent MRN complex formation (Falck et al., 2002). I have already 
shown that Bod1L depletion can alter the MDC1-MRN interaction (Figure 4.5D), 
so there is precedent for Bod1L depletion to further affect this critical complex. 
Precisely how the MRN complex affects DNA synthesis is unknown, however 
recent studies have demonstrated that NBS1 binds to the E2F1 transcription 
factor, an interaction that directly influences S-phase progression. The 
significance of this interaction is further strengthened with the evidence that 
E2F1-NBS1 binding is almost completely lost in NBS and A-TLD cells (Ahn et 
al., 2004; Maser et al., 2001). 
 
I discussed previously how Chk2 mediated phosphorylation of BRCA1 at S988 
promotes repair via HR, inhibiting the more error-prone NHEJ (Lou et al., 2003; 
Zhang et al., 2004). Literature evidence showed that knock-in of an equivalent 
S988 mutation in mice revealed that the BRCA1S971A/S971A mice displayed 
increased instance of spontaneous tumour formation and were hypersensitive 
to DNA damaging agents (Kim et al., 2004; Wu et al., 2012). Given that I have 
shown that Bod1L depletion leads not only to defective HR repair, but also 
compromised Chk2 activation, future investigation is needed into assessing the 
phosphorylation of BRCA1 following DNA damage. A Bod1L-dependent loss of 
phospho-S988 BRCA1 phosphorylation could explain the defective HR 
phenotype I observe, occurring as a result of defective Chk2 activation. 
 
 
 
 245 
Chapter 6 - Discussion and Future Directions 
Bod1L is a novel DNA damage response protein, required for robust DNA 
repair 
The data presented in this thesis, combined with recently published work from 
the Stewart group, reveal Bod1L as a novel component of the DNA damage 
repair machinery (Higgs et al., 2015). I identified Bod1L as a novel chromatin 
bound protein, with a C-terminal cluster of multiple NLS and a single A-T hook 
that is necessary for nuclear localisation (Figure 3.1). ATM/ATR substrate 
specific phospho-proteomics studies, in addition to ultradeep phospho-
proteomics, revealed that Bod1L was highly modified, with a number of 
phosphorylation events occurring in response to DNA damage (Matsuoka et al., 
2007; Sharma et al., 2014). I confirmed two of these phosphorylation sites, 
S1145 and S1710, were phosphorylated at sites of DNA damage, with S1710 
phosphorylated by DNA-PK in vitro. 
 
Depletion of Bod1L from multiple cell types resulted in phenotypes associated 
with a failure of DNA damage repair, including fragmented, acentric chromatin 
and nuclear morphology changes (Constantinescu et al., 2010; Terradas et al., 
2009)(Figure 3.2). In addition, treatment of Bod1L depleted cells with genotoxic 
stresses led to severe hypersensitivity, consistent with compromised DNA 
repair. Indeed, assessment of DNA repair by HR revealed that depletion of 
Bod1L reduced HR efficiency in a manner similar to ATM inhibition (Figures 3.3 
and 3.4). 
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As mentioned previously, phospho-proteomic analysis of ATM/ATR substrates 
in response to DNA damage identified two Bod1L phosphorylation sites, S1145 
and S1710, which were confirmed using phospho-specific antibodies raised 
against these sites (Figures 3.6 and 3.10) (Matsuoka et al., 2007). Bod1L 
S1710 is rapidly phosphorylated at sites of DNA damage in a manner 
analogous with the phosphorylation of γH2AX and the γH2AX dependent 
recruitment of MDC1. I utilised recombinant DNA-PK, which shares identical 
specificity to ATM in vitro (Kim et al., 1999; O'Neill et al., 2000), to confirm that 
phospho-Bod1L S1710 is likely phosphorylated by ATM in response to DNA 
damage. Investigation into the phosphorylation of phospho-Bod1L S1145 by 
ATM remains on going. Whilst the data clearly shows damage dependent 
phosphorylation of Bod1L at DNA lesions, the functional significance of this 
modification remains unclear. Preliminary functional rescues of Bod1L depletion 
revealed that mutation of either site individually, or together, had no effect on 
the ability of Bod1L-GFP to rescue clonogenic sensitivity to MMC. As such, 
investigation is needed to understand the mechanistic implication of this 
modification. As Bod1L is bound constitutively to chromatin and other protein-
interactors, one could hypothesise that ATM phosphorylation could regulate 
such interactions, perhaps driving the release of proteins bound to Bod1L. Use 
of the phospho-mutant and phospho-mimic Bod1L mutants will be vital in 
understanding this mechanistic step. 
 
Work from the Stewart group identified Bod1L as a component of a pathway 
that safeguards genome stability following replication stress (Higgs et al., 2015), 
with loss of Bod1L resulting in sensitivity to replication stress and catastrophic 
genome instability. They elegantly demonstrated that Bod1L functions 
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downstream of BRCA2 to stabilise Rad51 nucleofilaments at damaged 
replication forks, protecting such damaged forks and preventing resection of 
nascent DNA strands by DNA2. Rad51 localisation to forks was unaffected 
following Bod1L depletion, suggesting that Bod1L acts to stabilise these 
nucleofilaments once formed. Whilst this study reveals an additional functional 
consequence of Bod1L depletion not explored in this thesis, little mechanistic 
detail is discussed regarding the position and function of Bod1L in this complex 
pathway. Unlike the data presented in this thesis, no replication defects or 
phenotype could be detected in cells solely depleted of Bod1L, with all 
phenotypic observation dependent upon the use of MMC to induce replication 
stress. Whilst the use of such agents is practical in exacerbating subtle 
phenotypes, if the principle function of Bod1L was to safeguard genome stability 
following replication stress, one would expect a more pronounced phenotype 
occurring as a result of any endogenous replication stress. In addition to this, 
the data consistently revealed the presence of fragmented and acentric 
chromatin visible during mitosis, in addition to abnormal nuclear morphology; 
established indicators of unrepaired DNA DSBs (Constantinescu et al., 2010; 
Fan et al., 2004; Kumareswaran et al., 2012; Terradas et al., 2009). Whilst the 
precise molecular mechanism for Rad51 nucleofilament stabilisation by Bod1L 
remains unclear, the authors did demonstrate that Bod1L interacts with a 
number of key components of the DDR, including Mre11 and BRCA2. 
Combining this information, along with the extensive phenotypic data from this 
thesis and the evidence of unrepaired DSBs in the absence of Bod1L, it is 
highly likely that Bod1L plays a dual role in both the repair of DSBs as well as 
Rad51 nucleofilament protection during replication stress.  
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Initial Bod1L sequence analysis revealed a highly conserved, proline-rich region 
at the N-terminus of the protein, located prior to the COMPASS homology 
domain. Proline-rich repeats have been shown to facilitate a range of protein-
protein interactions with a variety of proteins containing SH3, WW and EVH1 
domains (Kay et al., 2000), in addition to playing an important role in a number 
of cellular process, such as the response to DNA damage (Shafman et al., 
1997). The necessity of this proline-rich region of Bod1L was not investigated 
during this study, yet given the proximity of this region to the COMPASS/Bod1 
homology domain of Bod1L, it presents an interesting avenue of investigation 
for future work. 
 
As mentioned previously, methylation of H3K4 has been shown to be involved 
in the DNA damage response in both yeast and mammalian cells (Nakamura et 
al., 2011). Unlike damage-dependent PTMs, histone methylation appears to 
occur constitutively, with damage-induced changes in histone methylation 
correlating with DDR progression (Seiler et al., 2011). Studies in yeast have 
revealed that cells with a Δset1 mutation preventing H3K4 methylation, are 
defective in NHEJ repair and show compromised S-phase progression in the 
presence of replication stress (Faucher and Wellinger, 2010). These examples, 
in addition to other work, highlight the function of H3K4 modification in altering 
chromatin structure and directing signalling at sites of DNA damage to allow for 
robust repair. Contained within the Bod1-homology domain of Bod1L is a region 
of homology with the Complex proteins associated with SET1 protein 
(COMPASS) component Shg1. Recent data has shown that Bod1L interacts 
with a key accessory subunit of the COMPASS complex, Ash2L, suggestive of 
Bod1L being part of the Ash2L containing H3K4 methyltransferase complex. 
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The study found that H3K4 methyltransferase complexes bind to the Bod1L 
promoter, suggesting that regulation of chromatin structure at Bod1L locus may 
be important in regulating cellular H3K4 di- and tri-methylation (Ciotta, 2011). 
Subsequent work has also identified Bod1L as an interacting partner of the 
Dpy30 (WRAD) complexes, with Bod1L exclusively present in Set1A/Set1B 
methyltransferase complexes (van Nuland et al., 2013). These observations, 
combined with our preliminary data that suggests H3K4 methylation may be 
decreased in the absence of Bod1L, provide a tantalizing insight into an 
additional role of Bod1L in the regulation of cellular H3 methylation, possibly in 
response to DNA damage. This potentially PP2A-independent role of Bod1L 
certainly warrants investigation in the future. 
Bod1L controls MDC1 and PP2A-B56 recruitment at sites of DNA damage 
I have shown that Bod1L acts as a chromatin-bound scaffold that facilitates the 
delivery of MDC1 to sites of DNA damage and regulates multiple phospho-epitopes 
within MDC1. Depletion of Bod1L results in two defects that occur at different 
timescales; first, the delivery of MDC1 to sites of DNA damage is impaired in the 
first few minutes after damage, which also compromises the targeting of 
downstream repair factors (Figure 4.1). At longer timescales, control of MDC1 
accumulation is lost, and this interferes with repair at sites of DNA damage. Bod1L 
binds MDC1, and possibly through this interaction to NBS1; these interactions are 
constitutive and are partially reduced after damage (Figure 4.3). Bod1L binds 
PP2A-B56 exclusively in damaged cells and together these factors moderate the 
proper level of MDC1 phosphorylation. The data suggest that unbalanced 
hyperphosphorylation of MDC1, caused by loss of the dephosphorylation of 
phospho-MDC1 T4 by PP2A-B56, results in the excessive accumulation of MDC1,  
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Figure 6.1: Bod1L regulates the recruitment of MDC1 and PP2A-B56 to 
sites of DNA damage 
In the absence of DNA damage, Bod1L and MDC1 are constitutively bound on chromatin. 
Following recognition of a DNA double-strand break (DSB) and the subsequent activation of 
ATM, Bod1L is phosphorylated in an ATM dependant manner, allowing MDC1 to bind to H2AX 
(pS139). Bod1L binds the PP2A-B56 holo-complex, which acts to ‘buffer’ the phosphorylation of 
MDC1 by ATM, controlling the localisation of MDC1 to sites of DSB. In the absence of Bod1L, 
MDC1 accumulation at sites of DNA damage is slowed, and PP2A-B56 fails to localise leading 
to increased MDC1 pT4 phosphorylation and uncontrolled oligomerisation at sites of damage. 
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possibly through unregulated dimerisation/oligomerisation of this critical DNA repair 
scaffold.   
 
The data suggests there is a defined order of events for MDC1 targeting to sites of 
DNA damage (Figure 6.1).  Bod1L constitutively binds a fraction of MDC1 and 
following damage; activated ATM phosphorylates H2AX, MDC1 and Bod1L.  Whilst 
the exact order of these events is not yet known, Bod1L phosphorylation occurs 
relatively early in the DDR process, as I detected phospho-Bod1L S1710 staining 
by IF as soon as 5 minutes after damage (Figure 3.8). Based on the evidence 
presented in this thesis, I hypothesise that these modifications decrease the affinity 
of Bod1L for MDC1, allowing MDC1 to bind to γH2AX and provide a platform for 
further protein recruitment and signal amplification (Lou et al., 2006). Bod1L binds 
to the regulatory subunit of PP2A-B56 exclusively in the presence of DNA damage, 
resulting in accumulation of the phosphatase at sites of DNA damage (Figure 4.7). 
This recruitment is consistent with a previous study which reports a novel function 
of DNA-PKcs in recruiting PP6 to sites of DNA damage to facilitate 
dephosphorylation of γH2AX (Douglas et al., 2010). I have demonstrated that 
PP2A-B56 dephosphorylates phospho-MDC1 T4, thus ensuring that accumulation 
of MDC1 is controlled and limited. The balance of ATM and PP2A-B56 activities at 
DNA lesions then controls the accumulation of MDC1 and the proper repair of DNA 
damage (Figure 6.1). In the absence of Bod1L, MDC1 is slower to accumulate at 
sites of DNA damage due to loss of interaction with Bod1L and associated 
“priming” mechanism. The loss of PP2A-B56 localisation at DNA lesions as a result 
of Bod1L depletion leads to increased MDC1 pT4 phosphorylation and uncontrolled 
oligomerisation of MDC1.   
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The data are in agreement with studies showing that disruption of MDC1 
dimerisation/oligomerisation at DSBs can lead to disruption of proper DDR 
(Jungmichel et al., 2012; Liu et al., 2012; Luo et al., 2011; 2015). Dimerisation 
through the FHA domain of MDC1 is evolutionarily conserved (Drosophila 
melanogaster and Schizosaccharomyces pombe), suggesting the importance of 
this activity (Luo and Ye, 2012). Indeed, it is only the dimerisation capacity and 
not Chk2/ATM phospho-dependent binding by MDC1 that is conserved, further 
strengthening the importance of the dimerisation process. Relatively few studies 
have explored the functional consequence of increased 
dimerisation/oligomerisation of MDC1 during the DDR, with the data in this 
thesis hitherto unreported. This is unsurprising given the lack of data regarding 
phosphatase involvement during the early DNA damage response. A very 
recent study revealed a previously unrecognised FHA domain in the fission 
yeast Schizosaccharomyces pombe MDC1 homologue, Mdb1, which mediates 
functionally important homodimerisation. Similar to the drosophila MDC1 
homologue, Mdb1-FHA lacks all of the conserved phospho-binding residues, 
yet it forms a stable homodimer upon DNA damage. Disruption of this 
homodimer disrupts DNA damage-induced Mdb1 focus formation and in vitro 
binding of γH2A by Mdb1, leading to defective DNA repair (Luo et al., 2015). 
The investigation of MDC1 and other DDR protein dimerisation in response to 
DNA damage represents an exciting future direction for this study. 
 
I show that in the absence of Bod1L, PP2A-B56 is not recruited to sites of DNA 
damage (Figure 4.7), therefore PP2A-B56 function at these sites is perturbed, 
resulting in hyperphosphorylation of phospho-MDC1 T4. Whilst I have shown that 
PP2A-B56 can directly dephosphorylate phospho-MDC1 T4 in vitro, it is likely that 
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the phosphatase is responsible for the dephosphorylation of other DDR proteins 
during early focus assembly. This presents an exciting opportunity for future 
investigation as loss of the Bod1L-PP2A association at DNA lesions may have 
effects on additional phospho-dependent processes. I hypothesise that the 
resulting uncontrolled increase of MDC1 at damaged sites as a result of increased 
phospho-MDC1-T4, sterically hinders CK2 phosphorylation of phospho-MDC1 
S329/T331 (Figure 4.5), preventing interaction with NBS1, which is critical for 
downstream break processing (Chapman and Jackson, 2008; Melander et al., 
2008; Spycher et al., 2008).  
 
Whilst I have defined an elegant molecular mechanism for the compromised 
DDR associated with Bod1L depletion, I have only briefly looked into 
downstream consequence of loss of MDC1 regulation with regard to DDR 
protein recruitment. I detected significantly fewer Rad51 foci upon DNA damage 
induction, which was a likely explanation for the reduction in HR efficiency 
detected with the DR-GFP assay (Figures 3.4 and 4.1). More work is needed to 
investigate the full affect of Bod1L depletion on downstream DDR protein 
recruitment to understand and explore the full mechanistic detail into how 
MDC1 over-accumulation leads to compromised HR repair. 
 
Several studies have identified many crucial phosphatase roles in the reversal 
of post-translational modifications upon resolution of DNA damage, particularly 
the dephosphorylation of γH2AX and p53 (Li et al., 2015; Lu et al., 2014). Whilst 
the data presented in this thesis establishes a role for Bod1L in the regulation of 
PP2A-B56 during the initial DDR, an unanswered question is whether Bod1L 
also plays a key role in the dissolution of DNA damage foci following damage 
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repair, through the regulation of PP2A-B56. This also leads onto investigation 
into the biochemistry of the interaction between Bod1L and the B56 regulatory 
subunit of PP2A. Previous studies have shown that the Bod1/PP2A-B56 
interaction is dependent upon a putative CDK phosphorylation site and 
downstream aspartate residue (Porter et al., 2013). Interestingly, these residues 
are not conserved in Bod1L, suggesting that the interaction between Bod1L and 
PP2A-B56 is via an entirely different domain. This also perhaps explains why 
interaction between Bod1L and PP2A-B56, unlike Bod1/PP2A-B56 interaction, 
does not lead to inhibition of the phosphatase activity. 
Cells depleted of Bod1L display defective cell-cycle arrest in response to 
DNA damage due to loss of Chk2 phosphorylation 
Under basal physiological conditions, Chk2 is held in a dephosphorylated state 
via an interaction with a number of phosphatases, including PP2A-B56, which 
prevents the phosphorylation-dependent activation of the kinase (Figure 6.2A). 
Activation of ATM in response to genotoxic stress deactivates this Chk2/PP2A-
B56 negative feedback loop, promoting the phosphorylation of Chk2 by ATM at 
T68 and subsequent activation and downstream Chk2 signalling (Carlessi et al., 
2010; Freeman et al., 2010). The presence of sustained T68 phosphorylation 
has been demonstrated as being central during the early activation phase, to 
promote full activation of the kinase (Ahn and Prives, 2002). 
 
The data presented in this thesis present strong evidence for an interaction 
between PP2A-B56 and Bod1L, yet show no interaction directly between Bod1L 
and Chk2. Given that loss of Bod1L profoundly affects sustained phospho-Chk2 
T68 phosphorylation, I hypothesise that Bod1L acts as an additional regulator of 
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Figure 6.2: Working model for role of Bod1L and PP2A in the activation 
and activity of Chk2 
(A) Schematic representation of the phosphatase regulation of Chk2. Adapted from (Peng and 
Maller, 2010). 
(B) Schematic representation of Chk2 phosphorylation and dephosphorylation following DNA 
damage. Chk2 and PP2A-B56 interact under physiological conditions (A). ATM activation 
bought about from DNA damage dissociates the complex. Activation of Chk2 is then regulated 
by antagonistic kinase and phosphatase activity in the presence of Bod1L. In the absence of 
Bod1L, normal PP2A-B56 function is perturbed and as such the kinase:phosphatase dependent 
phosphorylation of Chk2 is disrupted resulting in a loss of phospho-Chk2 T68 and associated 
down-stream signalling. Depletion of PP2A-B56 perturbs proper ATM activation, preventing 
phosphorylation of Chk2 at T68. 
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Chk2 activation, possibly acting to release Chk2 from the inhibitory Chk2/PP2A-
B56 phosphatase complex upon DNA damage, thus allowing the kinase to 
phosphorylate downstream substrates. Based on the evidence presented in 
figures 5.1-3, I theorise that loss of Bod1L leads to unregulated PP2A-B56 that 
is able to promiscuously dephosphorylate Chk2, disrupting the normal 
physiological inhibition of phosphatase activity (Figure 6.2B). The initial, rapid 
phosphorylation of phospho-Chk2 T68 seems largely unaffected by Bod1L 
depletion, which is consistent with the data that shows that ATM activity is 
unaffected under these conditions. The loss of sustained phosphorylation is 
highly indicative of hyperactive phosphatase activity. Consistent with these 
observations, inhibition of PP2A during DDR with LB100 induced constitutive 
hyperphosphorylation Chk2, suggesting that a fine phosphorylation balance of 
Chk2 is needed for robust DDR signalling (Chang et al., 2015). 
 
The data from this thesis suggest that the failure to maintain the phospho-Chk2 
T68 modification during initial activation of the kinase renders the downstream 
signalling compromised as a result of an inactive, or partially inactive, kinase. 
Further investigation using phosphorylation specific mass-spectrometry, or use 
of phospho-specific antibodies, is required to determine whether the auto- and 
trans-phosphorylations associated with active Chk2 are present in the absence 
of Bod1L (Zannini et al., 2014). A reduction in the presence of these ‘activating’ 
phosphorylations would verify the hypothesis that Chk2 is less active in the 
absence of Bod1L. Another open question that remains is how Bod1L fits into 
this pathway. It has been previously reported that whilst Chk2 and MDC1 may 
interact upon DNA damage, Chk2 undergoes only a transient interaction with 
DSBs, from where it rapidly spreads throughout the nucleus (Lukas et al., 
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2003). One hypothesis, which is supported by the data in this thesis, describes 
Bod1L associating with and “tethering” PP2A-B56 at sites of DNA damage, thus 
preventing free PP2A-B56 from interacting with free nuclear phosphorylated 
Chk2. This would act to essentially release Chk2 from the inhibitory 
Chk2/PP2A-B56 phosphatase complex. Although this would present a rather 
elegant working model, more work is needed to determine whether in the 
absence of Bod1L, more Chk2 can be detected in the inhibitory Chk2/PP2A-
B56 phosphatase complex, which would help strengthen this model. 
Closing Remarks 
The data presented in this thesis offers strong evidence for the role of Bod1L as 
a critical mediator in regulating the DNA damage response. These data strongly 
suggest that regulation, as opposed to simple inhibition, of serine/threonine 
protein phosphatases at DNA lesions is critical in the DDR, with Bod1L central 
in this process. Whilst the action and importance of the PI3K kinase family have 
been studied in great depth during this process, research into the activity of the 
antagonistic phosphatases remains is in its infancy. The scope for the 
importance of these dephosphorylation events is huge, with one key 
quantitative mass spectrometry-based study identifying a considerable number 
of sites that undergo DNA damage-induced dephosphorylation (Bennetzen et 
al., 2010). This growing body of evidence suggests that phosphatases play a 
more important part early in the DDR than hitherto reported.
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